Oxycodone: A Current Perspective on its Pharmacology, Abuse and Pharmacotherapeutic Developments

James E. Barrett, Aryan Shekarabi and Saadet Inan

Center for Substance Abuse Research
Lewis Katz School of Medicine
Temple University
Philadelphia, PA 19140

Address correspondence to:
James E. Barrett, Ph.D.
Center for Substance Abuse Research
Department of Neural Sciences
Lewis Katz School of Medicine
Temple University
3500 N. Broad Street
Philadelphia, PA 19140
jebarrett@temple.edu

Partial support for the preparation of this manuscript was provided by NIDA Award DA047700.
ABSTRACT

Oxycodone, a semi-synthetic derivative of naturally occurring thebaine, an opioid alkaloid, has been available for over 100 years. Although thebaine cannot be used therapeutically due to the occurrence of convulsions at higher doses, it has been converted to a number of other widely used compounds that include naloxone, naltrexone, buprenorphine, and oxycodone. Despite the early identification of oxycodone, it was not until the 1990s that clinical studies began to explore its analgesic efficacy. These studies were followed by the pursuit of several preclinical studies to examine the analgesic effects and abuse liability of oxycodone in laboratory animals and the subjective effects in human volunteers. For a number of years oxycodone was at the forefront of the opioid crisis, playing a significant role in contributing to opioid misuse and abuse, with suggestions that it led to transitioning to other opioids. Several concerns were expressed as early as the 1940s that oxycodone had significant abuse potential similar to heroin and morphine. Both animal and human abuse liability studies have confirmed, and in some cases amplified, these early warnings. Despite sharing a similar structure with morphine and pharmacological actions also mediated by the μ-opioid receptor, there are several differences in the pharmacology and neurobiology of oxycodone. The data that have emerged from the many efforts to analyze the pharmacological and molecular mechanism of oxycodone have generated considerable insight into its many actions, reviewed here which, in turn, have provided new information on opioid receptor pharmacology.
Significance Statement

Oxycodone, a \( \mu \)-opioid receptor agonist, was synthesized in 1916 and introduced into clinical use in Germany in 1917. It has been studied extensively as a therapeutic analgesic for acute and chronic neuropathic pain as an alternative to morphine. Oxycodone emerged as a drug with widespread abuse. This article brings together an integrated, detailed review of the pharmacology of oxycodone, preclinical and clinical studies of pain, abuse, and also covers recent advances to identify potential opioid analgesics without abuse liability.
Oxycodone: A Current Perspective on its Pharmacology, Abuse and Pharmacotherapeutic Developments

I. Introduction
   A. Brief History of Early Opioid Pharmacology
   B. The Opioid Crisis
   C. History of Oxycodone
   D. Illicit Use and Abuse of Oxycodone
   E. Transition to Heroin
   F. Pain, Oxycodone and Abuse

II. Basic Pharmacology of Oxycodone
   A. Receptor Binding and Comparisons with Morphine
   B. Role of Kappa and Delta Opioid Receptors in the Effects of Oxycodone
   C. Respiratory Depression
      1. Human Studies
      2. Animal Studies
      3. Polydrug Use and Respiratory Depression
   D. Tolerance and Cross Tolerance
   E. Dependence and Withdrawal
   F. Pharmacodynamic and Pharmacokinetic Effects

III. Pharmacogenomic /Pharmacogenetics of Oxycodone
   A. Genotype Variations in Humans and Responses to Oxycodone
   B. Gene and Protein Expression Studies in Animals
   C. Summary

III. Pain and Analgesia – Clinical Studies
   A. Cancer Pain
   B. Neuropathic Pain
   C. Surgical Procedures
   D. Gender Differences in Pain and Analgesia

IV. Pain and Analgesia – Preclinical Studies
   A. Neuropathic Pain
   B. Mechanistic Studies of Oxycodone
C. Sex Differences

V. Psychopharmacology and Human Subjective Effects of Oxycodone
   A. Early Studies
   B. Studies in Non-Opioid-Abusing and Nondependent Opioid Users
   C. Studies in Opioid Drug Abusing Volunteers – Pain, Comorbidities and Drug History
   D. Gender Differences in Abuse Liability

VI. Oxycodone Abuse Liability Studies in Animals
   A. Drug Self-Administration
   B. Reinstatement and Craving Impulsivity
   C. Impulsivity
   D. Sex Differences in Abuse Liability of Oxycodone
   E. Drug Discrimination
   F. Imaging

VII. Pharmacological Modulation of Oxycodone in Laboratory Animals
   A. Ultra-Low Dose Naltrexone
   B. Kappa Opioids
   C. Nociceptin/Orphanin FQ
   D. Lorcaserin
   E. Orexin/Hypocretin
   F. Glucagon-Like Peptide-1 (GLP-1)
   G. Cannabinoids
   H. Biased G Protein-Based Mu Opioid Receptor Agonist TRV-130
   I. NK1 Receptor
   J. Dopamine D3 Receptor Compounds

VIII. Pharmacological Modulation of Oxycodone in Humans
   A. Buprenorphine/Naloxone
   B. Pioglitazone, A PPARγ Receptor Agonist
   C. Ibudilast
   D. Cannabis
   E. Lorcaserin
F. Minocycline

G. NK1 Antagonists

IX. Vaccines to Treat Opioid Use Disorders
   A. General Introduction
   B. Historical Background
   C. Recent research and Development

X. Future Directions: Analgesia Without Opioid-Related Side Effects

XI. Conclusions
   Authorship Contributions
   References
ABBREVIATIONS:
CCI, Chronic Constriction Injury
CPP, Conditioned Place Preference
DSM, Diagnostic and Statistical Manual of Mental Disorders
ICD, International Classification of Diseases
i.c.v., intracerebroventricular
i.t., intrathecal
i.v., intravenous
KO, knockout
NAc, Nucleus accumbens
NOP, Nociceptin/Orphanin FQ
OUD, Opioid Use Disorder
P-gp, P-glycoprotein
SNI, Spinal nerve injury
SNL, Spinal nerve ligation
STZ, streptozotocin
SUD, Substance Use Disorder
I. Introduction

A. Brief History of Early Opioid Pharmacology

Issues surrounding the effects and potential abuse liabilities of opioids have been known for over 150 years. In a review of “Morphine addiction and its physiological interpretation based on experimental evidences”, Tatum et al. (1929) believed that the renowned French physiologist Claude Bernard was the first scientist to give a careful and complete description of the dose-related effects of morphine in dogs, with low doses leading to salivation, retching and vomiting, and higher doses producing analgesia, sedation, convulsions and death (Bernard, 1864). Bernard also described the development of tolerance following repeated exposure to morphine. Subsequent studies some years later by Tatum et al. (1929) on ‘morphine poisoning’ in the dog and rhesus monkey also described acute effects of morphine leading to convulsions and lethality and made the observation that if the dogs or monkeys were treated with sodium barbital and paraldehyde during the convulsions, they could ‘recover’ the animals and stop the progression to respiratory mortality. This finding suggested that lethality is not related to direct depression of the respiratory center by morphine because the addition of a depressant (sodium barbital) should lower rather than raise the lethal dose of morphine. “The fatal outcome of morphine at this stage of its action in the monkey can be combatted by the use of certain depressants” (Tatum et al., p 460). These early studies by Bernard, Tatum et al., and others on dogs, cats, rabbits, and monkeys, separated in time from a larger and more expansive experimental focus on the wide range of opioid pharmacology, provided the foundation for subsequent approaches to further investigate tolerance and cross tolerance, dependence, abstinence, and withdrawal, and respiratory depression, together with the analgesic and antinociceptive effects of opioids (see also Seevers, 1936; Deneau and Seevers, 1964). These studies also presaged countless developments that followed over the course of several decades that have vastly improved our understanding of opioid receptor diversity and pharmacology and reaffirmed the commitment to discover a safe and effective analgesic lacking abuse liability. The seemingly unrelenting opioid crisis has become part of this quest and oxycodone emblematic of the many unresolved challenges.
B. The opioid crisis

The current opioid crisis has its basis in several intersecting developments that have included inappropriate prescribing and marketing, diversion, illicit trafficking of less expensive opioids, and misuse for the treatment of acute and chronic noncancer pain. There were several early indications of a developing crisis. Okie (2010), in an article entitled “A flood of opioids, a rising tide of deaths” provided evidence that deaths from unintentional overdoses in the United States had been rising steeply since the early 1990s, with the increase propelled by the rising number of overdoses of synthetic versions of opium. In 2020 an average of 44 people died each day from an overdose involving prescription drugs (Center for Disease Control and Prevention, 2021). The staggering number of opioid-related deaths over the past two decades has come at an economic cost of more than $2.5 trillion between 2015 and 2018, and an estimated $700 billion to $1 trillion in 2018 alone (Kharasch et al., 2022), not to mention the toll on the emotional burden to families and friends. COVID-19 also has had a significant impact on opioid use and misuse, overdose, and mortality, with opioid overdoses continuing to evolve since the onset of COVID-19 (Gian-Gabriel et al., 2022). The CDC has published provisional data for the 12-month period ending in April 2021 where there were an estimated 100,306 drug overdose deaths in the U.S., an increase in approximately 29% from the same period the year before (https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm).

Contributions to opioid use and misuse include a related epidemic – that of pain which affects somewhere between 40-100 million adults with societal costs exceeding the combined costs of heart disease, cancer, and diabetes; it is also deeply rooted in the over prescription and overuse of oral opioids combined with ‘avaricious and illegal marketing of prescription oral opioids’ (Kharasch et al., 2022; Seltzer, 2020). An important aspect of the patterns of opioid abuse is related to trends in the initiation of heroin use where, according to the National Survey on Drug Use and Health, the heroin incidence rate was 19 times higher among those individuals who reported prior nonmedical pain reliever use. This survey also reported that 4 out of 5 heroin users report previous use of nonmedical prescription opioid pain relievers (Muhuri et al., 2013). There is evidence that the nonmedical use of prescription opioids in childhood and early
adolescence is strongly associated with transitions to heroin use in adolescence and young adulthood (Cerdá et al., 2015).

Related to these statistics is the licit and illicit increase in oxycodone use over the past few decades. Oxycodone prescriptions for the treatment of pain for conditions other than cancer increased by 588% between 1998 and 2007 (Kanouose and Compton, 2015; Manchikanti, 2007). As would be expected, there has been a concurrent increase in adverse events, including overdose and death. The number of visits to emergency departments related to oral use of opioids increased from 59 to 121 per 100,000 between 2004 and 2008, with a 123% increase attributed to hydrocodone and 152% attributed to oxycodone (Webster et al., 2011).

Oxycodone has been a major factor in these multifaceted issues. Even though oxycodone has been available for clinical use for over 100 years, and its clinical analgesic effects have been studied for some time, until relatively recently, there has been very little work on its basic preclinical pharmacology. Although the abuse of other opioid drugs such as fentanyl has been the focus of research and societal concern more recently, this review is intended to organize and provide a comprehensive review of the experimental research involving the pharmacology of oxycodone. It will review the key features of oxycodone, including its initial discovery, basic and clinical pharmacology, clinical and preclinical analgesia, early concerns identifying its abuse liability, and studies directed towards arriving at a clearer understanding of its excessive abuse. Several studies of the human behavioral pharmacology of oxycodone have been directed towards assessing its subjective effects in laboratory settings are covered in this review and represent important contributions, together with experiments using animal models of oxycodone drug self-administration to assess abuse liability and potential treatment approaches. Gender differences in the analgesic effects and abuse liability of oxycodone will also be covered. The review will conclude with studies probing available drugs for possible treatment approaches to oxycodone (i.e., ‘repurposing or repositioning’) and developments in the use of vaccines for OUDs, anticipating that these efforts will be beneficially applied to the misuse of other opioids. Finally, the review will briefly focus on recent developments in bitopic and biased opioid receptor modulators being pursued as alternative approaches to analgesics devoid of or with reduced abuse liabilities. It is hoped that this review of a pivotal drug spanning over 100 years with a
significant pharmacological and societal impact, will be informative and might also be beneficial in the evaluation of new opioids that may be considered for therapeutic use in the future.

C. History of Oxycodone

Oxycodone (Figure 1), a semisynthetic derivative of the opioid alkaloid thebaine, is a \( \mu \)-opioid receptor agonist synthesized in 1916 and introduced into clinical use in Germany in 1917 (Kalso, 2005). Although high doses of thebaine can produce convulsions and cannot be used therapeutically, it can be converted into a variety of opioids including, not only oxycodone, but also naloxone, buprenorphine and oxymorphone (Olkkola et al., 2013). Ironically, the effort at the time oxycodone was initially synthesized was to discover a potent opioid analgesic devoid of the dependence and abuse liability surrounding heroin that was marketed at the time as an analgesic (Sneader, 2005). Despite the original effort to develop an opioid analgesic devoid of abuse liability and dependence, oxycodone in its various dosage forms, shares the abuse liability of other \( \mu \) opioid agonists and reports of its abuse and addiction potential occurred shortly following its introduction in 1918 (see Eddy et al., 1957 for a detailed overview of early clinical studies of oxycodone). Reports of early studies conducted in Germany cautioned that the use of oxycodone should be restricted to the lowest adequate dose and administered for the shortest possible time. Additional studies cited by Eddy et al. (1957) describe other reports that determined the addiction liability of oxycodone to be at least as great as that of morphine.

Oxycodone became available for use in the U.S. in 1939, with formal approval by the FDA in 1991. Initially, oxycodone was only available as a combination product that included either salicylates or acetaminophen. In 1995 oxycodone became available in a sustained-release formulation and, in 1996, as an immediate release formulation and a single entity product. The sustained release formulation of oxycodone, OxyContin\textsuperscript{©}, has been used for the treatment of moderate to severe acute and postoperative pain, neuropathic pain, and cancer pain (Kalso, 2005; Moradi et al., 2012). By 2001, oxycodone was the best-selling narcotic pain reliever in the United States, with 2008 sales in the U.S. reaching approximately $2.5 billion. Despite its beneficial clinical applications, oxycodone became one of the most widely used drugs of abuse
in the U.S. Roughly between the years 1996 and 2016, the U.S. was responsible for approximately 73% of the world’s total consumption of oxycodone (Kinnunen et al., 2019). The illicit use of oxycodone has been reduced due to a number of restrictions on prescribing practices, heightened sensitivity to its widespread abuse and abuse potential, and the growth in the illicit use of other less costly and more readily available opioids, such as fentanyl.

D. Illicit Use and Abuse of Oxycodone

Although there is a perception that concerns surrounding oxycodone abuse emerged relatively recently, there were concerns as early as 1954 in France that, the 3-methyl congener of oxymorphone, also known as 14- dihydroxycodeinone or oxycodone (Murphree, 1962) ‘has proved to be particularly dangerous with regard to drug addiction … and that it seems to act more like heroin than like morphine’ (Vaille and Stern, 1954). In the U.S., the addiction potential of oxycodone was emphasized first in 1963 (Bloomquist, 1963) where the ‘habit forming potential’ was said to approach that of morphine, prompting a revision of the detail literature to state that oxycodone ‘may be habit forming’. The revised warning, was deemed unfortunate because oxycodone production increased in the U.S. from 9 kilograms in 1948-1950 to 569 kilograms in 1960, resulting in increased misuse and addiction of ‘numerous persons normally not associated with the illicit drug traffic’. Bloomquist (1963) also pointed out that oxycodone acquired the ‘unenviable status’ of being the principal choice as a substitute for individuals physically dependent on heroin in California, describing several cases of individuals with diverse occupations with ages from 15-85 that developed severe oxycodone misuse, abuse and dependence. Halpern and Bonica (1976) concluded that ‘we find the risk of addiction [to oxycodone] to be greater than that attributed to morphine … and do not recommend the use of oxycodone past the initial phases for the treatment of pain’. There were numerous additional concerns about the use and abuse of oxycodone that arose such that Sapienza wrote in 2003 that “all data point to a serious problem with the diversion and abuse of oxycodone … and to a very serious problem with OxyContin … “. An examination of theft data of controlled substances reported to the DEA showed that oxycodone thefts involving armed robberies and robberies of pharmacies in which suspects sought oxycodone or OxyContin occurred more than four times
more frequently than those involving the next most frequently encountered substance” (p 85; see also Young, 2001).

Approximately 60+ years later, following the initial warnings and concerns in the 1950’s and 1960’s, Remillard et al. (2019) published a manuscript entitled “Oxycodone’s unparalleled addictive potential: Is it time for a moratorium?” Remillard et al. conducted a survey of 86 study participants, all of whom were diagnosed with opioid use disorder or dependence. The study participants were stratified into two groups, one group who exclusively used non-heroin opioids enterally, and a second group who injected opioids, primarily heroin. Based on the results of the survey, and on the known pharmacology of oxycodone, Remillard et al. concluded that ‘oxycodone possesses pharmacologic qualities that render it disproportionally liable to abuse and addiction’ such that the risks outweigh the benefits. Oxycodone was rated the most desirable prescription opioid by 60% of the responders and by 75% of the drug-using peers. Remillard et al. (2019) also summarized the results of studies and surveys that provided evidence for oxycodone serving as the gateway drug to heroin. Other survey studies involving a much larger number of participants (896 in Katz et al., 2008; 1818 in Cicero et al., 2010) examined prescription opioid-dependent patients entering drug treatment programs. These studies, together with a larger study of 3,520 opioid-dependent patients (Cicero et al., 2013), uniformly concluded a higher use rate of oxycodone products (designated as ‘favorite’ and ‘most desirable’) with surprising preferences for oxycodone even over fentanyl (Katz et al, 2008) and heroin (Cicero et al., 2010, 2013). Although acknowledging certain limitations to data collected by surveys and self-reports, Remillard et al. concluded that their review of the literature supported the conclusion that ‘oxycodone is the most addictive and thus [is an] abuse-liable prescription opioid’, a conclusion also echoed by Wightman et al (2012) who reported that, based on extensive database searches (MEDLINE and EMBASE), oxycodone demonstrated an elevated abuse liability on the basis of its high likability scores and relative absence of negative subjective effects (see also Kibaly et al., 2021). This study also reported that patients with a history of drug misuse preferred oxycodone over other opioids, confirming results reported by Cicero et al. (2010), a conclusion supported further by several experimental laboratory studies of oxycodone in human heroin users, summarized later in this review, that have supported the results of these findings. The literature corroborated oxycodone’s place as the drug of choice for most
prescription opioid abusers. Zacny et al. (2003a, 2008) published a series of studies, described in more detail later in this review, with non-drug-abusing individuals that compared the ‘likeability’/abuse liability of oxycodone to other opioids that included hydrocodone, methadone and hydromorphone. The participants in these studies reported greater scores of subjective psychological reward (e.g., “dreamy,” “elated,” “high,” “sedated [calm, tranquil]”, drug liking and desiring it again) during estimated peak plasma oxycodone levels compared to the alternate opioids or to placebo. Interestingly, during trough levels of the drug, drug-liking and desiring it again were notably lower for oxycodone compared to morphine or hydrocodone. Although many of the subjective and pain-relieving effects of oxycodone were similar to those of other μ-opioid agonists, oxycodone produced stronger and different psychopharmacological effects. Among human heroin-dependent individuals, oxycodone was considered to be the ‘Rolls Royce’ of opioids (Comer et al., 2008).

E. Transition to heroin

As mentioned previously, oxycodone has been viewed to be the most addictive prescription opioid and has been considered as a primary gateway to heroin use (Remillard et al., 2019). In addition to the abuse liability of oxycodone, there are a number of reports documenting a relationship between illicit oral use of oxycodone or OxyContin, leading to dependency, followed by the transition to the initiation of heroin abuse (Carlson et al. 2016; Mars et al., 2013). The Mars et al. study documented pathways to heroin injections in Philadelphia and San Francisco between 2010 and 2012. In both cities, the majority of young heroin injectors began their drug-use trajectories with opioid pills, usually with oxycodone and acetaminophen, oxycodone or OxyContin before transitioning to heroin. Using the Ohio Substance Abuse Monitoring Network, Siegal et al. (2003) examined recently initiated heroin users where most of the subjects reported prior use of OxyContin before initiating heroin use. Although the sample was relatively small, subjects reported that they switched to heroin after developing tolerance to OxyContin, that heroin was more readily available and less expensive, and they believed that they would never have tried heroin had they not developed an addiction to OxyContin. Cerdá et al. (2015) in a sample of 223,534 respondents to a National Survey on Drug Use and Health...
reported that nonmedical use of prescription opioids in childhood and early adolescence is strongly associated with transitions to heroin use in adolescence and young adulthood. Those initiating non-medical use of opioids at ages 10-12 years had the highest risk of subsequently transitioning to heroin use and the conclusions were independent of race/ethnicity or income. These findings have prompted a number of studies comparing the effects of oxycodone exposure during adolescence and adulthood, and to the identification of genes that may be involved in some of these effects (see section IV.C. on Gene and Protein Expression Studies). Data collected by Dart et al. (2015) over a decade between 2003 and 2013 have shown a relationship between the introduction of the reformulated release abuse-deterrent version of OxyContin in 2010 and the dramatic rise in the rate of heroin use over the next three years. This finding was also reported earlier by Cicero et al. (2012) for the three-year period from 2009-2012, where it was demonstrated that there was no evidence that OxyContin abusers ceased their drug abuse as the result of the abuse-deterrent formulation, but rather shifted their drug of choice. Cicero et al. (2012) also point out that the newer formulation may actually have produced an unanticipated outcome, namely the shift to heroin which may pose a much greater public health risk than OxyContin, suggesting that abuse-deterrent formulations may not be the “magic bullets” for solving the growing problem of opioid abuse.

F. Pain, Oxycodone, and Abuse

During the first decade of 2000, the rate of opioid use for the relief of pain increased greatly (Kolodny et al., 2015). Maruta and Swanson (1981) had pointed out problems with the use of oxycodone in patients with chronic pain, stating that their clinical observations indicated that patients taking oxycodone have greater difficulty tapering off the medication than do patients taking other analgesics. From 1999 to 2011, the rate of opioid pain reliever use in the United States increased substantially, with the consumption of oxycodone increasing by nearly 500% (Jones, 2013). During this same time, opioid-related overdose death rates nearly quadrupled (Chen et al., 2014). In the early 2000’s a number of individuals noted the high consumption of opioids, particularly the controlled-release form of oxycodone (Cicero et al., 2005), along with an increase in oxycodone-related deaths in certain regions of the U.S. (Baker
Barrett et al., Oxycodone and Jenkins, 2008; Forrester, 2007), and in individuals seeking opioid detoxification from oxycodone (Sproule et al., 2009). In the Sproule et al. study, over the 4-year period from 2000-2004, the number of admissions related to controlled release oxycodone increased significantly from 3.8% to 55.4% of the total opioid admissions to the Centre for Addiction and Mental Health in Toronto, Ontario. The significant comorbid pain, psychiatric conditions, and other psychoactive substance use problems, coupled to the finding that prescriptions were an important source of opioids all contributed to the rise in controlled-release oxycodone abuse. Despite these early indications of potential abuse and overdose mortality with oxycodone, most studies of oxycodone prior to 2000 were predominantly clinical in nature along with studies examining its pharmacokinetics and pharmacodynamics. Detailed studies of the preclinical pharmacology of oxycodone did not fully emerge until the second decade of 2000.

II. Basic Pharmacology of Oxycodone

A. Receptor binding and Comparisons with Morphine

Although oxycodone and morphine share many pharmacological characteristics, with both being effective analgesics, oxycodone differs from morphine in a number of pharmacological, clinical and physiologically relevant aspects that will be described throughout subsequent sections of this review (Kiyatkin, 2019; Lemberg et al., 2006a,b, 2009; Nielsen et al., 2007; Olkkola et al., 2013). Pert and Snyder (1973) were the first to examine receptor binding affinities for morphine and oxycodone, using competition against [3H]naloxone, and reported ED_{50} (nM) values for morphine and oxycodone of 7 and 30,000 nM, respectively. Mu receptor binding of morphine and oxycodone were also examined by Chen et al. (1991) using [3H]DAMGO that, unlike naloxone, is highly specific for the μ-opioid receptor. In these experiments, the K_{i} (nM) for morphine was 1.2 and with oxycodone it was 47.4. Chen et al. (1991) also studied thebaine, from which oxycodone is derived, which had a K_{i} value of 636.2 nM. Generally, however, depending on the assay, the affinity of oxycodone for the μ-opioid receptor is between 5-40 times lower when compared with morphine (Chen et al., 1991; Lalovic et al., 2006; Olkkola et al., 2013). Studies comparing the receptor binding of oxycodone to other opioid receptors have demonstrated μ-opioid receptor specificity with lower Ki values for the δ-
opioid receptor (958 ± 499) and κ-opioid receptor (677 ± 326; the Ki (nM) of oxycodone was 18 ± 4 (Monory et al., 1999). In comparison, morphine has been reported to bind to the μ-opioid receptor with an affinity of 1.8 nM, with an affinity of 90 nM for the δ site, and 317 nM for the κ site (Robson et al., 1983). Some studies of oxycodone receptor binding have reported that the selectivity of μ over κ has been as much as 196 (Yoburn et al., 1995) compared to the selectivity ratio of 38 in the Monory et al. (1999) study. In general, and with some variation in the results that depend upon on the specific properties of the assays, oxycodone and morphine are relatively selective μ-opioid receptor agonists, both with lower affinities for the δ- and κ-opioid receptors, and with the potency of morphine higher than that of oxycodone at the μ-opioid receptor.

B. Role of Kappa and Delta Opioid Receptors in the Effects of Oxycodone

Despite the relatively low affinity of oxycodone at the κ- and δ-opioid receptors, there have been several experimental reports suggesting that the antinociceptive effects of oxycodone are mediated in part by these two other opioid receptors. Most of these suggestions appear to be related to the route of administration. For example, although both morphine and oxycodone produce potent antinociception when administered intramuscularly or intravenously, oxycodone and morphine differ in their effects when administered epidurally or intrathecally. Whereas oxycodone is not particularly effective when administered epidurally or intrathecally in humans, morphine has a powerful spinal analgesic effect (Kalso, 2005; Pöyhiä and Kalso, 1992).

An early study that examined the effects of intracerebroventricular (i.c.v.) administration of oxycodone reported that the antinociceptive effect of oxycodone, assessed by tail-flick latency to radiant heat, was blocked by the administration of naloxone indicating that the analgesic effects were opioid mediated (Leow and Smith, 1994). However, because the reported affinity of oxycodone (K_i = 47.4 nM) for the μ-opioid receptors in the brain was significantly lower than that reported for morphine (K_i = 1.2 nM), Leow and Smith suggested that other opioid receptor subtypes may be involved in the antinociceptive effects of oxycodone. A subsequent study using more selective antagonists than naloxone reported that the analgesic effects of i.c.v. oxycodone were completely attenuated by the κ-selective opioid antagonist norbinaltorphimine (nor-BNI), whereas the selective μ or δ opioid receptor antagonists naloxonazine and naltrindole,
respectively, were without effect (Ross and Smith, 1997). Importantly, nor-BNI did not prevent antinociception produced by i.c.v. morphine. This group of investigators also compared the onset of nociception produced by i.c.v. oxycodone and morphine and showed that the onset of nociception by oxycodone was approximately 5-7 minutes, whereas that of morphine was approximately 30-40 minutes (Leow and Smith, 1994; Ross and Smith, 1997). Additional studies comparing the antinociceptive onset of several κ-opioid agonists such as U68,593, U50,488H and bremazocine, all produced a rapid onset similar to that of oxycodone, lending further support to the view that analgesia produced by i.c.v. oxycodone is mediated through interactions with the κ-opioid receptor. These investigators concluded that their findings support the concept that oxycodone and morphine produce antinociception through distinctly different opioid receptor populations and that oxycodone seems to act as a κ-opioid agonist with a relatively low affinity for the μ-opioid receptor. In contrast to this perspective, Lemberg et al. (2007) have stated unequivocally that oxycodone is a μ-opioid receptor agonist and not a κ-opioid receptor agonist, suggesting that the low intrathecal potency of oxycodone is related to its low efficacy and potency to stimulate intracellular G protein activation of the μ–opioid receptor in the spinal cord. Lemberg et al. (2007) conclude that the key to understanding these differences may lie in the complex pharmacology of the CNS G protein receptors, a statement with foresight considering how the field of G protein-coupled opioid receptors has evolved over the past 15 years since (Wang et al., 2023).

The conclusion that the activity of oxycodone is mediated by actions at the κ-opioid receptor is tempered further by several other studies. Aceto et al. (2002) showed that the antinociceptive activity of oxycodone, administered s.c, in the tail flick assay, was antagonized by β-Funaltrexamine (β-FNA), a μ-selective opioid receptor antagonist. However, this group did not find that oxycodone had κ-opioid properties since the κ-opioid receptor antagonist nor-BNI was ineffective against the antinociception produced by oxycodone, as was naltrindole, the δ opioid receptor antagonist. Similar conclusions noting a lack of κ-opioid receptor activity were reported by Beardsley et al. (2004), showing that the selective μ-opioid antagonist β-FNA, but not the κ-opioid receptor antagonist nor-BNI or the δ-opioid receptor antagonist, naltrindole blocked the antinociceptive effects of oxycodone when administered s.c. in mice in the tail-flick test. The analgesic effects of oxycodone in squirrel monkeys were examined using the warm
water tail withdrawal procedure (Withey et al., 2018). Oxycodone produced antinociceptive effects, as did heroin, buprenorphine and methadone. When the antinociceptive and behaviorally disruptive effects of oxycodone and buprenorphine were characterized using Schild plots to calculate the apparent pA2 values for the antagonism by naltrexone, the results suggested that μ-opioid receptor mechanisms were likely mediating both the antinociceptive and behaviorally disruptive effects of these drugs. Several other studies have shown that withdrawal from morphine is not suppressed by κ-opioid receptor agonists, nor does morphine completely suppress signs of κ-opioid receptor mediated dependence (Fukagawa et al., 1989; Gmerek and Woods, 1986). Additionally, oxycodone has been shown to substitute for morphine, completely suppressing signs of morphine withdrawal in rhesus monkeys, a finding suggesting that oxycodone produces μ-opioid dependence and μ-opioid selectivity (Beardsley et al., 2004).

Studies described later in this review using drug self-administration and drug discrimination procedures to assess abuse liability and subjective effects, show that, in contrast to oxycodone, κ-opioid receptor agonists are not self-administered, nor do they substitute in drug discrimination studies when the training drug is a μ-opioid receptor agonist.

Just as there have been suggestions for an involvement of the kappa opioid receptor in mediating the actions of oxycodone, there have also been suggestions that the delta opioid receptor contributes to the analgesic effect produced by oxycodone (Yang et al. 2016). Using μ receptor knockout mice, Yang et al. found that high doses of oxycodone (40 mg/kg, s.c.) resulted in a small but significant antinociceptive effect as measured by the tail flick response. The δ-opioid receptor antagonist naltrindole blocked this effect suggesting a role for this receptor in mediating the antinociceptive effects of oxycodone. Further, administration of oxycodone i.c.v. to the μ-opioid receptor knockout mice produced comparable levels of antinociception to that found in wild type mice and these effects were also blocked by i.c.v. naltrindole. Yang et al. (2016) concluded that both mu and delta receptors contribute to the central antinociceptive effects of oxycodone. The authors recognized that these findings differed from those found in the Ross and Smith (1997) study that did not observe an antagonism of oxycodone’s analgesic effect when naltrindole was administered. Yang et al. (2016) comment that the reasons for the differences in the two studies may be due to different experimental conditions, drug doses, the species of animals, and the possible formation of
mu/delta receptor complexes, all of which require further investigation. In a subsequent set of experiments, Yang and colleagues reported that naltrindole, administered i.p., did not affect the antinociceptive efficacy of oxycodone (s.c.) in the tail flick test, nor did it block the respiratory depression produced by oxycodone. However, naltrindole did attenuate the tolerance and withdrawal induced by chronic oxycodone administration. In addition, using the CPP method of assessing potential abuse liability of drugs, naltrindole (i.p.) attenuated the development of preference for the oxycodone-related chamber and also attenuated re-instatement following a period of extinction. These effects were also obtained with the delta receptor antagonist ICI 154,129 administered i.c.v. Finally, the decrease in intestinal transit, or constipating effects of oxycodone, were also reduced by naltrindole (Yang et al., 2019). Yang et al. (2019) suggested that a combination of naltrindole and oxycodone may be a potent analgesic with reduced side effects of addiction liability and constipation. In keeping with the disparity in findings related to the antinociceptive and other effects of oxycodone, these findings by Yang et al. stand in contrast to those of Bossert et al. (2019) who, in a study of oxycodone self-administration and context-induced oxycodone reinstatement, found that naltrexone, a μ-opioid receptor antagonist, decreased reinstatement and oxycodone self-administration, but neither naltrindole, a δ−opioid receptor antagonist, nor LY2456302, a κ−opioid receptor antagonist affected these two indices of oxycodone abuse liability. Bossert et al. concluded that μ-opioid receptors but not κ and δ receptors, are involved in oxycodone’s reinforcing effects and relapse.

A series of experiments that bears on the question of the relative role of μ-, κ- and δ−opioid receptors involvement in oxycodone’s pharmacological effects comes from research using BOLD (Blood Oxygen Level Dependent) imaging in awake wild-type and μ-opioid receptor knock-out mice (Moore et al., 2016). Using this technology with the wild-type and the knock-out mice, provided an opportunity to evaluate the response to oxycodone, administered i.p., and to compare the BOLD signal change in 122 areas of the brain relevant to the different opioid receptors. Following the administration of 2.5 mg/kg oxycodone, BOLD activation was detected in 72 regions with the activation most prominent in areas of high μ-opioid receptor density. Oxycodone-induced positive BOLD activation was eliminated in most brain regions in the μ-opioid receptor knock-out mice except in some regions where receptor expression is low or absent in the wild-type mice. Although most of the changes in BOLD by oxycodone indicate that
the effects are mediated through the μ-opioid receptor, Moore et al. point out that ‘off target’ effects of oxycodone in the knock-out mice may suggest that those effects are mediated by κ- and δ- opioid receptors. While Moore et al. comment that the data from their study does not contest the findings by others (e.g., Ross and Smith, 1997) for a role of κ-opioid receptors in oxycodone’s pharmacological effects, they do point out that since there are no μ- and δ- opioid receptors in the cerebellum, there are κ-opioid receptors that are activated by oxycodone in the knock-out mice suggesting a possible interaction with the κ receptor and the conclusion that future studies using BOLD imaging should address the effects of oxycodone in κ-opioid receptor knock out mice.

Taken collectively, the majority of the several studies that have examined the role of the three opioid receptors in mediating the antinociceptive and other pharmacological effects of oxycodone provide strong support that the predominant pharmacological activity of parenterally administered oxycodone is related to its actions at μ-opioid receptors and that some of the ambiguity in the discrepant results involving κ- or δ-opioid receptors may be related to the route of administration, to the species, or to a significant role for the metabolites of oxycodone (Aceto et al., 2002; Lemberg et al. 2006, 2007; see also Zacny and Gutierrez, 2003).

C. Respiratory Depression

Respiratory depression is a leading cause of death due to opioid overdose and continues to be a serious public health concern (Montandon, 2022). Early assessment of respiratory depression is undoubtedly one of the key criteria for assessing the safety of new analgesic compounds particularly those that interact with μ-opioid receptors. Hill and Canals (2022) have provided a number of experimental considerations critical for the assessment of in vivo and in vitro opioids to evaluate their pharmacological activity and to address many of the issues surrounding the analysis of candidate opioids and their transition to further clinical development.

The leading cause of death related to opioid overdose is hypoxia caused by opioid-induced respiratory depression (White and Irvine, 1999). The μ-opioid receptor is expressed
throughout the brainstem where μ-opioid receptor agonists reduce respiratory drive and the responsiveness of the respiratory centers to increased CO₂, such that minute ventilation increases that would normally be triggered by hypercapnia are depressed. Webster et al. (2020) point out that there is no standard definition of respiratory depression and that, generally, it refers to a failure to maintain normal pulmonary exchange of CO₂ and O₂. With respiratory depression there is an inadequate response to hypercapnia or hypoxia resulting in increased CO₂ and/or decreased O₂ blood levels (see Bateman et al., 2023 for a review on understanding and countering opioid-induced respiratory depression).

1. Human Studies: Several studies in humans have examined the effect of oxycodone on various measures of respiration. One of the earlier studies (Tarkkila, et al. 1997) compared the respiratory effects of i.v. tramadol and oxycodone in a placebo-controlled, double-blind study. Tramadol, an opioid with low affinity for the μ-opioid receptor, is also a serotonin and norepinephrine reuptake inhibitor. Whereas a tramadol dose of 0.6 mg/kg had no effect on respiratory depression that differed from placebo, oxycodone, given at a dose of 0.04 mg/kg, produced significant respiratory depression that was observed as an increase in the inspiratory-expiratory oxygen difference and in end-tidal CO₂ concentrations as well as in respiratory rate. Comparable effects were also obtained in an exploratory study that compared equianalgesic doses of oxycodone with tapentadol, also a μ opioid receptor agonist and noradrenalin reuptake inhibitor and found an advantage of tapentadol over oxycodone on respiratory depression (van der Schrier et al., 2017). Leino et al. (1999) studied time course changes in breathing patterns and compared morphine (35.1 mg) with oxycodone (41.3 mg), given in incremental i.v. doses, by examining pulse oximetry and plethysmography to measure breathing patterns. Four of the planned oxycodone infusions had to be stopped because of respiratory depression as determined by pulse oximetry; none of the morphine infusions had to be terminated. The investigators suggested that the more profound changes with oxycodone were most likely due to dosing, where 1 mg of oxycodone is equivalent to 0.78 mg of morphine, not necessarily the different actions of the two drugs. Chang et al. (2010) added to the differences in the effects of morphine and oxycodone on respiration in a randomized double blind, placebo-controlled study in patients undergoing elective surgery. Although patients receiving either morphine (0.1 mg/kg) or oxycodone (0.05, 0.1 or 0.2 mg/kg) i.v. demonstrated significant respiratory depression, as
measured by changes in minute volume relative to placebo, the mean reduction from baseline was approximately 23% for the morphine group and 53% for the oxycodone group, with dose dependent increases up to 89% for oxycodone. All three doses of oxycodone produced statistically significant respiratory depression and several patients in the oxycodone group, even at the lowest dose, required naloxone administration when, if at any point during the first 10 minutes after the study medication was administered, the respiratory rate decreased by ≥ 33% and/or the end-expiratory CO2 had risen by ≥ 1.5 kPa. The speed and extent of oxycodone-induced respiratory depression was greater for oxycodone than for an equivalent dose of morphine.

Webster et al. (2020) studied the effects of 30 and 60 mg of orally administered oxycodone in 19 men and women ages, 27 to 41 years of age, who were recreational opioid users as determined by a naloxone challenge. Respiratory drive was assessed by measuring the ventilatory response to hypercapnia (VRH - excessive CO2 in the bloodstream caused by inadequate respiration) and by assessing the maximum decrease in minute ventilation after drug treatment. Compared to placebo, and with several doses of buprenorphine administered as a buccal film, the 60 mg dose of oxycodone produced a significant decrease in respiratory drive, whereas respiratory drive was not affected at any dose of buprenorphine. In a follow up to this report, Webster et al. (2022) conducted a proof-of-concept study to evaluate whether it was possible to predict the relative risk of oxycodone’s potential to produce respiratory depression by measuring VRH. A focus of the study was to determine whether this method, incorporating end-tidal CO2 and minute ventilation, could serve to predict the relative effect of a drug on respiratory depression, a result that might have widespread utility. Using the 30 mg dose of oxycodone that did not produce respiratory depression in their previous study, Webster et al. (2022) found that this dose of oxycodone produced a significant reduction in minute volume and also reduced the slope of the ratio of minute volume to end tidal volume at the Cmax of oxycodone. The authors conclude that this method might have clinical utility and be advantageous in assessing drugs in development that are at risk for producing respiratory depression, for informing clinicians for improved decision making, and for stratifying drugs on the basis of their relative effects on respiratory depression.
2. Animal Studies: An extensive study in male Sprague-Dawley rats examined the in vivo profile of several opioids (morphine, morphine-6-glucuronide, fentanyl, oxycodone, buprenorphine, [D-penicillamine$_{2,5}$]-enkephalin (DPDPE), a selective δ-opioid receptor agonist, and the κ-opioid receptor agonist U69,593), all administered i.c.v., for their effects on antinociception, constipation and respiratory depression (Kuo et al., 2015). No two compounds had the same profile across these conditions suggesting that the effects are regulated differentially. With regard to the effects of the different drugs on respiratory depression, the profile and potency rank of oxycodone were similar to that of fentanyl with a rapid onset and with peak effects at 15 min following administration of the drug. The administration of morphine, oxycodone and fentanyl produced dose-dependent antinociception in the warm water tail withdrawal procedure and were full agonists. The results from these studies with morphine, oxycodone, fentanyl and buprenorphine are summarized for antinociception, constipation and respiratory depression in Table 1 for the ED$_{50}$ values and in Table 2 for the rank order of potencies in each assay. Kuo et al. suggested that for constipation and respiratory depression, oxycodone appeared to be a partial agonist at the μ opioid receptor based on the ceiling effects of the drug in these two assays. Kuo et al. concluded that the different pharmacokinetic profiles of these opioids suggest that it might be possible to discover potent analgesics with markedly improved adverse event profiles.

Kiyatkin (2019) compared the effects of morphine, oxycodone, fentanyl and heroin on respiratory depression and brain hypoxia in rats. Brain oxygen recordings were measured using oxygen sensors coupled with fixed-potential high speed amperometry surgically implanted in the NAc or into subcutaneous space in the medio-frontal area of the rat’s head, an area densely vascularized and an area with little or no metabolism. The latter measurements permit a surrogate for changes in systemic blood oxygen levels, a parameter directly related to respiratory activity. The animals were also prepared with intravenous catheters that permitted drug infusions. Heroin and fentanyl produced a rapid and strong dose-related decrease in NAc oxygen levels within the first 3-4 minutes following administration of the drug. Measurements
of oxygen in the subcutaneous space showed significant decreases in respiratory depression that lasted much longer, up to 60 minutes, at the 100 μg/kg dose of heroin and for approximately 40 minutes for fentanyl at 40 μg/kg. In contrast to these effects with heroin and fentanyl, low to moderate doses of oxycodone that maintain drug self-administration (0.3 and 0.6 mg/kg) actually increased NAc oxygen levels and, at the highest dose of 1.2 mg/kg, there was a short transient decrease followed by an increase in oxygen levels in the NAc. Based on these observations, oxycodone was approximately 6 times less potent than heroin and approximately 60-120-fold weaker than fentanyl in producing brain hypoxia. Morphine at 1.6 mg/kg also increased oxygen levels in the NAc and, at 6.4 mg/kg, there was a protracted 2 hr decrease followed by a gradual rise to that which exceeded baseline at approximately 2.5 hr. When morphine was compared to oxycodone, the time to maximum decrease in oxygen and the duration of the decrease was substantially higher than that of oxycodone, as well as that of fentanyl and heroin. Clearly, there are temporal differences in NAc oxygen levels following morphine and oxycodone suggesting that the increases in blood oxygen levels produced by oxycodone could be related to increased cerebral blood flow and vasodilation (Kiyatkin, 2019).

3. Polydrug use and Respiratory Depression: Hill et al. (2018) demonstrated that tolerance developed to the respiratory depressant effects of prolonged oxycodone administration and that cross tolerance also occurred to morphine. Of interest, and a concern surrounding polydrug use, tolerance to repeated administration of oxycodone was reversed by low-dose ethanol, pregabalin, and by calphostin C, a brain-penetrant inhibitor of protein kinase C (PKC). In keeping with this finding, Gonek et al. (2017) had reported that the benzodiazepine diazepam reversed the development of antinociceptive tolerance and, although the effects on respiratory depression were not studied, diazepam did reverse the tolerance to oxycodone on locomotor behavior. The respiratory depression produced by oxycodone was reversed by naloxone but not altered significantly by the δ receptor antagonist naltrindole or by the κ receptor antagonist nor-BNI, suggesting specific μ-opioid receptor mediated effects.

There has been heightened awareness of serious risks and deaths when combining opioids with benzodiazepines, with the FDA in 2016 issuing a strong boxed warning to the labeling of opioids and benzodiazepines (https://www.fda.gov/Drugs/DrugSafety/ucm518473.htm). The National Institute on Drug Abuse has reported that in 2020 the co-usage of opioids with
benzodiazepines or antidepressants resulted in over 12,290 and 5,597 overdose deaths, respectively (https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates). In an effort to further evaluate drug interactions of oxycodone with diazepam on respiratory depression, and to set the stage for a broader analysis of opioid – drug interactions, Xu et al. (2020) developed a rat model that measured increases in arterial partial pressure of oxygen and carbon dioxide (pCO₂) to detect changes in respiratory depression. These measures are commonly used clinically to reflect respiratory function where drug-associated increases in resting arterial pCO₂ suggest that the normal ventilatory response to compensate for increased CO₂ is blunted. Studies were conducted with diazepam doses of 2, 20 and 200 mg/kg and with oxycodone doses of 6.75, 60, 150 mg/kg, with all doses and dose combinations given orally. Oxycodone produced a dose-dependent decrease in arterial partial pressure of oxygen and an increase in arterial partial pressure of carbon dioxide, both effects consistent with respiratory depression. Diazepam produced similar partial pressure changes only at the highest dose. When rats were co-administered 150 mg/kg of oxycodone, which produced significant respiratory depression, together with 20 mg/kg of diazepam, which had no effect on respiratory depression, decreases in arterial partial pressure of oxygen and increases in arterial partial pressure of carbon dioxide occurred that were consistent with an exacerbation of respiratory depression produced by oxycodone alone. Further, the potentiation of respiratory depression by diazepam and oxycodone was seen also in PK/PD analyses where the C_max of oxycodone was 100% higher than that of animals administered oxycodone alone. This study could set a precedent and provide an experimental model to further pursue other psychotherapeutic drugs that, in combination with opioids, might interact in a similar manner as was obtained with diazepam and oxycodone. Although the Xu et al. (2020) study used a dose of oxycodone that alone produced respiratory depression, it would be important to have dose interactions with oxycodone and diazepam where the oxycodone dose does not produce respiratory depression and where there is tolerance following chronic administration to the effects of oxycodone on respiratory depression prior to administration of the other drugs.

A follow up study by Xu et al. (2021) compared the effects of several psychotrophic drugs in combination with oxycodone on respiratory depression, also in the Sprague-Dawley rat. These drugs cover a spectrum of conditions and mechanisms that are summarized in Table 3. As
in their previous study, oxycodone was given at a dose of 150 mg/kg and administered orally with one dose of the other drugs. The selection of the dose that was given in combination with oxycodone was determined after evaluating blood concentrations of three doses of each drug and also using drug effects on pCO₂ and pO₂. The doses were selected based on the human dose equivalent according to the FDA conversion guidance, drug concentrations in previous studies with rats, and the recorded lethal dose of 50% of rats when this information was available. Thus, for each drug, the low dose was determined as the human dose equivalent, with the middle dose being equivalent to the non-toxic literature concentrations, and the high dose was below the LD₅₀ to avoid severe toxicity. The PD analysis of pCO₂ and pO₂ of each drug, together with the PK parameters were used in determining dose and scheduling of the combination experiments. With the exception of topiramate, the middle dose was selected for all drugs given in combination with oxycodone. The low dose was used for topiramate due to the finding that it had no PD effect, whereas the middle and high doses decreased pCO₂. Significant increases from baseline in resting arterial pCO₂ occurred at all three doses with carisoprodol, duloxetine and paroxetine. Paroxetine, administered alone, resulted in increases in pCO₂, whereas none of the doses of quetiapine administered without oxycodone produced any change in pCO₂ at any of the doses tested.

At clinically relevant exposures, paroxetine, trazodone, and quetiapine administered with oxycodone resulted in significant increases in resting arterial pCO₂ that were above the effects of oxycodone alone. When co-administered with oxycodone, the increases in pCO₂ for paroxetine and quetiapine were correlated with the increased Cₘₐₓ and AUC exposure to oxycodone. These findings indicate that the interactions between opioids and non-opioid drugs can exacerbate respiratory depression and that these effects were mostly due to pharmacokinetic interactions that resulted in large increases in exposure to oxycodone.

An experimental focus on drug interactions with oxycodone also requires that these interactions are examined under conditions where oxycodone and other μ-opioid receptor agonists are administered chronically to more closely parallel typical usage in pain management.
and under conditions of OUDs. Although not focused on respiratory depression, Lawson et al. (2023) investigated oxycodone-benzodiazepine interactions following acute and chronic administration of oxycodone using ex vivo, in vivo and in silico techniques. These studies examined the possible pharmacodynamic interactions between oxycodone and benzodiazepines when oxycodone was administered acutely and chronically for 15 days. Acute co-administration of oxycodone, the benzodiazepines diazepam, and diclazepam to mice inhibited the metabolism of oxycodone, resulting in higher levels than those reached with oxycodone alone. When diclazepam was administered to mice that had been chronically treated with oxycodone for 15 days, the levels of oxymorphone, a toxic metabolite, were dramatically increased. In vitro studies conducted suggested that, whereas acute combinations of these drugs produce oxycodone accumulation, benzodiazepines administered following chronic oxycodone exposure, produce metabolic interactions that inhibit oxycodone metabolism through CYP3A4 which is diverted towards CYP2D6. Thus, the overdoses and toxicity associated with oxycodone and benzodiazepine combinations are related to the usage patterns, i.e., whether the use of oxycodone is acute or more chronic. The early finding mentioned earlier in this review by Tatum et al. (1929) suggesting that an overdose of morphine during convulsions prevented the progression to respiratory arrest and mortality remains somewhat of an enigma considering the several studies that have been conducted since that initial observation.

D. Tolerance and Cross Tolerance

In preclinical studies of tolerance and cross tolerance, oxycodone has demonstrated many of the same effects observed with other μ-opioid receptor agonists. Tolerance developed to the antinociceptive effects of oxycodone in the complete Freund’s adjuvant (CFA) and chronic constriction injury (CCI) models of inflammatory and neuropathic pain, respectfully, following twice-daily administration of oxycodone for 7 days in Sprague-Dawley rats (Thorn et al., 2017). For those rats in the CFA condition, the administration of repeated oxycodone produced an approximate 16-fold rightward shift in the dose response curve, whereas for the CCI group, this shift was approximately 15-fold. Lilius et al. (2018) studied the development of tolerance to morphine (9.6 mg/day) or oxycodone (3.6 mg/day) administered for 6 days through subcutaneous minipumps to Sprague-Dawley rats. Tolerance developed to the antinociceptive
effects of morphine and oxycodone using the hot plate. Acute administration of ketamine (10 mg/kg) and norketamine (30 mg/kg) attenuated the tolerance to both morphine and oxycodone, although the effect was of shorter duration in the oxycodone-treated animals. These investigators also found that ketamine and norketamine increased the brain concentrations of morphine but did not alter brain concentrations of oxycodone, suggesting that the differences may be due to the inhibition of morphine metabolism by ketamine and norketamine.

In a study that examined the role of βarrestin2 on opioid tolerance, Raehal and Bohn (2011) reported that although βarrestin2 knockout mice did not develop tolerance to the antinociceptive effects of chronic morphine in the hot place assay, tolerance did develop to chronic oxycodone, fentanyl and methadone. These findings suggested that different μ-opioid agonists can produce different effects on antinociceptive responses mediated by opioid receptors in a βarrestin2 dependent manner. In a subsequent study from this laboratory Schmid et al. (2017) evaluated morphine, oxycodone and a biased μ-opioid receptor agonist, SR-17018, for tolerance development and for efficacy in the hot plate assay. In cellular assays SR-17018 preferentially stimulates GTPγS binding over the recruitment of βarrestin2, demonstrating pathway signaling bias. In the hot plate assay, SR-17018 produced analgesia with potencies comparable to those of morphine but with less respiratory depression. SR-17018 did not produce tolerance to the antinociceptive effects, whereas morphine did. Pantouli et al. (2021) continued this line of investigation and examined the effects of acute and repeated dosing of morphine, oxycodone and SR-17018 in several pain models that included the mouse warm water tail immersion assay, the formalin inflammatory pain model, and a chemotherapeutic-induced neuropathic pain (CINP) model induced by paclitaxel. In the warm water tail immersion procedure, all three compounds produced tolerance when administered repeatedly. However, whereas tolerance did develop to oxycodone in the formalin model, tolerance did not develop to repeated administration of SR-17018 in the formalin or CINP procedures. These findings suggest that it may be possible to develop biased μ-opioid receptor agonists that are devoid of some of the unwanted effects of opioid agonists. Clearly, an effective opioid analgesic lacking respiratory depression, tolerance and abuse liability would be a significant advance in the pharmacological management of pain (see also Section X in this review for an elaboration of this view).
Other studies, conducted earlier, examined the possibility of differential profiles between oxycodone and morphine in their effects on tolerance and cross tolerance (Nielsen et al., 2000). The Dark Agouti rat was used in these studies because this rat is genetically deficient in the CYP2D1 enzyme that catalyzes the O-demethylation of oxycodone to oxymorphone, a potent μ-opioid agonist (Cleary et al., 1994). This rat strain is therefore more appropriate to examine the potential relevance to humans because the O-demethylation of oxycodone to oxymorphone, undergoes glucuronidation to oxymorphone-3-glucuronide and accounts for less than 5% of an oxycodone dose in humans (Pöyhä et al., 1992). Rats were administered equi-antinociceptive doses of oxycodone (2.5 or 5.0 mg) or morphine (10 mg or 20 mg) intravenously over a 24 to 84-hour period to produce tolerance to the tail-flick response. Subsequently, when drug-naïve rats and rats that were tolerant to morphine-induced antinociceptive effects were administered bolus i.c.v. injections of oxycodone, the ED$_{50}$ values of oxycodone on the tail-flick response in the drug-naïve and morphine-tolerant rats were comparable, suggesting an absence of cross-tolerance between supraspinally administered oxycodone and i.v. morphine. However, when i.c.v. morphine was administered to oxycodone-tolerant rats, there was a high degree of cross tolerance. Similarly, there was no indication of cross tolerance between morphine and oxycodone when i.v. doses of oxycodone were administered to morphine tolerant rats. Following the administration of i.c.v. morphine, the dose-response curves of both oxycodone- and morphine-tolerant rats were shifted to the right of the naïve rats, indicating cross tolerance to i.c.v. morphine in rats made tolerant to i.v. oxycodone. Although the rightward shift in the dose-response curve for the oxycodone tolerant rats administered i.v. morphine was not as great as that of the morphine tolerant rats administered i.v. morphine, this result does suggest evidence of a degree of cross tolerance to oxycodone in rats tolerant to morphine when the same route of administration is used to develop tolerance and assess cross tolerance.

Thus, in summary, when rats developed tolerance to the antinociceptive effects of i.v. morphine, neither i.c.v. or i.v. administration of oxycodone produced evidence of cross tolerance. However, following the development of tolerance to oxycodone, there was cross tolerance to morphine following both i.c.v. and, to a lesser extent, i.v. routes of morphine administration. Nielsen et al. (2000) posited the view that the asymmetric cross-tolerance between oxycodone and morphine suggested that, following chronic i.v. administration,
oxycodone is metabolized to a μ-opioid agonist metabolite which is then responsible for the substantial tolerance developed to i.c.v. morphine. However, following the development of tolerance to i.v. morphine, the administration of i.c.v. oxycodone, where metabolism is negligible, resulted in a lack of cross tolerance. The explanation provided by Nielsen et al. (2000) does not appear to take into consideration that cross tolerance to i.v. morphine was observed in rats tolerant to i.v. oxycodone, as evidenced by the right-ward shift of the morphine dose-response curve in the oxycodone tolerant rats away from the naïve animals. These authors conclude that after parenteral but not supraspinal administration, oxycodone is metabolized to a μ-opioid agonist metabolite, thereby accounting for the asymmetric and incomplete cross-tolerance between oxycodone and morphine. Finally, the authors conclude that these results support their view that the antinocicptive effects of oxycodone and morphine are mediated through different opioid receptor populations, a theme that occurs in a number of studies reviewed previously. However, it seems appropriate to conclude that there is cross tolerance between morphine and oxycodone when the same route of administration is used.

E. Dependence and Withdrawal

Preclinical studies of physical dependence and withdrawal produced by oxycodone have, as in experiments on tolerance and cross tolerance, demonstrated many of the same effects observed with other μ-opioid receptor agonists (Carper et al., 2021). An early study demonstrated that rhesus monkeys given increasing intragastric doses of oxycodone up to 80 mg/kg every 12 hours over a 20-day period, showed signs of physical dependence that when challenged with naloxone, precipitated withdrawal (Swain et al., 1977). A number of studies have examined oxycodone-induced dependence and withdrawal, mainly in mice, although in a study using rhesus monkeys, oxycodone produced a dose-dependent suppression of withdrawal signs following the discontinuation of morphine (Beardsley et al., 2004). In a series of studies that examined physical dependence of oxycodone, Enga et al. (2016) administered increasing doses of oxycodone from 9.0-33.0 mg/kg, s.c. over 9 days and then administered increasing doses of naloxone from 0.1 – 10.0 mg/kg, s.c. Naloxone administration produced dose-dependent increases in several somatic signs of withdrawal that included paw tremors, jumps, and increases in body weight, similar to those seen with morphine in other studies. A second
feature of this study included oral self-administration of oxycodone, developed using an operant conditioning procedure, that initially involved post-prandial consumption of water that was followed by switching water availability to increasing doses of oxycodone. The sequence of steps ended with a period whereby the post-prandial feature was discontinued but oxycodone remained available by responding under a fixed ratio 4-response schedule of lever pressing. As the concentration of oxycodone was increased, the estimated consumption of oxycodone increased and opioid-like behavioral signs were observed that consisted of Straub tail and hyperlocomotion at the higher concentrations of oxycodone. When the prandial procedure was discontinued and oxycodone remained available, the mice continued to lever press to obtain oxycodone, suggesting oxycodone was serving as a reinforcer and that the procedure could be used to develop dependence.

Carper et al. (2021) induced dependence on oxycodone using an incremental dose regimen of s.c. oxycodone for eight days, reaching a final dose of 33 mg/kg on day nine that was followed by the administration of naloxone 1.0 mg/kg 6 hr after the final dose of oxycodone. Both precipitated and spontaneous withdrawal (no naloxone) resulted in jumping, paw tremors and decreases in body weight, with these measures greater and more intense in the naloxone precipitated withdrawal animals at 6 hr, whereas more withdrawal signs were seen at 24 hr in those mice that underwent spontaneous withdrawal. These studies provide evidence that chronic administration of oxycodone produces tolerance, dependence and withdrawal that is not distinctive from that of morphine. Following the suggestions obtained thus far with compounds possessing selective signaling properties, it may ultimately be possible to identify and develop efficacious μ-opioid receptor agonists that do not produce tolerance and which, therefore, should not produce dependence as well.

F. Pharmacodynamic and Pharmacokinetic Effects

As pointed out in an updated review of the clinical pharmacokinetics and pharmacodynamics of oxycodone by Kinnunen et al. (2019), although oxycodone has a lengthy history of clinical use, since most studies were conducted in the 1990s, it is without a detailed knowledge of its PK. A major difference between morphine and oxycodone recognized quite early, is that oxycodone has much better oral bioavailability, with the bioavailability of oxycodone between 60-87%, whereas with morphine it is only 19-30% (Pöyhiä et al, 1993).
Oxycodone is relatively well-absorbed following oral administration, with approximately 40% of oxycodone bound to plasma proteins in vitro, results that are similar to those of morphine (Lemberg et al., 2009). The half-life of oxycodone administered i.v. is approximately 2-3 hr, whereas when administered i.m. it is approximately 5 hr and following oral administration is between 3-5 hours with the extended-release form roughly 8 hr (Umukoro et al., 2021). The volume of distribution at steady state was 2-5 L/kg in adults, which is also comparable to that of morphine (Olkkola et al., 2013). In healthy female volunteers, the clearance of oxycodone on a weight-adjusted basis was found to be 25% slower than in men (Kaiko et al., 1996).

Oxycodone is primarily metabolized via CYP3A4/3A5 and to a lesser extent via CYP2D6. Women metabolize oxycodone faster than men and women also have higher metabolite levels when compared to men; exposure is greatly increased in the elderly with patients over 70 years of age having 50-80% higher exposure to oxycodone (Liukas et al., 2008; Umukoro et al., 2021). The predominant metabolic pathways in a variety of species, including humans, involve oxidation to oxymorphone and noroxycodone, conjugation to α-D-glucuronic acid and conversion to 6-oxycodol. O-demethylation by CYPD6 leads to the formation of the main active metabolite, oxymorphone (Cone et al., 1983; Ishida et al., 1982). It appears that noroxycodone and noroxymorphone are not able to significantly affect the analgesic properties of oxycodone (Lemberg et al., 2006; 2008). In clinical studies, when administered orally, intramuscular, or intravenously, oxycodone produces pain relief similar to that of other μ-opioid receptor agonists (Pöyhä and Kaiko, 1991, 1992b). However, as mentioned previously, oxycodone and morphine differ in their effects when administered epidurally; whereas oxycodone is not particularly effective, morphine has a powerful spinal analgesic effect (Kalso, 2005). In humans, epidurally administered morphine has been shown to be 10 times more potent than oxycodone following abdominal surgery (Backland et al., 1997). In rats, intrathecal administration of morphine has been shown to be approximately 14 times more potent than oxycodone, whereas with s.c. and i.p. administration, oxycodone is 2-4 times more potent than morphine (Pöyhä and Kalso, 1992a). The nature of these differences remains rather unclear, but it has been suggested that they are related to the effects of intrathecal oxycodone on κ opioid receptors, a recurring theme that persists along with findings implicating the involvement of δ-opioid receptors (Bossert et al., 2019; Olson et al., 2019; Ordóñez et al., 2007; Ruan et al., 2017; Yang et al.,...
Lemberg and colleagues (2006) noted the discrepancy in clinical efficacy after systemic administration and the loss of potency after spinal administration, commenting that even after considerable clinical use the pharmacology of oxycodone was poorly understood, requiring a better understanding of the pharmacokinetics of oxycodone and its metabolites. A number of studies reviewed by Kalso (2005) summarized results conducted in healthy volunteers and those individuals with kidney or liver failure, and also included pharmacokinetic drug-drug metabolism interactions. As oxycodone is metabolized in the liver by O-demethylation to form oxymorphone in a reaction catalyzed by the P450 2D6 enzyme, it is likely that pharmacokinetic interactions that block CYP 2D6 are anticipated. Due to the fact that the active metabolite of oxycodone, oxymorphone, may contribute significantly to analgesia, it is expected that there would be a decrease in the efficacy of oxycodone in poor metabolizers and during co-administration of drugs that inhibit CYP 2D6. A case report in fact did suggest that fluoxetine hydrochloride, a potent CYP 2D6 inhibitor increased the oxycodone requirement in a poor metabolizer (Otton et al., 1993).

Oxycodone and morphine have distinctly different metabolic pathways and active metabolites may complicate the comparison (Nielsen et al., 2007). A series of studies mentioned earlier was conducted that drew starkly different conclusions about whether oxycodone produced its analgesic effects through the μ-opioid receptor or through the k-opioid receptor (Lemberg et al., 2006, 2007; Nielsen et al., 2007; Ross and Smith, 1997; Smith et al., 2007). Lemberg et al. (2009) compared oxycodone and its metabolite oxymorphone in a variety of analgesia models and found that in the tail flick assay, both s.c. oxycodone and oxymorphone produced dose-dependent analgesia, whereas in the hot plate and mechanical models of nociception, oxymorphone was much more effective than oxycodone, with analgesia produced by oxymorphone lasting for a much longer duration. These effects were also found when the effects of oxycodone and oxymorphone were measured following intrathecal administration. Oxymorphone appears to be critically important in producing analgesia after systemic administration.

A major difference between oxycodone and morphine that might account for some of these differences could be in the passage of these opioids through the blood–brain barrier (BBB). The concentrations of oxycodone are 3-fold higher in the brain interstitial fluid compared with...
plasma, whereas the reverse is true with morphine. (Kalso, 2007). Both drugs have similar logD values (are equally hydrophilic) but the higher concentration in the brain three times higher than in blood suggests the presence of an active influx transporter for oxycodone (Boström et al. 2006). Okura et al. (2008) have suggested that this may be accomplished by an organic cation transporter. The concentrations of the unbound drug in the target organ (brain) correlate more closely with the CNS drug effects (analgesia) than the plasma levels. For the same unbound concentration in blood, the concentrations of unbound oxycodone in brain are six times higher than those of morphine. This difference could explain the higher efficacy of oxycodone compared with morphine at similar plasma levels. (Kalso, 2007).

Hassan et al. (2007) reported that repeated administration of oxycodone for 6 days to male Sprague-Dawley rats at a dose that was antinociceptive in the hot plate test (5.0 mg/kg, i.p.) stimulated P-gp ATPase activity, increasing P-gp protein levels that significantly decreased the tissue distribution of the chemotherapeutic agent paclitaxel. These findings suggest that oxycodone is a P-gp substrate that when administered repeatedly, may affect the pharmacokinetics and pharmacodynamics of other drugs that are also P-gp substrates. Additionally, the upregulation of P-gp induced by repeated administration of oxycodone may lead to the reduction of oxycodone levels in the CNS resulting in the development of tolerance to the analgesic effects of oxycodone and to cross tolerance to other μ-opioid receptor agonists such as morphine and methadone.

The pharmacodynamic properties of oxycodone and its metabolites have been reviewed by Olkkola et al. (2013) and by Ruan et al. (2017). The pharmacodynamic effects of oxycodone are comparable to those of other opioid analgesics such as morphine, and include pain relief, sedation, nausea, vomiting and respiratory depression (Chan et al., 2007; Tarkkila et al, 1997). In addition to differences in oral bioavailability, oxycodone has been reported to produce less nausea compared to morphine when administered to cancer patients (Kalso and Vainio, 1990). The primary metabolite of oxycodone, nororoxycodone, is 4 times lower than that of oxycodone at the μ-opioid receptor and produces 4 to 6 times lower G-protein activation as measured in a GTPγ[35S] binding assay. Oxymorphone, the other primary oxidative metabolite, has approximately 50-fold higher G-protein activation than that of oxycodone (Lalovic et al., 2006; Thompson et al., 2004). Lalovic et al. conclude that the metabolites of oxycodone do not...
contribute to the central effects due either to their low potency or low abundance in the circulation, or as a result of their poor uptake into the brain.

Finally, although not specifically related to pharmacodynamic and pharmacokinetic effects, Lyu et al. (2022) have published data demonstrating that long-term developmental exposure to oxycodone in utero has a long-standing effect on the gut microbiome when microbiota are examined in adulthood. In this study female mice were treated daily with 5 mg of oxycodone for two weeks prior to breeding and then throughout gestation. Male and female offspring pups were examined using a variety of behavioral and metabolic tests and fecal boli were collected and analyzed in adulthood. Several bacteria in females and males were elevated in mice exposed to oxycodone, though these elevations were not uniform across sexes. The bacterial changes were correlated with metabolic pathway alterations which could affect drug action throughout the lifespan. Although this may affect children born to mothers that have been using oxycodone or other opioids, further work is clearly needed and of importance.

III. Pharmacogenomics/Pharmacogenetics of Oxycodone

A. Genotype variations in humans and responses to oxycodone

Pharmacogenomics, sometimes also referred to as pharmacogenetics, is an important element of precision medicine and of pharmacology. The term ‘pharmacogenetics’ is attributed to the German pharmacologist Friedrich Vogel who coined it in 1959. The use of the term followed the publication by Motulsky who wrote about how ‘drug reactions may be considered pertinent models for demonstrating the interaction of heredity and environment in the pathogenesis of disease’ (see Pirohamed, 2011). The benefits of developing an understanding of the genetic associations with drug dose, efficacy, and toxicity as a means of optimizing clinical care of patients are self-evident (Cascorbi and Tyndale, 2014; Sadée et al., In press). In clinical oncology the presence of mutations in tumor tissue is critical in determining treatment approaches and similar examples can be found in cardiovascular diseases and in psychiatry (Crettol et al, 2014). The role of pharmacogenomics has emerged as a significant area of interest to aid in the selection of the most appropriate opioid analgesic for palliative care for cancer.
patients where there is existing pharmacogenonomic evidence to guide the prescribing of codeine and tramadol based on their relationship to CYP2D6 gene variants (Wong et al., 2022).

Research with oxycodone has increased due in part to its widespread use and abuse as well as interests in its unique analgesic actions. Individual responses to oxycodone have been shown to vary due to genetic differences. Umukoro et al. (2021) published a narrative literature review of the pharmacogenomics of oxycodone and have provided an excellent review of pharmacokinetics, pharmacodynamics and genetic factors affecting the pharmacodynamics of oxycodone. In their review, Umukoro et al. conclude that there is conflicting evidence for a clinical effect of genetic polymorphisms but there is much stronger evidence linking polymorphic genetic enzymes CYP2D6 and CYP3A with therapeutic outcomes.

Samer et al. (2010a) evaluated the effects of the CYP2D6 genetic polymorphism and CYP2D6 and CYP3A on drug-drug interactions and on the pharmacodynamic effects (antinociception, pupil size, sedation, respiration, side effects) of oxycodone in healthy male volunteers. Both CYP2D6 genetic polymorphism and drug-drug interactions by CYP2D6 and CYP3A had major effects on the antinocceptive responses to oxycodone. CYPD2D6 activity was correlated with the assessment of experimental pain in ultra-rapid metabolizers of CYP2D6 who experienced greater analgesic effects, whereas the poor metabolizers had reduced CYP2D6 and showed no change in these measures. Several other differences between high and low metabolizers of CYP2D6 were reported that included greater sedation and respiratory depression when CYPD2D6 was high; ultra-metabolizers also reported mild to severe side effects whereas no toxicity was reported among poor metabolizers.

Inhibition of CYP2D6 with quinidine greatly reduced the analgesic effects of oxycodone so that the results in the pain test were no different than those of placebo. Further, CYP2D6 inhibition significantly increased exposure to oxycodone along with a decrease in oxymorphone and noroxymorphone suggesting that oxycodone may not be responsible for the analgesic effects (see also Samer et al., 2010b). In the Samer et al. (2010b) study, CYP3A inhibition with ketoconazole produced significantly higher pharmacodynamic effects than those with placebo. The conclusion of this extensive set of experiments was that oxycodone has to be used with extreme caution in ultra-high metabolizers, especially when a CYP3A inhibitor is co-prescribed. Finally, it was also suggested that for those deficient metabolizers for CYP2D6, analgesic
activity may be reduced, and perhaps other alternative treatments should be provided. This emphasis was also reinforced in a subsequent study urging the development of personalized oxycodone dosing focused on determining the patient’s metabolic response through testing the CYP2D6 phenotype to improve the safety and efficacy of oxycodone (Linares et al, 2014).

Pharmacogenetic approaches have been incorporated into postoperative pain management in a prospective randomized study of pain medication following hip and knee arthroplasty (Hamilton et al., 2022). These investigators performed pharmacogenetic testing for genetic variants that included CYP2D6, CYP2C9, OPRM1 and CYP1A2. Pharmacogenetic testing of these patients prior to surgery allowed for the collection of information on pain and on pain management following surgery. Genetic variants were found in a number of patients that influenced drug metabolism. It was concluded that when patient’s pharmacogenetics are identified and medications customized to their genetic profile, pain scores and opioid use are greatly reduced for 10 days following surgery.

A study conducted in Sweden that controlled for allelic frequency found a significant association between the 118G allele in the OPRM1 gene and heroin addiction (Bart et al., 2004). However, there are a number of reports, including a large meta-analysis of 16 case-control studies of opioid dependence in a total of 5169 subjects, that concluded there was a lack of association between the A118G allele and genotype frequencies and opioid dependence (Coller et al, 2009; see also Franke et al., 2001 for an earlier study with similar conclusions). Coller et al. did add a few qualifiers to their conclusions including the suggestion that there was significant heterogeneity between the studies and that although there was no evidence of a direct association with the risk of dependence, A118G may still have an influence on the pharmacological response to opioids.

Two studies by Zwisler et al. (2009, 2012) examined the possible association of OPRM1 and ABCB1 polymorphisms in response to experimental and postoperative pain and adverse effects in humans following treatment with oxycodone. The G allele of the A118G single nucleotide polymorphism (SNP) of the opioid receptor gene (OPRM1) has been shown to influence analgesia, respiratory depression, emesis, and adverse reactions produced by the active metabolite of morphine, morphine-6-glucuronide (Romberg et al., 2005; Skarke et al., 2003). The ABCB1 gene encodes P-glycoprotein, the efflux transporter that influences drug transport in
the intestine, kidneys, and blood-brain barrier, thereby altering the pharmacokinetics of some drugs. P-glycoprotein activity can be influenced by genetic variability of the C343 5T and G2677T/A single nucleotide polymorphisms (SNPs).

In their initial study Zwisler et al. (2010), examined the antinociceptive and possible adverse effects of single nucleotide polymorphisms in 33 healthy subjects exposed to experimental pain that included electrical nerve stimulation and the cold pressor test. The variant G allele of the A118G SNP was associated with a reduced antinociceptive effect of oxycodone in the electrical nerve stimulation pain tolerance procedure (i.e., a lower increase in pain tolerance threshold) compared to placebo, but there was no effect on adverse drug reactions to oxycodone. Carriers of the variant T allele of the C3435T SNP had less adverse reactions (dizziness, nausea/vomiting, itching) to oxycodone than the wild type carriers, whereas the carriers of the T allele of the G2677T/A SNP had a better antinociceptive response in the cold-pressor procedure following oxycodone than the wild type carriers, a result that was accompanied with less severe adverse drug reactions.

A subsequent study that included a total of 268 patients undergoing various surgical procedures examined the possible association between the single-nucleotide polymorphisms A118G in OPRM1 and C3435T and G2677T/A in ABC1 in the response to oxycodone in postoperative pain (Zwisler et al, (2012). In contrast to their prior study (Zwisler et al., 2010) there was no association between these single nucleotide polymorphisms and changes in the analgesic effects of oxycodone or in adverse drug reactions. The authors conclude that the contradictory findings may be related to the different types of pain that were studied in the two experiments (i.e., experimental vs postoperative pain), to the fact that many of the patients were co-medicated with P-gp inhibitors, and to the low consumption of oxycodone.

Jones et al. (2019) took a step towards attempting to predict individuals that might be susceptible to opioid use disorders by assessing genetic polymorphisms in an effort to determine whether those polymorphisms were associated with the subjective responses to oxycodone. The 36 volunteers (33 men and 3 women) for this study had previously used opioids as part of pain management exclusively for medical use. Several gene variations were examined, including the μ-opioid receptor (ORPM1), the δ-opioid receptor (OPRD1, the κ-opioid receptor (OPRK1 and the major dopamine-metabolizing enzyme, catechol-O-methyltransferase (COMT). A number of
findings were noted with the small nuclear proteins (SNPs) encoding the μ-opioid and δ-opioid receptors influencing the subjective effects of oxycodone with the SNP in the δ-opioid receptor being the most robust predictor of opioid reward. This study, together with those of Samer et al. (2010a, b), Linares et al. (2014) and Wong et al. (2020), point to the utility and the necessity of further research examining the pharmacogenetic and pharmacogenomics of oxycodone as well as other opioids. Further, considerations of ‘phenoconversion’, a condition where genotypic extensive metabolizers are converted into phenotypic poor metabolizers, due to concomitant drug administration should be incorporated into these approaches to safely and effectively reduce pain and to allow for the stratification of individuals for effective pain management that are at lower risk to convert to abuse (Deodhar et al., 2021).

B. Gene and Protein Expression Studies in Animals

A number of studies have examined gene expression in animals following periods of exposure to oxycodone to develop a better understanding of the neurobiological mechanisms underlying oxycodone, particularly under conditions when it is self-administered. Zhang et al. (2014) provided access to i.v. oxycodone in male C57BL/6J mice using a nose-poking response for 14 days in daily extended (4 hr) or shortened (1 hr) experimental sessions and assessed the effects on striatal neurotransmitter receptor gene expression. Mice exposed to the 4 hr sessions escalated the amount of oxycodone that was self-administered and showed changes in a number of neurotransmitter receptor genes in the dorsal striatum, including the GABAA receptor subunit beta 2 (Gabrb2) as well as changes in cholinergic receptors, neuropeptide Y, 5-HT3, and the glycine receptor relative to saline controls. The investigators of this study point out that the mRNA of only one subunit of the GABAA receptor, Gabrb2, showed a significant decrease in mice that had self-administered oxycodone and suggest that decreases in this mRNA may underlie the mechanism responsible for the increased intake of oxycodone during the extended periods of self-administration. In contrast to these changes, mice in the 1 hr condition did not escalate intake of oxycodone nor did this group show changes in the expression of neurotransmitter genes. This study also incorporated a ‘yoked control’ group that received saline, not oxycodone; this group did not show sustained responding throughout the 14-day
period. It would be interesting to determine the effects of a ‘true’ yoked control where the yoked animals received the same frequency of oxycodone deliveries but did not have to respond for oxycodone as was the case with the active oxycodone subjects.

A follow-up study by Zhang et al. (2017) examined whether oxycodone self-administration under the extended access procedure affects gene expression in the terminal areas of the nigrostriatal and mesolimbic dopaminergic pathways in mice. Several alterations in the expression levels of genes related to inflammation and immune functions were found suggesting that the systems related to inflammation and immune genes undergo large changes during the chronic administration of oxycodone.

Zhang et al. (2015), studying the i.v. self-administration of oxycodone (14 consecutive days at 2 hr/day at 0.25 mg/kg/infusion) in adolescent and adult C57BL/6J mice measured gene expression in the hippocampus. Prior to self-administering oxycodone, it was shown that adolescent and adult control mice differed significantly in the expression of several genes that included those coding for mitogen-activated protein kinase (mapk1), calcium/calmodulin-dependent protein kinase II gamma subunit (Camkl2g), the glutamate receptor, ionotropic AMPA 2 (Gria2), and the metabotropic glutamate 5 receptor (Grm5). Self-administered oxycodone produced a significant alteration in a number of genes, particularly those involved in synaptic plasticity. For example, Pim1, a proviral integration site that belongs to the Ca2+/Calmodulin-dependent protein kinase family and is known to attenuate apoptosis was increased in both adult and adolescent mice. A second gene that was increased significantly in the self-administration animals compared to saline controls was thymoma viral proto-oncogene 1, (Akt1), also a serine-threonine protein kinase like Pim1, that is a key mediator of growth factor-induced neuronal survival. The Akt1 pathway plays an important role in cell proliferation, differentiation, and survival. One interpretation of these findings is that oxycodone may be inhibiting the process of neurogenesis in the hippocampus and these changes in gene expression may be activated to counteract or to compensate for these changes.

This group of investigators has also demonstrated that extended access to oxycodone self-administration produced alterations in the expression of several genes related to axon guidance gene families that include integrins, semaphorins and ephrins (Yuferov et al., 2018). Yuferov et al. speculated that oxycodone-induced alterations in these genes produce neuroadaptations in
axon-target connections and synaptogenesis that may play a role in the neurobiological adaptations that occur in OUDs. Some of these genes are also known to modulate glutamate transporter currents in astrocytes and to alter dendritic morphology and synaptic connectivity.

The question of whether exposure to opioids such as oxycodone during adolescence affects responses to opioids in adulthood and may be a factor in subsequently transitioning to heroin use (Cerdá et al., 2015) has been the focus of a number of investigators using animal models. Myer-Blackwell et al. (2014) studied self-administration of oxycodone by adolescent (28-day old) and adult C57BL/6 mice (78-days old) to determine whether there was a differential expression of genes in the dorsal striatum. Adolescent mice self-administered significantly less oxycodone than adult mice over a 14-day period and there were more gene changes in the adolescent mice than in the adult mice. Adolescent mice had lower monoamine oxidase A mRNA levels. In addition to these changes, there were significant differences between adolescent and adult mice with regard to the gene encoding neuropeptide Y (Npy5r) where the levels of this mRNA were lower in the adolescent mice than in the adults. One other difference that was found in this study was that gene expression of gastrin-releasing peptide receptor (Grpr) was increased in mice that had self-administered oxycodone as adolescence, but this was decreased in the adults that also self-administered oxycodone. Even though the adolescent mice self-administered lower amounts of oxycodone than the adult mice, there were a larger number of genes altered in the adolescent group than in the adults, suggesting that the adolescent brain is more sensitive to oxycodone, changes that may persist into adulthood.

Adolescent exposure to oxycodone and its impact on subsequent behavior has also been addressed by Sanchez et al. (2016) who studied both early exposure to oxycodone as well as gene expression changes together with other potential behavioral consequences. In this study adolescent C57Bl/6 male mice (postnatal day 28) received oxycodone (3.0 mg/kg/day), delivered through an osmotic minipump for 28 days and then underwent a 28-day period of withdrawal when they were adults (postnatal day 84). Adult mice (postnatal day 56) were treated identically to the adolescents and both groups were subsequently tested with morphine in the CPP procedure, as well as in assays to assess sensitization, anxiety, and depressive behaviors. In addition, this group also examined the expression of genes related to reward that included dopamine D1 and the dopamine transporter. Exposure to oxycodone during adolescence significantly increased the
response to morphine in the CPP procedure during adulthood and also reduced the expression of D1 in the NAc and transporter expression in the ventral tegmental area. Exposure to oxycodone as adults did not have any effect on morphine-induced conditioned place preference and for both groups there were no differences in behavioral assays with the exception of a significant reduction in corticosterone to the stress induced in the forced swim test for those mice that received oxycodone during adolescence. Although there was a significant decrease in D1 mRNA expression in the NAc and a reduced expression of the dopamine transporter in the ventral tegmental area for those mice treated with oxycodone in adolescence, these changes, as the authors of the publication point out, may be confounded with the changes in the developing brain where expression levels of D1 decline with age. Based on these results, however, it was concluded that adolescent exposure to oxycodone produced alteration in the mesolimbic pathway associated with opioid abuse that may contribute to the subsequent sensitivity in adulthood to the effects of morphine and that these effects are long lasting. This finding was followed by Carpenter et al. (2021) who, using procedures similar to those of Sanchez et al. (2016), demonstrated that oxycodone exposure during adolescence produced long-lasting epigenetic modifications at key genes related to dopamine transmission.

Blackwood et al. (2019a) also studied neurobiological consequences of withdrawal from oxycodone under escalated (9 hr) and non-escalated (3 hr) oxycodone self-administration conditions. After 20 days of self-administration, both groups were withdrawn from oxycodone and over a 31-day period were tested for cue-induced reinstatement. One of the main findings of this study was that the long-assess group could be further differentiated into rats with high levels of oxycodone intake and rats that responded for lower amounts of oxycodone. Rats responding for higher amounts of oxycodone showed an increase in the expression of hippocampal μ and κ receptors, whereas there were no changes with δ receptor expression in any of the short or long-access animals. The authors speculated that large doses of oxycodone may produce changes in hippocampal-dependent learning and memory processes that could also trigger psychiatric disorders in individuals addicted to opioids.

The possible role of μ-opioid receptor variants in the effects of oxycodone was studied by Collins et al. (2020) using both CPP and oxycodone self-administration, both procedures that examine the reinforcing effects of drugs and potential abuse liability. The mice were developed
based on the knowledge that, in humans, the μ-opioid receptor gene (OPRM1) contains a single nucleotide polymorphism (SNP), A118G, which has been associated with opioid addiction risk. Collins et al. compared the effects of oxycodone in A112G male and female mice that possess a functionally analogous SNP in the mouse μ-opioid receptor gene (Oprm1). These effects were compared with mice homozygous for the A112 (wild type; AA) or the G112 (GG) allele. Although there was no effect of genotype or gender in the CPP procedure, both male and female GG mice self-administered significantly more oxycodone compared to the wild type AA littermates. The results of these experiments suggest that the G allele contributes to increased oxycodone intake and may be a factor in OUDs.

Blackwood et al. (2020) used a model of extended oxycodone self-administration access where rats received response-contingent foot shock, a procedure that resulted in two groups of rats: one being a ‘shock sensitive’ group that reduced responding for oxycodone and the other, the ‘shock resistant’ group that continued to lever press to receive oxycodone. Differences between these two groups were also seen in the expression of immediate early genes where the shock resistant rats showed increases in the prefrontal cortex of egr3, suggesting that this gene may play a role in the persistence of taking oxycodone under adverse consequences.

More recently, Beierle et al. (2022) reported the identification of a candidate gene, Zhx2, that appears to be involved in gender-specific sensitivity to the reinforcing effects of oxycodone (see section VI.C., Sex differences in abuse liability).

C. Summary

Several pharmacogenetic studies in both animals and humans have demonstrated that polymorphisms of drug metabolizing enzymes, transporters and receptors can significantly contribute to their expression and in the response to drugs. As Sadee and Dai (2005) commented nearly 20 years ago, pharmacogenomics has emerged as the harbinger of personalized medicine. Corresponding advances in pharmacometabolomics and systems pharmacology will undoubtedly aid in helping to resolve some of the many challenges facing progress in these areas as many diseases are unquestionably complex and a large number of factors that include age, gender, nutrition, as well as epigenetic differences, contribute to the
variability in an individual’s phenotype and response to a drug (Beger et al., 2016; Danhof, 2016).

Advances in the study of genetics have provided significant opportunities to probe potential genetic contributions to the risk of developing substance use disorders, to the occurrence of adverse effects, as well as to individual therapeutic responses to the opioid management of pain. A better understanding of specific genes and gene variants can shed insight into the pharmacogenetics of SUDs and can aid in the development of personalized medicine for these challenging conditions (Crist et al., 2019; Sadée et al., 2023). Although studies of gene variants hold significant promise in the study of the pharmacogenetics of OUDs, at the present time there are mixed and/or equivocal results likely based on the substantial variability between cohorts due to the lack of statistical power in individual studies, methodological differences, or other factors in the genetic background of individuals that add to the confounding of results. As Crist et al. (2019) suggest, OUD research will need to move beyond the more common variants to explore other sources of variation that include gene-environment effects, gene-gene interactions and epigenetic factors.

IV. Pain and Analgesia – Clinical Studies

A. Cancer Pain

In clinical studies, when administered orally, intramuscular, or intravenously, oxycodone produces pain relief similar to or, in some cases, more effectively than that of other μ-opioid receptor agonists (Heiskanen and Kalso, 1997; Kalso et al., 1991; Kalso and Vainio, 1990; Pöyhiä et al., 1991, 1992; review by Gallego et al, 2007). One of the earlier clinical studies compared the analgesic effects of intramuscular oxymorphone, a metabolite of oxycodone, with morphine in patients with chronic cancer pain (Beaver et al., 1977. Using the intensity and duration of analgesia as a measure of the total analgesic effect, intramuscular oxymorphone was 8.7 times as potent as morphine and 13 times as potent in terms of its peak effect. When the duration and intensity of analgesia was assessed following oral administration, oxymorphone was 1/6th as potent as the intramuscular form with the peak effect only 1/14th as potent. Side effects of equianalgesic doses were qualitatively and quantitatively similar for oral and intramuscular morphine and for intramuscular oxymorphone and morphine. Beaver and
colleagues also compared the analgesic effects of oral and intramuscular codeine with oral and intramuscular oxycodone in cancer patients (Beaver et al., 1978a). A companion publication to this study compared the analgesic effects of intramuscular oxycodone with intramuscular morphine and codeine (Beaver et al, 1978b). When oral oxycodone was compared with intramuscular oxycodone, oxycodone retained at least half its analgesic activity when administered orally, compared to morphine where the oral to intramuscular ratio was 1/6th as potent.

Additional studies have reported that high doses of oxycodone or controlled release forms can effectively relieve pain in patients suffering from cancer-related pain (Bercovitch and Adunsky, 2006; Gimble et al, 2003; Heiskanen and Kalso, 1997; Schmidt-Hansen et al., 2017; Watson and Babul, 1998; Watson et al., 2003). Bruera et al. (1998) studied controlled-release oxycodone and morphine in patients with cancer-related pain who were permitted to use escape analgesics as needed for pain control. Pain was well controlled by both oxycodone and morphine but patients that received oxycodone consumed significantly more escape doses and the mean pain intensities were significantly greater when oxycodone was administered after morphine. A few of the patients receiving morphine in the Heiskanen and Kalso (1997) study showed a tendency to have nightmares as well as in the Kalso and Vainio (1990) study who reported hallucinations and delirium that were attenuated when switched to oxycodone (Maddocks et al, 1996). Less nausea, hallucinations and pruritus have been reported with oxycodone compared with morphine (Ordóñez et al, 2007).

Ong (2008) studied the effects of controlled-release oxycodone in 67 patients with moderate to severe neuropathic pain. There were 35 patients with neuropathic pain unrelated to malignancy and 32 patients with pain secondary to malignancy. The patients with nonmalignant causes included postherpetic and trigeminal neuralgia, and radiculopathy, whereas the patients with malignant neuropathic pain predominantly included lung and breast cancer but also colorectal and cervical cancer. Baseline pain using the Visual Analog Scale in the nonmalignant group ranged between 8 and 10 at the initiation of the study and, after 2-4 weeks of 25 mg/day of oxycodone, pain scores decreased to 1-2 to 10 in 94% of the patients. The average dose of oxycodone for the subgroup with neuropathic pain secondary to malignancy was 40 mg/day; the baseline score was 10 which improved to 2-4 on the follow-up after 2-4 weeks of treatment.
Though a relatively small non-randomized study, the results suggest that controlled release of oxycodone may be effective in this population of patients.

In a systematic review of randomized controlled trials on the effectiveness of opioids for the treatment of cancer pain, Koyyalagunta et al. (2012) concluded that there was fair evidence for the efficacy of transdermal fentanyl but, overall, poor evidence for morphine, tramadol, oxycodone, methadone and codeine. However, there were differences in the number of trials with morphine (6) compared to oxycodone (1) and transdermal fentanyl (4). The conclusions are also limited because the studies included cancer pain having different etiologies and types, making it rather difficult to draw definitive conclusions about the relative efficacy of these compounds for cancer pain. The authors concluded that there is no concrete evidence for the effectiveness and safety of opioids in chronic cancer patients. However, when focusing on a more homogeneous population, a randomized controlled study comparing controlled release forms of oral morphine (30mg/day) or oxycodone (20 mg/day) in pancreatic cancer pain found no difference between these drugs in terms of efficacy or in the occurrence of adverse effects (Mercadante et al. 2010).

A more recent review of oxycodone for cancer-related pain was published by Schmidt-Hansen et al. (2022), in the Cochrane database where the comparison was with morphine. The analysis evaluated 42 studies with over 4,485 participants that included 3,945 analyzed for efficacy and 4,176 for safety. Constipation and hallucinations occurred less frequently with controlled release oxycodone than with controlled release morphine but, overall, there was very little difference between oxycodone and morphine in the management of pain related to cancer. This conclusion was similar to that of Guo et al. (2018) who, through a meta-analysis, compared oxycodone with morphine for the treatment of patients with moderate and advanced cancer pain and reported no differences in analgesic efficacy or tolerability for the two drugs. Although some of the studies included in their analysis did not directly compare morphine and oxycodone, the authors propose the conduct of prospective, randomized clinical trials to directly compare these two drugs and to do so while also evaluating the treatment effects based on gene polymorphism analyses to more effectively provide the best treatment.

Although there are differences in the pharmacokinetics and analgesic effects with oxycodone when compared to morphine, depending on the route of administration, there appear to be
relatively little differences between these two analgesics in the treatment of cancer pain either in terms of efficacy or adverse effects.

B. Neuropathic Pain

Injury to peripheral nerves, including chemotherapy-induced neuropathies and other diseases such as diabetic neuropathy, often lead to abnormal neuropathic pain states that include hyperalgesia, allodynia and spontaneous pain, which frequently remain long after the injury heals, or the initiating conditions have resolved. Although opioid agonists remain the gold standard for the treatment of moderate to severe non-neuropathic pain, they have been shown to have reduced efficacy against neuropathic pain (Martinez-Navarro et al, 2019; Zochodne and Max, 2003). Alles and Smith (2018) in a review of the etiology and pharmacology of neuropathic pain have commented that the ‘various manifestations of neuropathic pain are notoriously resistant to the actions of opioids and, in contrast to the noted efficacy of opioids in nociceptive pain, there is not a comparable degree of efficacy for the treatment of neuropathic pain (see also Yekkirala et al., 2017). Alles and Smith comment further that ‘any pain that is opioid resistant is likely neuropathic pain.’ Although a few studies have reported that high doses of oxycodone or controlled release forms can effectively relieve neuropathic pain induced by post-herpetic neuralgia or diabetic neuropathy (Gimble et al., 2003; Watson et al., 1998; 2003), the evidence for oxycodone efficacy, as well as other strong opioids is low for these particular indications (Cooper et al., 2017; Derry et al; 2016; Els et al., 2017; Gaskell et al., 2016; McNicol et al, 2013). Clinical studies that have reported significant efficacy may be biased due to small sample sizes, the manner in which dropouts were handled, or the results based on a relatively brief treatment duration. The general conclusion is that there is equivocal and insufficient evidence to conclude that opioid treatments, including oxycodone, are effective in the management of neuropathic pain and that the risks outweigh the benefits.

C. Surgical procedures

In one of the first studies comparing oxycodone with morphine, Kalso et al. (1991), conducted a randomized double-blind study that compared i.v. oxycodone and morphine...
following major abdominal surgery and found that significantly less oxycodone was required to control postoperative pain compared to morphine. Additionally, the first stage of pain relief was achieved faster for oxycodone than for morphine (28 minutes compared to vs 46 min) and lasted longer (39 min vs 27 min). Although this study suggested a favorable analgesic effect for oxycodone, the fact that identical doses of oxycodone and morphine were used may be a limiting aspect for drawing any definitive conclusions. A subsequent study of patients undergoing breast reconstruction or major back surgery, where i.v. patient-controlled analgesia (PCA) was used along with bolus doses of morphine (45 ug/kg) and oxycodone (30 ug/kg), the same amount of morphine and oxycodone was consumed, with no difference in the quality of analgesia or in the incidence of side effects (Silvasti et al., (1998). Backlund et al. (1997) compared the effects of epidural and intravenous oxycodone for pain with epidural morphine following abdominal surgery; Yanagidate and Dohi (2004) conducted a similar comparison following gynecological surgery. Epidural administration of oxycodone resulted in poor analgesia compared to morphine suggesting that most of the analgesia with oxycodone is the result of systemic absorption (Lemberg et al., 2009). Pain relief at rest immediately after surgery was somewhat higher with morphine, compared to pain scores with either intravenous or epidural oxycodone. At 14 hours after surgery, and when coughing, pain scores were significantly lower in the oxycodone groups compared to morphine but at 17 hours pain scores while coughing were significantly higher in the intravenous oxycodone group than in either of the two groups receiving epidural oxycodone or morphine. There were no differences in all groups in the incidences of nausea or pruritus. Overall, this study concluded that there were no significant advantages of epidural oxycodone over that of morphine for the doses that were studied, and no significant advantages of epidural oxycodone over that of intravenous route of administration. Similar conclusions were made by Cuvillon et al. (2021) who found that intravenous oxycodone did not significantly reduce opioid-related side effects following total hip arthroplasty compared to morphine within the first 24 hours post-surgery.

Finally, in a review of 26 clinical trials of several surgical procedures including spine surgery, knee arthroplasty, caesarean section, cardiac surgery, bunionectomy, breast surgery and laparoscopic colorectal surgery, when compared to intravenous opioids, oral oxycodone produced superior analgesia, provided comparable or better pain control, and reduced the
demand for rescue medication (Cheung et al., 2017). This study also reported that patients receiving oxycodone experienced fewer opioid-related side effects than those on other opioids and had similar occurrences of postoperative nausea and vomiting as patients on placebo. However, as Cheung et al. point out, it is important to acknowledge that there are a limited number of randomized double-blind studies in individual surgical procedures as well as the exploration of few dose-ranging comparisons that make it difficult to draw definitive conclusions about the efficacy and side effects of oxycodone compared to morphine.

D. Gender Differences in Pain and Analgesia

There has been growing recognition over the past several years that there are significant male-female differences in the perception and response to pain, as well as in responses to pain therapeutics. Women experience more severe pain and have more chronic pain that is longer lasting than in men (Fillingim and Gear 2004; Riley et al., 1998; Unruh, 1996). Moreover, the prevalence of several common pain conditions such as fibromyalgia, migraine, chronic tension-type headache, and interstitial cystitis is greater in women than in men (Edwards et al., 2003). Mogil (2020) has provided a very comprehensive review of qualitative sex differences in pain, concluding that the processing of pain is ‘robustly sex dependent’. Bartley and Fillingim (2013) conclude in their review of gender differences in pain that both epidemiological and clinical studies ‘demonstrate convincingly’ that women are at substantially higher risk for many common pain conditions, commenting that multiple biopsychosocial factors contribute to gender differences in pain, and to the variability in many of the findings. These include gender hormones, endogenous opioid function, genetic factors, and gender roles, all of which require further research to elucidate the mechanisms contributing to the gender differences in the response to pain and to its pharmacological treatment.

Opioids are known to show marked interindividual differences with respect to analgesia and unwanted side effects. Although some of these differences may be due to pharmacogenetic factors, gender is known to contribute to the effects of opioids with regard to the potency of opioid analgesia, and in the prevalence of side effects that occur following opioid administration. Gender differences occur across the different opioid receptor subtypes (Berkley, 1997; Fillingim and Gear, 2004; Fillingim, 2002; Keck et al., 2000) and occur under several conditions where
opioids are used or abused. Subsequent sections of this review, for example, include an overview of sex and gender differences in both animal and human abuse liability studies.

Despite the differences between males and female animals in response to pain and opioids, human studies do not appear to indicate greater opioid analgesia among females. Direct comparisons of the role of gender in the effects of oxycodone, as well as in other opioid receptors are difficult to summarize as there are multiple variables underlying the contributions to any experimental study. Often it is not stated whether and how many women were included, making cross comparisons challenging to arriving at definitive conclusions. In a review of oxycodone and its use in the management of pain, Riley et al. (2008) concluded that “gender … [has] been shown to have no significant effects on the analgesic efficacy of oxycodone”. One experimental study of 10 women and 10 men, all sporadic prescription opioid users, found that intranasal oxycodone significantly decreased pain in the cold-water pressor test (Lofwall et al., 2012). Subjective measures of opioid liking and the estimated street value of oxycodone were also recorded and a number of differences between females and males emerged. Females were more sensitive to oxycodone than males, vomited more frequently, and compared to males, also gave higher ratings of street value and other abuse-related measures that included ‘opiate desire’ to oxycodone. The relative paucity of data from humans on potential differences between females and males suggests that future studies should include an equivalent number of females and males.

V. Pain and Analgesia - Preclinical Studies

Oxycodone has been evaluated in a variety of preclinical models of pain. Generally, oxycodone has shown potent antinociceptive effects in multiple analgesia assays including the mouse paraphenylnquinone writhing test, hot-plate, and the tail-flick (Beardsley et al., 2004). Several studies have compared the analgesic effects of oxycodone with those of morphine. One of the earliest studies in rats using the tail flick and hot plate procedures showed that in both tests the subcutaneous and intraperitoneal administration of oxycodone was 2-4 times more potent than that of morphine, whereas following intrathecal administration, morphine was 14 times more potent than oxycodone (Pöyhä and Kalso, 1992). The antinociceptive effects, induction of catalepsy and loss of reflexes produced by both oxycodone and morphine were reversed by
administration of naloxone, suggesting a µ-mediated basis for the effects of both drugs. However, Pöyhiä and Kalso were puzzled by the finding that oxycodone was more effective than morphine following subcutaneous and intraperitoneal administration and speculated that oxycodone might be a partial µ/κ-agonist since intracerebroventricular administration of some κ-agonists produced antinociception. As indicated elsewhere in this review, this has been the subject of a number of studies, the majority of which attest to oxycodone’s specific pharmacology mediated by µ-opioid receptors. In models of inflammatory pain, the potency of oxycodone was increased in CFA-induced arthritis in male but not in female rats (Cook and Nickerson, 2005). Oxycodone was also shown to be more potent than morphine in the formalin-induced inflammation model (Meert and Vermeirsch, 2005) and showed potent antihyperalgesic effects in carrageenan-induced inflammation in rats (Lemberg et al., 2008).

Meert and Vermeirsch (2005) compared several different opioids for their antinociceptive effects using the tail withdrawal test for acute thermal nociception and the formalin test for chemically induced inflammatory pain, with pain assessed using the von Frey method for mechanical hypersensitivity. These investigators also used a drug discrimination method to evaluate the discriminative stimulus properties associated with fentanyl. The opioids that were included in this study were morphine, fentanyl, buprenorphine, codeine, hydrocodone, and oxycodone, all were administered s.c. Most drugs produced a dose-related increase in tail withdrawal latencies. The effects with buprenorphine, however, differed from those of the other drugs in that the maximal effect, achieved at 2.5 mg/kg was the peak analgesic dose with all other higher doses from 10-80 mg/kg resulting in decreases from the 2.5 mg/kg dose. The onset of analgesia was fastest for fentanyl and the order of potency (ED50 values) in the tail withdrawal was fentanyl > buprenorphine > morphine and hydrocodone > oxycodone > codeine.

Following intraplantar injections of formalin, all drugs decreased the number of flinches during Phase I (the first 10 min following the pretreatment time). With buprenorphine, however, there was an initial decrease in the number of flinches at the lower doses (0.01-0.16 mg/kg, that was followed by increases in the number of flinches that, at the highest dose of 40 mg/kg, resulted in more flinches than in the control animals. Similar results were obtained in Phase II (subsequent 40 minutes) with the lower doses of buprenorphine producing effects comparable to those of fentanyl but, again increases in flinches occurred as the doses of buprenorphine were
increased. The order of potency for the drugs administered in the intraplantar portion of the study following fentanyl and buprenorphine was oxycodone > morphine > hydrocodone > codeine. The differences in the potency of oxycodone and morphine in the inflammatory and thermal pain procedures likely reflect differences in pain modalities and differential sensitivity to the opioids used in these experiments.

In the drug discrimination procedure, Meert and Vermeirsch (2005) found that all drugs substituted for the training drug, fentanyl (0.04 mg/kg, s.c.), showing that all compounds shared the discriminative stimulus effects and the pharmacological mechanism(s) mediated by the μ-opioid receptor. The drug discrimination procedure is typically an additional measure of potential abuse liability, the other being drug self-administration. It is of some interest that for oxycodone, in contrast to all the other compounds with the exception of buprenorphine, the ED50 for responding to the fentanyl stimulus was lower than that for analgesia, suggesting that animals were responding to the subjective effects of oxycodone prior to the achievement of the analgesic dose which may translate to potential abuse liability. Buprenorphine’s ‘ceiling’ effect, with higher doses producing a decrease in analgesia, may imply a safety margin for adverse effects.

In summary, there were differences between μ-opioid receptor compounds concerning relative potency and maximal analgesic effect with the type of pain influencing the results. Morphine, fentanyl, hydrocodone and codeine had their highest potency in the tail withdrawal procedure that is an assessment of acute pain. The formalin assay is considered to measure tonic pain and inflammation and, in this procedure, buprenorphine and oxycodone were more potent than the other compounds. Across the two types of analgesic tests, fentanyl was the most potent, followed by buprenorphine, oxycodone, morphine, hydrocodone and codeine. These orders of potency are in agreement with data from the treatment of pain in humans (Reisine and Pasternak, 1996).

A. Neuropathic Pain

As mentioned previously, opioids are not very effective in alleviating neuropathic pain in humans. A number of studies using a variety of animal models of neuropathic pain have shown
mixed results. It has been recognized for some time that systemically administered morphine has relatively low antinociceptive efficacy in animal models of neuropathic pain (Obara et al., 2004; Ossipov et al., 1995; Przewlocki and Przewlocka, 2001; Rashid et al., 2004), findings that have been supported in controlled clinical trials, suggesting that morphine lacks potent analgesic activity in relieving neuropathic pain (Arnér and Meyerson, 1988; Cooper et al., 2017; Martínez-Navarro, et al., 2018; see also Section IV.B). In the Rashid et al. study, using partial sciatic nerve-injured mice as a model of neuropathic pain and the Hargreaves thermal test for the assessment of morphine analgesia, the dose response curves for subcutaneous and intrathecal administration of morphine were shifted to the right of the sham-operated group, whereas the dose response curves for intracerebroventricular administration of morphine were comparable to those of the sham operated mice. These findings of lower analgesic potency of systemically administered morphine suggested that the reduced effectiveness of morphine analgesia in neuropathic pain may be related to the loss of peripheral analgesia due to the decreased μ opioid receptor expression in the DRG.

In one of the first studies to compare oxycodone and morphine in rodent models of neuropathic pain, Nielsen at al., (2007) reported the potential involvement of the κ-opioid receptor in the chronic constriction injury (CCI) model of neuropathic pain. Using (CCI) of the sciatic nerve as well as the streptozotocin (STZ)-induced diabetes model, these investigators studied intrathecal (i.t.) administration of oxycodone and morphine in the CCI animals and s.c. administration in the STZ animals. Oxycodone at a dose of 35 nmol i.t. produced significant antinociception as measured by the paw withdrawal response to mechanical stimulation in both the ipsilateral and contralateral hind paws of the CCI animals. These effects of oxycodone were blocked by i.t. pretreatment with nor-BNI, again suggesting the involvement of κ-opioid receptors in the analgesic effect of oxycodone when administered i.t. and confirming earlier reports concerning κ-opioid receptor involvement in oxycodone analgesia. Oxycodone did not produce antinociception in non-operated or in sham-operated rats. These results differed from those found with morphine at the same 35 nmol dose administered i.t. in that morphine produced significant antinociception in both sham operated CCI animals and in non-operated animals. In contrast to the effects of nor-BNI and oxycodone, the effects with morphine were not attenuated by nor-BNI but were blocked by i.t. naloxone. The implication of κ-opioid receptor involvement
in these studies was also supported by binding studies that demonstrated higher affinity of oxycodone for κ-opioid receptors and relatively low affinity for μ-opioid receptors.

The STZ-diabetic rats in the Nielsen et al. (2007) report were studied over a 24-week period where there were differences in the efficacy and potency of morphine and oxycodone in the attenuation of the paw withdrawal responses. Increasing doses of morphine and oxycodone were administered over the 24-week period and ranged from 2.0 mg/kg to 14.2 mg/kg of morphine and from 0.9 mg/kg to 9.0 mg/kg of oxycodone. Whereas the efficacy of morphine was reduced over this time period, starting at approximately 3 weeks and showing the progressive development of morphine hyposensitivity, oxycodone retained full efficacy over the 24 weeks of the STZ study period. The effects of μ- or κ-opioid antagonists were not examined in the STZ diabetic model. Taken together, these studies suggest that oxycodone and morphine produce their antinociceptive effects through different opioid receptors.

Somewhat similar results with oxycodone and morphine were reported by Nozaki et al. (2005) who also studied STZ-diabetic mice. Previous studies by this investigator and colleagues suggested that diabetic mice were selectively hypo-responsive to the antinociceptive effects of μ-opioid receptor drugs, but the non-diabetic control group did experience significant nociception. These studies also reported that the κ-opioid receptor agonist U-50, 488H produced antinociceptive effects in both diabetic and non-diabetic STZ mice (e.g., Kamei et al., 1992; Suzuki et al., 2001). In the Nozaki et al. (2005) studies, 5.0 mg/kg s.c. oxycodone produced a robust antinociceptive response in both diabetic and non-diabetic mice, assessed using the latency of a tail flick response, whereas 5.0 mg/kg, s.c. morphine did not inhibit tail-flick latencies in diabetic mice but did produce a significant antinociceptive effect in non-diabetic mice. The antinociceptive effects of oxycodone were antagonized by the μ-opioid receptor antagonist, β-flunaltrexamine in both diabetic and non-diabetic mice. The κ-opioid receptor antagonist nor-BNI significantly reduced the antinociceptive effects of oxycodone in non-diabetic mice but abolished the peak and persistent effects of oxycodone in diabetic mice. The authors suggest that the antinociceptive effects of oxycodone are mediated by the μ- and κ-opioid receptors in diabetic mice and non-diabetic mice, but that κ-opioid receptors appear to be strongly involved in the antinociceptive effects of oxycodone in non-diabetic mice. It is
Barrett et al., Oxycodone
Page 57

interesting that the diabetic condition, modeled by STZ, influences the antinociceptive effects of oxycodone and appears to recruit or diminish the activity of different opioid receptors.

An extensive series of studies using mouse pain models focused on a comparison of the effects of oxycodone with morphine and fentanyl, and also examined potential differences in the mechanism of oxycodone from other opioids (Kanbara et al., 2014; Minami et al., 2009; Nakamura et al., 2013, 2014; Narita et al., 2008; Takasu et al., 2015). Narita et al. compared the pharmacological profiles of morphine and oxycodone in mice using a sciatic nerve ligation (SNL) model of neuropathic pain and an inflammatory pain procedure induced by complete Freund’s adjuvant (CFA). These investigators also examined [3H]DAMGO binding of morphine and oxycodone to mouse brain (without the cerebellum) and found that oxycodone binding was approximately 10-fold lower than that of morphine. In the radiant tail flick procedure, 3.0 mg/kg, s.c. of oxycodone attenuated the antinociceptive response and that was antagonized by the μ receptor antagonist β-FNA but not by NTI or nor-BNI, δ and κ receptor antagonists, respectively. Narita et al. also reported that in the sciatic nerve-ligated mice, morphine significantly decreased the antinociceptive tail-flick response, whereas oxycodone produced ‘profound antinociception in’ these animals. These investigators also found that i.t. and i.c.v. morphine or oxycodone produced maximal antinociceptive effects comparable to those of sham-operated animals. When the effects of s.c. morphine or oxycodone were studied in the sciatic nerve-ligated mice in a CPP procedure, neither drug produced a place preference in the neuropathic pain-like state whereas in the sham animals, both morphine and oxycodone produced a preference for the drug associated place. The failure to find a preference for the compartment where the SNL animals achieved antinociceptive relief from pain with either morphine or oxycodone is somewhat surprising as the alleviation of pain should be reinforcing but this finding remains as an outstanding issue to be addressed.

Minami et al. (2009) studied morphine, oxycodone and fentanyl in an SNL model of neuropathic pain with oxycodone showing the greatest efficacy. Although morphine and fentanyl also reversed the decreased withdrawal threshold, the doses that reversed this measure were close to or at the same doses that significantly affected withdrawal thresholds in the sham-treated group. All three drugs produced an antinociceptive effect on thermal nociception using the tail-flick procedure as well as on measures of paw withdrawal as assessed using von Frey
mechanical stimulation. These investigators concluded that the three opioids have different efficacies in these pain models and that the distinctive analgesic profile of oxycodone differs from those of fentanyl and morphine, suggesting that oxycodone may possess a distinctive pharmacological profile for some types of neuropathic pain that are currently not well managed by more traditional opioids, a conclusion also reported in a previous study by Lemberg et al. (2006). Other support for the efficacy of oxycodone in the neuropathic SNL model mirrors the clinical reports of oxycodone efficacy in painful diabetic neuropathy and in postherpetic neuralgia (Watson and Babul, 1998; Watson et al., 2003).

Minami et al. (2009) also examined whether morphine, oxycodone or fentanyl produce different efficacy profiles in a femur bone cancer pain induced by the injection of mouse osteolytic NCTC 2472 tumor cells. Although all three of the opioids reversed guarding behavior (the lifting time of the hind paw on the ipsilateral side during ambulation), only oxycodone and fentanyl significantly reversed limb-use abnormality; morphine, even at high doses (50 mg/kg) did not restore limb use to normal levels.

Although there has been speculation that oxycodone’s unique pharmacological effects could be mediated through the κ-opioid receptor (Nielsen et al, 2007), in a preliminary study cited by Minami et al. (2009), the effects of all three opioids in the femur bone cancer pain model were completely antagonized by the μ-opioid receptor antagonist β-FNA but not by the κ-opioid receptor antagonist nor-BNI. Oxycodone and morphine were also studied in a model of femur bone cancer pain (Nakamura et al., 2013). Activation or attenuation of oxycodone and morphine in pain related brain regions (e.g., periaqueductal grey, mediodorsal thalamus) was assessed through [35S]-GTPγS binding. The effects of oxycodone and morphine were differentially modulated in this model. Activation of the μ-opioid receptor was attenuated by oxycodone in brain regions related to pain signaling and compared to morphine, was attenuated less. When administered i.c.v. the overall potency of oxycodone was stronger than that of morphine. Nakamura et al. conclude that modulation of μ-opioid receptor in bone cancer pain is one of the mechanisms that confers the unique analgesic profile of oxycodone, thereby contributing to its analgesic efficacy and control of pain.

Using a relatively new model of thermal pain and operant responding in squirrel monkeys, Kangas and Bergman (2014) and Leonard and Kangas (2020) studied the effects of
oxycodone. In this procedure, the chair-restrained monkeys were trained to pull a thermode that was attached to a chain suspended from above. A pull on the thermode that lasted 3 seconds produced the delivery of sweetened condensed milk. The temperature of the thermode was initially 38°C which was approximately body temperature. The temperature of the thermode increased by 2°C on successive trial blocks until 20 seconds elapsed without a response. Thermal thresholds for the 6 squirrel monkeys were determined and were the primary measure of nociception and drug effects. A maximum of 60°C was established to preclude contact with the thermode that might result in tissue damage. Oxycodone (0.003 – 0.1 mg/kg, i.p.), studied against this baseline of thermal nociception, produced dose-related increases in thermal thresholds at doses of 0.01 and 0.03 mg/kg, with the highest dose of oxycodone abolishing responding in 5 of the 6 monkeys.

In summary, when studied in a variety of procedures involving neuropathic pain in experimental animals, oxycodone has been demonstrated to be effective in producing an antinociceptive effect. These findings of several positive effects obtained in preclinical models, particularly with morphine, stand in contrast to the lack of efficacy in humans suffering from neuropathic pain. Translational deficiencies or shortcomings are difficult to understand and address. Efforts to address this issue require close collaboration and interaction between preclinical and clinical researchers as well as the continued quest to discover and develop new chemical entities and mechanisms of action.

B. Mechanistic Studies of Oxycodone

In light of the differences observed between morphine and oxycodone, a number of studies have attempted to identify possible neuropharmacological dissimilarities between these two drugs, with most of these studies focusing on analgesia. As pointed out elsewhere in this review, although both morphine and oxycodone are both potent analgesics, they have different analgesic profiles that are separate and distinct from the studies described above focusing on the possible involvement of κ- and δ-opioid receptors mediating some of the effects of oxycodone. Despite the lower agonist affinity of oxycodone at μ-opioid receptors compared to morphine (Lemberg et al., 2006; Narita et al., 2008), these two drugs show equivalent analgesic effects when administered s.c., with oxycodone on occasion showing more potent analgesic effects than
morphine (Narita et al., 2008). Some of the differences between the in vitro and in vivo profiling of oxycodone and morphine may be related to differences in blood-brain barrier transport between the two drugs where a six-fold difference was found in the concentration of oxycodone in the rat brain compared to that of morphine (Bostrom et al., 2008). The differences in transport through the blood-brain-barrier, the different effects in potency and activity of oxycodone when administered systemically, and the similar potency of these two drugs when administered i.c.v. suggest that the mechanisms underlying the supraspinal and systemic antinociceptive effects of morphine and oxycodone differ. Certain studies, described below, have been conducted in an effort to explore other pharmacological variables that might help to account for some of the differences between these two analgesics.

Nakamura et al. (2014) investigated possible mechanisms involved in the in vivo antinociceptive effects of oxycodone at supraspinal sites, examining whether inhibition of KIR3 channels, known to play a role in mediating the effects of morphine at the spinal level (Marker et al., 2002, 2004), might account for the effects of oxycodone at supraspinal sites. Antinociceptive effects in the tail-flick test were examined in C57BL/6 male mice following i.c.v. or i.t. morphine and oxycodone. KIR3.1 siRNA knockdown mice were also studied. Both morphine and oxycodone, administered i.c.v. produced comparable effects, with similar ED50 and ED80 values and with a similar time course for onset of maximal antinociceptive effects. Following the i.c.v. administration of the KIR3 channel blocker tertiapin-Q, the antinociceptive effects of oxycodone were markedly attenuated, whereas the effects of morphine were not, suggesting a difference in the antinociceptive mechanisms of morphine and oxycodone at supraspinal sites with oxycodone’s effects mediated by tertiapin-Q. The oxycodone dose-response curve was shifted markedly to the right in a dose-dependent manner in the presence of tertiapin-Q, whereas the effects of morphine and tertiapin-Q showed only a small difference that was not dose-related. When these effects were examined following i.t. administration, tertiapin-Q produced marked shifts to the right for both oxycodone and morphine indicating that at spinal sites, the antinociceptive effects of both morphine and oxycodone involve a tertiapin-Q sensitive mechanism.

When this same approach was used to study chronic pain in a bone cancer model and neuropathic pain in an SNL mouse model, both oxycodone and morphine, s.c., produced
comparable analgesic effects assessed using mechanical stimulation paw withdrawal. When oxycodone and morphine were given together with tertiapin-Q, the antinociceptive effects of oxycodone were attenuated, whereas there was no effect with tertiapin-Q and morphine. These results provide very good evidence that, in addition to the differences in effects of oxycodone and morphine, depending on the route of administration, the effects of oxycodone in both acute and chronic pain are mediated by different signaling mechanisms with KIR3 channels playing an important role in the effects of oxycodone but not those of morphine.

Bone cancer pain was also studied by Takasu et al. (2015) who reported another difference between morphine and oxycodone in this model. KIR3.1 channels are known to be activated following the binding of opioid agonists to \( \mu \)-opioid receptors (Marker et al., 2004). Takasu et al. repeated the finding described above (Nakamura et al., 2014) with tertiapin-Q showing that KIR3.1 channels are critical for the supraspinal antinociceptive effects of oxycodone in the bone cancer pain model but not those of morphine. Takasu et al. went on to demonstrate in coronal slices from the bone cancer pain model that GABAergic synaptic transmission in the ventrolateral periaqueductal gray (VLPAG) neurons was enhanced. Oxycodone reduced the inhibition of presynaptic GABA release, but morphine did not. Takasu et al. concluded that the enhanced GABAergic synaptic transmission at VLPAG neurons in bone cancer pain is an important site of supraspinal antinociception by oxycodone mediated via KIR3.1 channel activation.

In addition to the importance of KIR3.1 channels contributing to the different effects of oxycodone and morphine, it has also been shown that the regulator of G-protein signaling RGS9-2, a brain specific splice variant of the RGS9 gene, modulates responses to oxycodone in both pain free states and in chronic neuropathic pain (Gaspari et al, 2017). Previous studies had shown that RGS9-2 is highly enriched in the NAc and dorsal striatum and is expressed at lower levels in the periaqueductal gray and spinal cord, regions known to be involved in the effects of morphine (Zachariou et al., 2003). In studies using morphine, RGS9-2 has been characterized as a “negative modulator” of \( \mu \)-opioid receptor signal transduction as well as interacting with dopamine signaling pathways, regulating a variety of \( \mu \)-opioid receptor mediated effects including analgesia, tolerance and reward (Gaspari et al., 2014 Psifogeorgou et al, 2007, 2011;
Traynor et al., 2009; Xie et al., 2012; Zachariou et al., 2003). In the Zachariou et al. (2003) study, acute administration of 15 mg/kg, s.c. morphine increased levels of RGS9-2 approximately 50% in the NAc and spinal cord of C57BL/6 mice, whereas chronic morphine (6 days of s.c. administration of morphine via an implantation of 25 mg morphine pellets on days 1 and 3) decreased RGS9-2 levels, also by approximately 50% in these brain regions. Mice that have had RGS9 deleted compared to the wild type mice, showed enhanced behavioral responses to both acute and chronic morphine that included increases in analgesia in the tail flick procedure, physical dependence, and withdrawal, as well as increases in reward across a broad dose range using CPP, findings that suggested that RGS9-2 is critical in regulating behavioral responses to opioids.

Based on subsequent studies with oxycodone, Gaspari et al. (2017) suggest RGS9-2 is a “positive modulator” of oxycodone reward in both pain-free states and in neuropathic pain. Acute administration of oxycodone did not affect the antinociceptive activity in mice lacking the RGS9-2 gene when tested using the hot plate. Additionally, RGS9-2 protected against the development of analgesic tolerance to oxycodone in models of both acute and chronic pain. The knockout mice were also less sensitive to the rewarding effects of oxycodone in the CPP procedure. Longer term treatment with oxycodone resulted in decreases in the antiallodynic effects in the spinal nerve injury model of neuropathic pain. Overall, these studies, indicate that RGS9-2 plays an important role in the pharmacological effects of μ-receptor opioids, that it can act as a positive or a negative modulator of opioid action, and that although oxycodone and morphine produce comparable behavioral and pharmacological effects, RGS9-2 modulates the actions of oxycodone differently than that of morphine and does so through different mechanisms.

Further differences between morphine and oxycodone have also been reported by Vander Weele et al. (2014). Using fast-scan cyclic voltammetry and microdialysis coupled to HPLC-tandem mass spectrometry, these investigators measured rapid dopamine transmission along with changes in GABA, glutamate, monoamines, and their metabolites following i.v. delivery of either oxycodone or morphine. Both morphine and oxycodone increased the release of dopamine from the NAc but the patterning of release was dramatically different. Oxycodone produced a robust and stable increase in dopamine concentration, whereas morphine produced a brief
increase in dopamine that was coincident with a surge in GABA. These patterning and differential effects of oxycodone and morphine on dopamine and on other neurotransmitters in the brain may account for some of the differences in the subjective effects of these two drugs that warrant further investigation to include other opioids and different outcomes following longer term administration.

C. Sex Differences

Vacca et al. (2014) performed a comprehensive analysis of sex-related differences in pain perception and recovery from neuropathic pain in female and male CD1 mice. Neuropathic pain was induced using the Chronic Constriction Injury (CCI) model and the mechanical threshold procedure to evaluate nociception. These investigators found that male mice showed a gradual decrease in CCI-induced allodynia that completely recovered 81 days after the nerve ligation procedure. Female mice, however, were still allodynic 121 days after the CCI surgery demonstrating a slower regenerative process compared to males. Sex-related differences were also found using proteomic analyses of proteins associated with nerve regeneration. Vacca et al. point out that although gender differences in the response to pain in humans can be influenced by sociocultural and experiential factors, study of the neurobiological differences contributing to differences in pain sensation and recovery from neuropathic pain where these factors do not play a role may yield insight into novel mechanisms and new therapeutic approaches to treatment.

Studies that have examined the effects of μ-opioid receptor agonists on nociception in male and female rats have shown that male rats are more sensitive to the antinociceptive effects of morphine than female rats. The differences in antinociception appear to be independent of estrus cycle (Peckham et al., 2005) and to the particular strain of rat, including the Sprague-Dawley, F-344 and Lewis rats that have been studied in a variety of antinociceptive assays including warm-water tail withdrawal, the hot plate assay, and in the abdominal constriction test using acetic acid injected i.p. (Cook et al., 2000; Cicero et al., 1996, 1997; Bartok and Craft 1997; Kest et al., 2000; Peckham et al., 2005). The presence of a sex difference in antinociceptive responsiveness was also not related to drug potency, efficacy or affinity, suggesting that sex differences in antinociception were related to differential opioid metabolism.
Peckham and Traynor (2006) examined whether differences in the structure-activity of compounds could account for whether μ-opioids would show a difference in antinociceptive responses between female and male rats. Sprague-Dawley rats were studied using the warm water tail withdrawal assay. Morphine, administered s.c., was found to be more potent in males compared to females, with ED50 values of 2.17 and 6.08 mg/kg for males and females, respectively. There was no difference in the rank order of potency of the compounds across male and female rats for the different compounds that included (in order of potency) fentanyl, oxymorphone, hydromorphone, heroin, methadone, oxycodone, morphine, hydrocodone and codeine. This study found no observable sex difference in the antinociceptive potency of oxycodone, heroin, methadone, or fentanyl, indicating that the difference between the male and female rats was specific to the compound.

Holtman and Wala (2006) studied the effects of oxycodone (0.25-4.0 mg/kg, i.p.) in male and female Sprague-Dawley rats using the tail flick response to radiant heat. An enhanced sensitivity to noxious stimuli (hyperalgesia) was noted at low doses of oxycodone (0.25 – 1.0 mg/kg) at the later time points (90 to 120 min) in male but not female subjects. Female rats in this study had a greater antinociceptive response to oxycodone compared to male rats with the dose-response curves for the female rats shifted to the left of the males. The potency of oxycodone was approximately two-fold greater in female that in male rats with ED50 values of 0.63 and 1.46 mg/kg, respectively. These results differ from those found with morphine that have shown male rats are more sensitive than females and have a greater antinociceptive effect, findings that differ from other studies, including that of Peckham and Traynor (2006), described above, where the ED50 for oxycodone was similar for males and females. Holtman and Wala speculate that their data with oxycodone appear to support work described previously suggesting that the antinociceptive effect of oxycodone is mediated to some degree by κ-opioid receptors and that sex differences in opioid antinociceptive effects may depend upon the receptor at which they act.

Chan et al. (2008) reported a number of significant sex-related differences in the pharmacokinetics and metabolism of oxycodone in Sprague Dawley rats. The clearance of i.v. oxycodone was significantly higher in male than in female rats but the systemic exposure to oxycodone was greater in female compared to male rats. Chan et al. (2008) suggested that the
higher systemic exposure in female rats, compared with males, may account for the more potent effect of oxycodone in the Holtman and Wala (2006) studies. The oral bioavailability of oxycodone was low in both genders at 1.2 and 5.0% of male and female rats, respectively, in contrast to the 60-87% bioavailability in humans following oral administration (Pöyhiä et al., 1992). The bioavailability of oxycodone following s.c. administration was found to be approximately 57% in male Sprague Dawley rats. Chan et al. suggest that intestinal absorption of oxycodone is likely rapid and complete and that first pass metabolism following oral administration is more extensive in the rat than in the human. These findings provide a cautionary note about the oral route of administration of oxycodone in rodent studies of antinociception, which may be a poor model of the human for studying pharmacodynamic effects.

Acknowledging that sex differences in opioid analgesia occur both in humans and rodents, Arguelles et al. (2021) examined sex differences and the role of the estrous cycle in analgesia. These investigators also examined sex and cycle differences in brain and plasma oxycodone levels along with metabolites. Females in diestrus achieved higher levels of analgesia, assessed using a thermal stimulus and tail flick latency, compared to males and females in estrus. Microdialysis measures of oxycodone brain levels in females in diestrus correlated with analgesia whereas brain levels of oxymorphone or noroxycodone and plasma blood or metabolite levels did not. Increases in brain oxycodone levels were increased following the administration of the CYP2D inhibitor propranolol in males and females in estrus but did not affect females in diestrus. Arguelles et al. conclude that sex and estrous cycle influence oxycodone-induced analgesia and brain levels of oxycodone, likely through the regulation of CYD2D metabolism of oxycodone and, insofar as CYP2D6 is expressed in the human brain, gender and cycle stage may influence analgesia in humans.

In summary, not all μ-opioid receptor agonists show potency or sensitivity differences between male and female rats, nor do these sex differences necessarily apply to other opioid receptor drugs acting at κ- or δ-opioid receptors (Craft, 2003). There still seems to be a number of inconsistencies and ambiguities in the literature with regard to sex differences in pain and analgesia that warrant further study. Although the sex-specific data with morphine in rodents appears relatively clear with regard to morphine, as Peckham and Traynor (2006) point out, not
all opioid analgesics are the same. Bartok and Craft (1997) made the point that methodological differences make contribute to the variability in findings and emphasize the importance of time- and dose-effect relationships when investigating the contribution of sex, particularly in studies of nociception. Recently, Gabel et al. (2022) suggested that some of the gender differences with morphine may be related to metabolism differences in the CNS. These differences may also play a role with oxycodone and may shed some light on the differences in analgesic efficacy of morphine vs oxycodone depending on the route of administration where the role of the k-opioid receptor has been implicated.

VI. Psychopharmacology and Human Subjective Effects of Oxycodone

A. Early Studies

A few early clinical and experimental studies set the framework for subsequently examining in more detail the effects of opioids in human subjects. The predominant focus has been on evaluating the subjective effects of drugs using self-scoring questionnaires. Initial studies were conducted by Lasagna et al. (1955) at Harvard Medical School in concert with studies performed at the U.S. Public Health Service Hospital in Lexington, Kentucky. Three groups of subjects were evaluated for their responses to amphetamine, pentobarbital, heroin, morphine, or placebo with all drugs administered subcutaneously with the exception of pentobarbital sodium which was given intravenously. The three groups were normal healthy male subjects (N=20, ages from 21-27), patients (N=30, ages 45-87) with a chronic disease (malignancies, neurological disorders), and “post addicts” (N=30, ages not specified), who were ‘incurable addicts’ with demonstrated “recidivist tendencies”; none of the subjects in this group had been more than a week without a narcotic, with some having used a narcotic as recently as two days prior to participation in the study. Although oxycodone was not studied, there were several striking findings that are directly relevant to the design and execution of studies with oxycodone that followed, as well as shedding interesting information on the different drugs that were used in this study. First, the subjective effects of the drugs differed across the groups that were studied. For the normal healthy volunteers, amphetamine generally was considered the most
pleasant drug of the five received. This group typically responded to heroin and morphine with
dysphoria, reporting that these drugs were predominantly unpleasant, although the effects
appeared to be somewhat dose related; pentobarbital yielded a mixed response. The rank
ordering of mood scores for the normal healthy volunteers ranked heroin and morphine as
dysphoric, without any euphoria, whereas amphetamine was considered euphoric without any
dysphoria. The responses of the patients to these drugs were generally mixed with many
experiencing pain relief with heroin, morphine and even amphetamine. The ‘post addicts’
reported that all of the drugs produced euphoria (pentobarbital was not studied in this group),
with morphine producing the highest level of euphoria and, in contrast to the effects of opioids
in normal volunteers and patients, the ‘post addicts’ reported virtually no dysphoria.

Lasagna et al. (1955) made several cogent points that, still today, are frequently overlooked
and reflect a failure to understand that abused drugs do not have uniform effects across
individuals. For example, Lasagna et al. pointed out that there was a strong tendency to
describe the central nervous system effects of a drug like morphine in oversimplified terms and
with sweeping generalizations as if morphine ‘produced a certain set of effects that were evident
in all persons at all times’ (p. 1016). Further, they pointed out that the subjective effects of
drugs can be dependent on the situation in which the drug is administered – i.e., the ‘context’,
results that have been found with a variety of abused drugs studied in non-human primates
(Barrett, 1985; Nader et al., 1992).

A number of studies have examined the effects of oxycodone in human subjects to
examine potential relative abuse liability of oxycodone compared with other opioids and to
more fully assess oxycodone’s subjective effects. Some of these experimental studies have
been conducted with non-drug abusing volunteers, whereas others were done in drug-using
volunteers (see next section). These studies have provided informative insights to aid in
developing a better understanding of the subjective effects of oxycodone.

An early preliminary study was conducted at the Addiction Research Center in Lexington
Kentucky in six subjects with a history of opioid use, but who were not physically dependent at
the time the study was conducted (Martin et al., 1966). The subjects were administered single
doses of oxycodone (25 or 50 mg, s.c., and 15 or 30 mg, i.v) or morphine (12.5 and 25 mg, s.c.).
Substitution studies with oxycodone and morphine were also conducted with 8 opioid
dependent subjects to evaluate whether these two drugs could suppress signs of abstinence. Although preliminary, these experiments, which used a quantitative ‘attitude’ questionnaire for evaluating opioid drugs (Fraser et al., 1961), demonstrated that oxycodone was slightly more potent than morphine in producing subjective effects (e.g., ‘liking’, ‘feel drug’); oxycodone also was effective in suppressing signs of abstinence (withdrawal signs and symptoms from morphine).

B. Studies in Non-Opioid-Abusing and Nondependent Opioid Users

A more detailed series of studies with larger numbers of subjects was initiated by Zacny and colleagues who characterized the subjective (psychopharmacological), psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers (Zacny and Gutierrez, 2003, 2009; Zacny and Lichtor, 2008). These studies were also conducted to evaluate the role of alcohol drinking and gender, as well as to determine the effects of oxycodone on individuals with generalized anxiety disorder (Zacny and Drum, 2010; Zacny et al. 2011). The examination of oxycodone in non-drug-abusing individuals was unique in light of the fact that many patients are administered oxycodone for its therapeutic effects, without prior experience with oxycodone, and a study in this population of ‘naïve’ individuals could provide information on abuse liability that might lead to abuse.

Zacny and Gutierrez (2003) and Zacny and Lichtor (2008) examined the effects of oxycodone on psychomotor and cognitive performance, comparing the effects of oxycodone with those of morphine. Zacny and Gutierrez (2003) also included the benzodiazepine lorazepam, to validate measures of performance and impairment. In general, oxycodone produced a profile of psychopharmacological and physiological effects that were consistent with those of other μ-opioid receptor agonists. Some effects were observed on the psychomotor and cognitive assessment with higher doses of oxycodone, but these did not approach the level of effects seen with lorazepam. On measures of euphoria, believed to be related to potential abuse liability, oxycodone produced an increase in this measure that was not observed with the 40 mg dose of morphine. However, after the end of the experimental session, oxycodone also produced unpleasant effects that included ratings of ‘feel bad’, along with headache and nausea, results that
were also obtained with other μ-receptor opioid agonists in non-drug-abusing volunteers. Zacny and Lichtor (2008) concluded that an oxycodone dose of 20 mg had more abuse liability-related effects and fewer aversive effects than a morphine dose of 60 mg. Intravenous oxycodone was also studied alone and with naltrexone in recreational opioid users. The combination was found to produce high ‘drug liking scores’ together with higher scores on using it again, along with reported ‘highs’, relative to the combination of oxycodone and naltrexone (Backonja et al, 2016).

Zacny and Gutierrez (2009) point out that, in the studies they performed, there were individual differences in the degree to which non-drug-abusing volunteers report liking or disliking the effects of opioids, making it difficult to make a general statement about the abuse liability of opioids in the population of subjects included in their studies. These subjects were physically healthy volunteers with a history of recreational drug use but without a history of substance use-related or psychiatric disorders. They acknowledge that a “worthwhile research endeavor would be to identify variables, either organismic or environmental, that modulate the abuse liability related effects of prescription opioids in this population as there may be risk factors for non-medical use”.

One of the first studies to examine this possibility was an investigation of the contribution of alcohol drinking and gender to the subjective and other effects of 10 and 20 mg of immediate release oxycodone (Zacny and Drum, 2010). Light (N=15, with 8 males and 7 females), and moderate (N= 8 males and 6 females) alcohol drinkers with some level of current recreational drug use were studied. There were differences in recreational drug use between the light and moderate drinkers with the moderate drinkers reporting a higher lifetime use of stimulants, marijuana, and hallucinogens than the light drinkers. Alcohol drinking levels prior to the study did not modulate the subjective, reinforcing and abuse-liability related effects of oxycodone, nor did those effects differ between male and female participants. Females reported larger and more dysphoric effects following the administration of oxycodone.

A further study attempting to assess whether there were other potential indicators of opioid use/abuse was directed towards the question of whether volunteers with generalized anxiety disorder (GAD) responded differently to oxycodone (Zacny et al., 2011). Epidemiological studies have suggested that individuals with GAD and other psychopathologies are associated with an increased vulnerability to nonmedical prescription opioid use and are more likely to develop
opioid dependence (Martins et al., 2009a,b). Zacny et al. (2011) refer to a number of studies suggesting that some opioid users report the use of opioids for tension and anxiety reduction, comments that are supported by Martins et al. (2009a,b) who reported that OxyContin® use was associated with a higher level of mental health problems, including anxiety. More recently, Bruijnzeel et al. (2022) reported that oxycodone decreased anxiety-like behavior measured in the elevated plus-maze, with male Sprague-Dawley rats showing a greater anxiolytic-like effect than females.

The possibility that oxycodone may have different effects on individuals with GAD was examined experimentally to evaluate whether volunteers with GAD would report greater reinforcing effects and drug liking than those without GAD. However, despite the fact that the subjects with GAD had significantly higher scores than the control subjects on several measures of anxiety that included not only anxiety but also obsessive-compulsive measures, depression, psychoticism and on the overall Global Severity Index, there were no differences (other than in dysphoria, which was higher in the control subjects) in the response to 10 or 20 mg of oxycodone between those individuals with GAD and control subjects. Zacny et al. (2011) acknowledge that one of the fundamental central tenants of behavioral pharmacology is the importance of the context in which a drug is administered as a determinant of the response to a drug and suggest that one contextual factor that might have contributed to the results is that participants in the GAD group did not report feeling anxious during the experimental session any more than did the control subjects (see also Lasagna et al., 1955 and previous comments on the role of context in SUDs).

The effects of repeated administration of oxycodone on its subjective and analgesic effects were studied in 10 (7 men and 3 women) normal healthy volunteers with no reported history of drug dependence or current drug use (Cooper et al., 2012). This study examined two different dosing regimens to determine if tolerance developed to the analgesic, subjective and physiological effects of oxycodone. The participants, aged 21-55, had to have taken opioids at least twice previously for medical purposes but had no history of recreational use of opioids. The study consisted of two separate 5-day phases. During one phase, oxycodone was administered daily, whereas in the other phase, dosing was intermittent, occurring on days 1 and 5 with placebo administered on days 2-4. On the first and fifth day, all participants received cumulative oral
doses of 0, 5 and 20 mg/70kg; on days 2-4 participants in the daily dosing phase received 15 mg, BID, also orally. Analgesia was assessed using the cold-water pressor test and subjective effects measured by the McGill Pain Questionnaire, a drug effects questionnaire, and a visual analog scale to assess a variety of mood and physiological states. When oxycodone was administered daily, tolerance did not develop to the analgesic effects, although tolerance did develop to some of the participant’s ratings of positive subjective effects. Under the intermittent dosing schedule, both the analgesic and positive subjective effects were greater on day 5 compared to day 1 of the dosing schedule, suggesting that the schedule and the frequency of oxycodone administration can impact both the analgesic and subjective effects of oxycodone. Cooper et al. also point out that, though the data were obtained under limited conditions, tolerance may not develop to the analgesic effects when oxycodone is given under a relatively brief period of administration and the decline in positive subjective effects may be beneficial with regard to abuse liability. Finally, the increase in analgesic effects under the intermittent dosing regimen suggests that this might be a beneficial dosing regimen, with the caveat that it may also increase the subjective effects.

Stoops et al (2010) compared the effects of intravenous oxycodone, hydrocodone and morphine in recreational opioid users with histories of IV opioid use. Generally, there were no significant differences in the physiological, subjective and performance effects of these three drugs at any of the doses studied (5, 10 and 20 mg/IV. The time course of the physiological effects of the drugs, including respiratory changes, decreases in pupil diameter for oxycodone and morphine were similar, typically lasted approximately 6 hours, whereas these effects with hydrocodone lasted only about 2 hours. The subjective effects (i.e., liking scores, good effects) dissipated quickly, within 30 minutes following dosing.

The subjective, reinforcing, and analgesic effects of oxycodone doses (10-60 mg/70 kg, p.o.) were examined in opioid-dependent individuals with chronic, non-malignant pain who were also maintained on sublingual buprenorphine and naloxone (Jones et al., 2011). Painful medical conditions included accident-related injuries, osteoarthritis or osteoporosis, scoliosis, spinal stenosis among other conditions, and the mean duration for using daily opioids was 43.6 months. The buprenorphine/naloxone combination did attenuate the pain symptoms. When given in addition to buprenorphine/naloxone, oxycodone also attenuated experimentally induced pain as well as clinical pain, with minimal aversive effects but with a number of positive subjective
effects. Of interest, although oxycodone produced increases in measures such as ‘feeling high’, the magnitude of these effects was diminished relative to other studies (e.g., Zacny and Gutierrez, 2003; 3009). Oxycodone under these experimental conditions did not produce effects that are typically related to abuse liability such as ‘drug liking’ and ‘would take again’. Jones et al. (2011) interpreted these results as suggesting that this population may not be taking chronic opioids for recreational purposes. Finally, oxycodone did not function as a reinforcer in this study, as measured by a choice procedure for either oxycodone or $20.00, suggesting that the buprenorphine/naloxone dosing regimen was responsible for the differences in results between prescription opioid-abusing pain patients and those using other opioids such as heroin. An additional conclusion of this study was that the ability of the buprenorphine/naloxone combination to reduce the subjective effects of oxycodone while maintaining analgesic efficacy suggests that sublingual buprenorphine may have utility as an opioid abuse treatment as well as a pain management tool with the caveat that it may be necessary to use additional opioids to address breakthrough pain.

C. Studies in Opioid Drug Abusing Volunteers – Pain, Comorbidities and Drug History

Relatively few non-epidemiological studies have been pursued that examined potential variables that contribute to the use and abuse of opioids. In addition to those studies described previously, that evaluated variables in non-drug abusers that potentially contribute to opioid use and abuse, other studies have suggested that drug use history and pain may modulate the reinforcing and subjective effects of opioids. Several studies have demonstrated in both animals (Colpaert et al, 1982; Dib and Duclaux, 1982; Shaham et al, 1992; 1993; Shaham and Stewart, 1994) and humans that a number of variables including the presence or absence of pain, drug history, and stress can influence the subjective and reinforcing effects, as well as some of the other effects, such as respiration (Borgbjerg et al, 1996). Pharmacological and behavioral history have been shown in squirrel monkeys to dramatically alter the behavioral effects of a number of abused drugs, including morphine, chlordiazepoxide, and amphetamine (Barrett, 1992; Barrett and Stanley, 1983; Glowa and Barrett, 1983; McKearney and Barrett, 1975; 1978). At this point, little is known about the underlying mechanisms associated with these dramatic changes.
whereby the pharmacological and behavioral history dramatically modify the behavioral effects of these abused drugs.

Walsh et al. (2008) examined the relative abuse liability of oral oxycodone, hydrocodone and hydromorphone in individuals that sporadically used prescription opioids recreationally. Of the 9 subjects studied (8 male and 1 female), there were no reported differences in the three drugs, including the subjective effects, with all three producing a profile of pharmacodynamic effects characteristic of μ-opioid receptor agonists.

The abuse liability or reinforcing effects, as well as the subjective physiological and performance effects of the prescription opioids, oxycodone, fentanyl, buprenorphine, morphine, and heroin, were evaluated in 8 heroin-dependent users maintained on orally administered morphine (Comer et al., 2008). Evaluation of the drugs was assessed following intravenous administration. A key finding of this extensive study was that the abuse liability of oxycodone appeared to be substantial. Oxycodone produced robust reinforcing effects, comparable to those of morphine and heroin, and also produced some of the most robust increases in positive subjective ratings that, unlike the other drugs studied, were without increases in ratings of ‘bad drug effects’. Comer et al. (2008) commented that heroin-dependent individuals reported oxycodone was the ‘Rolls Royce’ of opioids because it produces a ‘smooth’ high and that its pharmacological profile, coupled to the ready availability may contribute to the high prevalence of abuse.

Several studies have demonstrated that patients experiencing postoperative pain readily administer opioids using patient-controlled self-administration. Higher pain levels, together with heightened anxiety and less social support, correlated with the amount of the opioid being self-administered (Gil et al., 1990; Hudcova et al., 2006). The presence of pain also has been shown to increase the intravenous self-administration of fentanyl in healthy non-drug using volunteers undergoing experimentally induced pain induced by cold water immersion of the forearms (Zacny et al., 1996). Experiments in rats conducted by Colpaert and colleagues (Colpaert et al., 1982, 2001) using an adjuvant arthritis model of chronic pain induced by inoculation with the arthritogenic Mycobacterium butyricum, found that the oral intake of a fentanyl solution was higher in arthritic than in non-arthritic control rats. Several other studies have shown an increase in operant intravenous opioid self-administration and a sigma-1 antagonist following neuropathic
pain induced by partial ligation of the sciatic nerve or by spinal nerve ligation (Bura et al., 2013; Martin et al., 2007; Martin and Ewan, 2008; Wade and Fairbanks, 2014). Some of these studies also reported modulation of the subjective (humans) or anhedonic (rats) effects associated with pain reduction through self-administration (Zacny et al, 1996; Bura et al., 2013).

Pain has been shown in several other studies to modulate the subjective and reinforcing effects of opioids in both normal human volunteers and in those with opioid abuse histories (Comer et al., 2010; Conley et al, 1997; Zacny et al, 1996; Wolff et al., 1940). Comer et al. (2010) evaluated oxycodone abuse liability in prescription opioid abusers as a function of pain and drug use history to determine if pain and a drug use history would alter the subjective effects of oxycodone. Two groups of healthy volunteers were studied, with one group (N=9) that was abusing prescription opioids and a second group (N=9) that had used prescription opioids medically but did not abuse them. Experimental pain was induced using the cold water (4°C) immersion and the warm water (37°C) procedure. The results were quite striking with oxycodone producing similar subjective effects in prescription drug abusers and non-drug users. The main difference between the two groups was that the non-drug abusing subjects only self-administered oxycodone when in pain, whereas those subjects that were opioid abusers self-administered oxycodone regardless of the pain condition.

The relationship between the rate of oxycodone infusion on the subjective and reinforcing strength of oxycodone was studied in 12 heroin-dependent volunteers (Comer et al., 2009). Intravenous infusion rates over intervals that started at 2 minutes and ranged further from 15-90 minutes resulted in peak subjective and reinforcing effects of oxycodone at the shorter duration infusion; there were no differences in subjective ratings or liking between placebo and oxycodone over the 15–60-minute time period.

When Comer et al. (2013) compared choice behavior of opioid addicts maintained on sublingual buprenorphine, they found that when the choice was between morphine and oxycodone, the participants consistently preferred the high dose over the low dose of each drug compared to placebo. Under a different procedure where morphine and oxycodone were compared or money was an alternative, the participants chose money over both drugs. At the high doses of oxycodone and morphine, oxycodone was chosen more frequently than morphine.
D. Gender Differences in Abuse Liability of Oxycodone - Human Studies

There has been growing evidence that men and women differ with regard to their risks for substance abuse, but this view is not unequivocal as there are relatively few studies, sometimes small in numbers, and occasionally with inconsistent results. Becker and Hu (2008) and Becker et al. (2017) reviewed gender differences in drug abuse and concluded that gender differences are present during all phases in the progression from initiation, escalation, addiction, relapse and withdrawal but this view is predominantly based on rat models (see also Carroll et al., 2004). A series of 4 studies on “Sex differences in Addict Careers” published in 1987 covered 4 stages related to heroin abuse that started with the initiation of heroin use, “becoming addicted”, “being addicted” (Hser et al., 1987a,b; Anglin et al., 1987a), with the last article in the series focused on treatment (Anglin et al., 1987b) These studies, conducted with over 500 heroin-dependent people admitted to methadone maintenance treatment programs, permitted a systematic comparison between men and women with regard to antecedent behaviors leading to initial drug use and then proceeding through to addiction. Although these studies did not include oxycodone, they are, nevertheless, informative of the processes leading to SUDs and to potential differences between men and women in these different phases of OUDs.

Accumulated evidence has demonstrated the occurrence of several differences between male and females in the biological response, causes and correlates of drug abuse, craving and relapse, along with residual long-term effects (Lynch et al., 2002; Nicolas et al., 2022). Although the majority of the focus has been on alcohol, nicotine and cocaine, there are growing number of studies recognizing the importance of including women in behavioral and clinical studies in light of the increasing SUDs involving women. The role of gender in opioid use disorders in humans has been difficult to elucidate due to the challenges in attempting to isolate biological effects from environmental context, the ambiguities surrounding historical factors leading to the development of opioid use disorders, the role of genetics, and difficulties surrounding multidrug use. There are several other complications and difficulties in attempting to interpret the results of some studies comparing females and males due to inconsistent results, the lack of placebo controls, the heterogeneity of subjects and pain conditions and, typically the small numbers involved.
Gender differences in the initial exposure to abused drugs have been suggested to emerge due to differences in the initial likelihood of recreational exposure opportunities between males versus females, an emphasis which might be historical rather than current (Van Etten and Anthony, 2001; Van Etten et al., 1999). However, the outcome of this large study, conducted over a 15-year period with 131,226 residents of the U.S. that were recruited for the National Household Surveys on Drug Abuse, emphasizes the importance of environmental factors as drivers of initial exposure and continued involvement leading to SUDs, rather than biological or genetic predispositions. Gender differences at an early stage of drug exposure may account for differences in later stages of drug involvement that ultimately lead to dependence. Van Etten et al. also found that, across marijuana, cocaine, hallucinogens and heroin, the evidence demonstrated no difference between males and females in the probability of making a transition from the initial ‘exposure opportunity’ to more continued use. Van Etten et al. acknowledge that this study was not a prospective study and provides appropriate caveats about self-reported data.

There is one study on the effects of oxycodone in healthy volunteers that showed gender differences in several subjective effects of oxycodone (Zacny and Drum, 2010). Although both men and women reported dysphoric effects and nausea from oxycodone, women reported effects that were of greater magnitude.

Although these studies are informative, the number of subjects in each of the reports was small, occasionally with just a single woman, precluding the likelihood of drawing of any definitive conclusions. These and other studies of laboratory-based abuse liability assessments are covered in a subsequent section of this review.

VII. Oxycodone Abuse Liability Studies in Animals

A. Drug self-administration

Studies examining the abuse liability of oxycodone in experimental animals have been numerous. Oxycodone is a robust reinforcer, capable of initiating and maintaining responding in all species in which it has been studied. The maintenance of responding by oxycodone has been used frequently to evaluate novel and repurposed therapeutics for the treatment of OUD that will
decrease oxycodone-maintained responding but not affect responding maintained by other reinforcers such as food. These studies are summarized later in this review under “Treatment Approaches to Oxycodone Abuse”. Although the majority of studies examining oxycodone self-administration have used i.v., administration, an increasing number of studies have developed procedures using the oral route, which has been the usual form of oxycodone when used and abused (Enga et al., 2016; Fulenwider et al., 2020; Jimenez et al., 2017; Phillips et al., 2020; Slivicki et al., 2023; Zanni et al., 2020).

Oxycodone engendered relatively high rates of responding for i.v. infusions of oxycodone in rhesus monkeys with the rate of responding similar to those observed with alfentanil, a μ-opioid agonist also with high reinforcing efficacy (Woods et al. 2003). Leri and Burns (2005) studied oxycodone self-administration in male Sprague-Dawley rats including an examination of whether ultra-low-dose naltrexone would attenuate oxycodone self-administration as well as reinstatement. The combination of naltrexone and oxycodone enhanced oxycodone self-administration, suggesting a reduction in the reinforcing potency. The combination of oxycodone and naltrexone also reduced drug taking following a ‘priming’ dose of oxycodone, with the co-administration also reducing the ‘break-point’ under a progressive-ratio schedule of reinforcement (see below). Similar results were also reported with CPP that was used to evaluate the reinforcing effects of oxycodone (Olmstead et al., 2005).

Wade et al. (2015) compared the self-administration of several opioid analgesics in rats using the extended access model and responding under a progressive-ratio schedule of reinforcement. Animals were trained to self-administer heroin, fentanyl, oxycodone or buprenorphine under conditions where the response requirement to receive the drug progressively increased following the infusion of drug. The ‘breakpoint’ measured the ‘reinforcing strength’ or the motivational properties (Hodos, 1961; Richardson and Roberts, 1996) of each drug and was based on the last infusion taken in the 6 hr experimental session. Heroin, fentanyl and oxycodone produced an initial escalation of responding followed by stable lever pressing, whereas buprenorphine did not. Comparable increases in the breakpoint were seen at the middle doses for each of the three drugs, again with the exception of buprenorphine. The progressive escalation of oxycodone-maintained responding has been observed in a variety of studies in both rats and mice (Matzeu and Martin-Fardon, 2020; Nguyen et al., 2021; Wade et al. 2015; Zhang et al., 2014).
Zhang et al. (2009) reported a differential sensitivity to striatal dopamine levels following the self-administration of oxycodone in adolescent and adult mice. An initial period of self-administration concluded that adult mice self-administered more oxycodone across the spectrum of doses than did adolescent mice. When mice were subsequently implanted with a guide cannula implanted into the striatum and doses of oxycodone were administered i.p., followed by in vivo microdialysis, it was found that adolescent mice self-administered a lower number of oxycodone infusions at the lowest dose of oxycodone but had increased levels of striatal dopamine, suggesting to these authors a differential sensitivity to the reinforcing and neurobiological effects of oxycodone in younger mice.

More recently, Samson et al. (2022) were interested in determining whether alterations in dopamine transmission in the mesolimbic pathway were related to abstinence from oxycodone. Female and male Long Evans rats were trained initially to self-administer i.v. oxycodone in a session that was 6-hours long. Following acquisition, the rats were switched to an intermittent schedule for 10 days where access to oxycodone was limited to 5 minutes and was followed by a 25-minute period where drug access was not available. Access to oxycodone was then completely eliminated for either 1 or 14 days and, on these days, responding produced only the stimulus cue previously associated with oxycodone delivery. When tested on days 1 and 14, there was robust responding engendered by presentations of the stimulus associated with oxycodone and this was sustained over the 14-day period of abstinence. Dopamine uptake was dramatically reduced during this time period, leading to changes and a dysfunction in dopamine transmission. Samson et al. suggest that these changes in dopamine neurotransmission and the sustained responding to the drug-associated cue may be viewed as an index of ‘craving’, that is related to a compensatory response to a reduction in dopamine associated with opioid abstinence that, in turn, may contribute to drug seeking behavior. Samson et al. did not note any sex differences in any of the experiments in that both females and males responded similarly across conditions.

B. Reinstatement and Craving

In addition to drug self-administration procedures and drug discrimination procedures (see section VI.D) that are used frequently to evaluate the potential abuse liability of a drug, two other methods have been used with increasing frequency that broadly reflect key issues surrounding relapse. Relapse to drug use following a period of abstinence is of clinical
importance and has been the focus of a number of preclinical studies. This procedure typically establishes responding and maintains access to the drug of interest for a period of time that is followed by discontinuation of the drug’s availability (extinction). When responding declines to low levels due to the absence of drug reinforcement, responding can typically be reinstated by the brief administration of the drug (a ‘priming’ stimulus), by the presentation of a stimulus (‘cue’) that was previously associated with drug delivery, or by exposure to the context in which the drug has been administered previously (Venniro et al., 2016. The conditioned stimuli that have been paired with drug delivery have also been shown to maintain responding reinstated by foot shock or by a priming dose of oxycodone (Grella et al., 2011).

In the context of SUDs, craving has been defined as a persistent and intense desire to use a drug. Craving is listed in the International Classification of Diseases (ICD-11, 2018) as one of the six characteristics of psychoactive substance dependence and the 2013 DSM-5 (American Psychiatric Association) has recommended that craving become the recommended standard for diagnosing SUDs. Recently, there has been increasing focus on the neurobiological correlates of craving related to OUDs Kakko et al., 2019; Lueptow et al., 2020).

Susceptibility to relapse is, among other variables, frequently believed to be related to craving which has emerged as an important indicator of drug seeking and relapse. Gauld et al. (2023), following an extensive network analysis of opioids and other drugs, have concluded that craving is a potential central marker, connecting to the entire symptom network regardless of the specific substance, and can be used to aid and facilitate the understanding and treatment of SUDs.

An example of context-induced reinstatement using oxycodone was reported by Bossert et al. (2019) who trained rats to self-administer oxycodone in daily 6-hour sessions in one context (A); in a different context (B) responding was extinguished when oxycodone was not delivered. The two contexts also differed in terms of auditory, tactile and visual cues. During extinction, the number lever-press responses declined but when re-exposed to context A and B, responding increased in context A above that when the rats were exposed to context B. Bossert et al. (2019) were also able to show that the oxycodone’s effects were mediated by the μ-opioid receptor through administration of the antagonist naltrexone but there was no clear evidence for a role of δ or κ-opioid receptors in oxycodone self-administration.
Previous studies have reported that neurokinin 1 receptor (NK1R) is involved in SUDs and that antagonism of this receptor attenuates opioid self-administration (Ripley et al., 2002; Sandweiss et al., 2018; Shank, 2014). Fulenwider et al. (2020) studied the effects of NK1R antagonism on stress-induced reinstatement of oral oxycodone self-administration in male and female Long-Evans rats. Following the extinction of responding when water replaced oxycodone and using footshock to induce stress, Fulenwider et al. found lever pressing was increased. The administration of 15 mg/kg, i.p. of the NK1R antagonist L822429 significantly attenuated reinstatement of oxycodone self-administration in both male and female rats. More detailed studies with NK1R are given in section VII of this review under Pharmacological Modulation of Oxycodone in Laboratory Animals.

Reinstatement of extinguished responding that had been maintained by oxycodone, was attenuated by administration of buprenorphine and by a ‘biased’ μ-opioid receptor agonist TRV130 (Bossert et al., 2020) reaffirming the utility of buprenorphine as a treatment option for OUDs and suggesting that biased μ-opioid receptor agonists may also be effective treatment options for relapse. A number of studies addressing relapse associated with drug craving have focused on neurobiological sequelae that include the role of certain brain regions (Altshuler et al., 2021, Fredriksson et al., 2023), glutamate receptors in the rat hippocampus (Salisbury et al., 2021), changes in mRNA expression of fibroblast growth factors and immediate early genes (Blackwood et al., 2019b).

Reinstatement of oxycodone-maintained responding has been studied in male and female (N=4/sex) squirrel monkeys (de Moura et al., 2023). The study was focused on the availability of an alternative reinforcer (sweetened condensed milk) in its effect on oxycodone self-administration and reinstatement. The availability of milk decreased oxycodone self-administration and significantly attenuated oxycodone-primed responding in both male and female monkeys. Low milk concentrations were more effective in lowering self-administration in males whereas low concentrations of milk were more effective in decreasing priming reinstatement in the females. De Moura et al. suggest that treatment strategies that focus on the use of alternative reinforcers should be examined carefully for gender-specific effects.

Studies of potential abuse liabilities of compounds are increasingly incorporating reinstatement and relapse methods into experimental analyses in addition to drug self-
administration. Accordingly, the inclusion of these methods permits a more global assessment of the initiation, maintenance and cessation of drug taking behavior, along with environmental factors that occasion relapse to drug taking. Treatment approaches of SUDs must take these different facets into consideration when evaluating potential pharmacological as well as behavioral interventions.

C. Impulsivity

A number of studies have demonstrated that several drugs of abuse produce impulsive behavior in both human and animal models (de Wit, 2008; Perry and Carroll, 2008). Impulsivity is believed to be a determinant as well as a consequence of drug use whereby impulsivity is responsible for the initial drug taking and that drug use itself further drives behaviors related to impulsivity, poor decision making, lack of sensitivity to negative consequences, and risky behaviors (see also Poulton and Hester, 2020). The majority of research on impulsivity has focused on cocaine, amphetamine, methylphenidate, and alcohol and has used a variety of measures and methodologies, with a number of studies conducted with humans in addition to rodents (see Perry and Carroll, 2008 and de Wit, 2008 for extensive summaries of drugs and procedures to assess impulsivity and Weafer et al., 2014 for studies on the translation of impulsivity findings in relation to substance use). Very few studies have focused on opioids, although Kieres et al. (2004) and Pitts and McKinney (2005) have examined the effects of morphine in rats on measures of impulsivity and found an increase in impulsivity across a range of doses. Similar findings with morphine were also obtained in rats (Pattij et al., 2009) and in rats dependent on morphine (Harvey-Lewis et al., 2012), with comparable results also reported in rhesus monkeys (Maguire et al., 2012).

Hunt et al. (2020) studied the effects of oxycodone on sensitivity to the magnitude of reinforcement in rats using a procedure that assessed choice between a large or small reinforcer. Under control (non-drug) conditions, all rats developed a reliable preference for the larger reinforcer. Administration of oxycodone produced a dose-related decrease in the preference for the larger reinforcer, indicating that oxycodone decreased the sensitivity to reinforcer magnitude and did so without affecting any of the other behavioral measures such as motor function that might affect responding. The decreased sensitivity to reinforcement magnitude with oxycodone
and other \( \mu \)-receptor opioid agonists may represent an important behavioral and pharmacological mechanism that underlies the relationship between risky choice and impulsivity.

Although very few studies have examined the effects of oxycodone on measures of impulsivity in humans, Zacny and de Wit (2008) examined the effects of orally administered oxycodone (5, 10 and 20 mg) on several measures of impulsivity in 12 healthy volunteers and found no effects of oxycodone on any of the tasks that were examined. Although the authors of this study commented that there was considerable variability on all of the measures of impulsivity, and that some of the data were not usable, limiting sample size, they concluded that oxycodone in the doses used were unlikely to increase impulsive or risky behaviors in most patients.

D. Sex Differences in Abuse Liability of Oxycodone – Animal Studies

Although, traditionally, the focus of most substance use-related research was conducted in male animals, this has changed considerably with the recognized need to use both male and female subjects in studies of SUDs. Most of the studies in animals have examined opioids other than oxycodone. However, gender differences in several dimensions, including antinociceptive activity, discriminative stimulus properties, dependence and abuse liability ascertained in drug self-administration studies prompt a review of all these areas that are likely to expand as more attention is directed towards delineating sex and gender differences in SUDs, particularly when it comes to treatment options and future medications.

Although not investigating oxycodone, but illustrative of the type of study examining the abuse liability of opioids in female and male rats, Cicero et al. (2002) found strong sex differences in i.v. self-administration of heroin and morphine, with female rats consuming significantly greater amounts of these drugs than males. In addition, the ‘breakpoint’, i.e., where the animals stop responding to increases in the response requirement to obtain the drug, was higher in females than in males. Although these results were similar to findings reported earlier with heroin (Lynch and Carroll, 1999), they differed from those reported by Stewart et al. (1996). Although the basis of the differences between the outcomes of these studies remains somewhat unclear, there were differences in the range of doses examined, and other features, including
schedule parameters, that could have contributed to the different outcomes. In any event, these
findings reinforce the need to include both male and female subjects in the various procedures
examining opioid pharmacology.

Several studies that have examined the effects of various opioids in drug self-administration
in an effort to determine whether there are differences in drug-seeking behavior between male and
female rats and mice. Generally, despite some variations in procedures, drugs such as heroin,
fentanyl and morphine result in higher intake in female than in male rats (Bossert et al., 2022;
D’Ottavio et al, 2022), suggesting that \( \mu \)-opioid agonists are more reinforcing in females
compared to males (see review by Craft (2008).

Studies that evaluated the effects of oxycodone self-administration in male and female rats
have also been reported. For example, Mavrikaki et al. (2017) established oxycodone self-
administration in male and female Sprague Dawley rats and compared these results with a
separate group of rats that were provided with sucrose pellets as a reinforcer to determine whether
there were gender-related differences between drug and food reinforcers. When the response
requirement was 1 to obtain food or an i.v. injection of 0.03 mg/kg, of oxycodone (Fixed Ratio or
FR 1), males made more lever responses to obtain oxycodone than females. Under the same FR 1
response requirement, females responded more to obtain sucrose pellets than males, with this
difference quite dramatic. However, when the schedule for the self-administration of 0.03 mg/kg
of oxycodone was changed to FR2 and FR5, the sex-related differences disappeared. Overall, at
the higher FR5 value, there was not a dramatic difference in the patterns or frequency of
oxycodone self-administration between males and females. The nature of the differences
depending on the different response requirements raises an important point about studies that
examine only a single response requirement when, in fact the schedule of reinforcement may play
an important role in the results. As drug seeking in humans typically involves multiple sequences
of responses, not just a single response, more experiments should examine a range of schedule
parameter values to explore the generality of the findings. The schedule under which a drug is
available is as important as the dose and both require careful consideration.

An operant oral oxycodone self-administration procedure (0.1 mg/ml) was used by
Fulenwider et.al., (2020) to examine sex differences in adult male and female rats. Female rats
consumed significantly more oxycodone than did males and the self-administration of oxycodone
was decreased in both sexes following repeated naloxone administration (10 mg/kg, i.p.). Similar findings were reported by Zanni et al. (2020) where both male and female Long-Evans rats readily consumed oxycodone and preferred it to water in a two-bottle chronic, continuous access paradigm with water in one bottle and oxycodone in the other. All rats readily drank the oxycodone solution and escalated their intake over a 22-week period. Females in this study self-administered twice as much oxycodone by body weight than males, resulting in higher blood levels of oxycodone.

Using an extended access procedure where rats were given 12-hr experimental sessions, Kimbrough et al. (2020) evaluated i.v. oxycodone self-administration (150 μg/0.1 ml infusion) and withdrawal behaviors in female and male Wistar rats. Both male and female rats showed a rapid escalation of oxycodone self-administration with female rats self-administering significantly more oxycodone than males. Overall hourly rates of intake were significantly higher for females during the final 4 hr of the experimental session. Although there were no differences between male and female rats in plasma oxycodone levels, levels of oxycodone in the brain of males were significantly higher than those in female rats at 30 min. Following a 12 hr period of withdrawal, rats were tested for sensitivity to paw withdrawal stimulated by von Frey fibers that produced pronounced hyperalgesia, with no differences between male and female rats.

Nicholas et al. (2022) reviewed experiments using cue-, context- and stress-induced reinstatement in animal models of opioid and psychostimulant craving in an effort to determine whether there was experimental support for sex difference in these two measures of reinstatement for assessing substance use. Overall, although there were a limited number of studies and none with oxycodone, there was little support for sex differences in cue-, context- and stress-induced reinstatement of opioid seeking. In a study that did focus on oxycodone, Phillips et al. (2020) reported no differences between sexes in cue-induced reinstatement of oxycodone self-administration in mice.

Using a different procedure, Collins et al. (2016) also found no differences between male and female C57BL/6J mice in the CPP procedure with oxycodone doses of 1,3 and 10 mg/kg, although at each of the doses, males spent more time in the compartment associated with oxycodone than did the females, but these differences were not statistically different. Locomotor activity in the open field was increased at all three doses in the females but only at the 3 and 10
mg/kg in the males. Plasma corticosterone levels were higher in females following the injection of oxycodone and, in tests of analgesia, there was no difference in the time course but the total antinociceptive effect using the hotplate was larger in males compared to the females. Collins et al. concluded that their data suggest that male and female mice are ‘modestly different’ in their response to oxycodone.

Acknowledging that the role of sex and gender in addiction has been difficult to elucidate, Ryan et al. (2018) studied oxycodone CPP in female and male Sprague-Dawley rats and examined possible changes in hippocampal opioid circuitry. Hippocampal neural circuitry of both sexes is known to be involved in associative memory formation and in encoding motivational incentives that may be important in the transition from initial drug use to drug abuse and dependence. Both female and male rats acquired CPP, but the development of oxycodone CPP produced several sex-dependent redistributions of opioid receptors in hippocampal circuits. Both μ-opioid and δ-opioid receptors redistributed differently in hippocampal circuits of males and females following the development of CPP. Among the many results is one in particular that stands out and may help to better understand the differences in the greater susceptibility of females to opioid abuse and in relapse. After oxycodone-induced CPP, μ-opioid and δ-opioid receptors redistributed in the hilar interneurons in females that, as a result, would enhance disinhibition of granule cells via two different circuits. According to Ryan et al., this redistribution could facilitate plasticity associated learning associated with oxycodone, which might account for the greater female susceptibility to μ-opioid agonists.

Sex differences were found by Randesi et al. (2019) who studied neuroplasticity and stress-related gene expression and protein levels in the hippocampus of male and female Sprague-Dawley rats following oxycodone-induced CPP. Both male and female rats exhibited CPP following repeated exposure to 3.0 mg/kg oxycodone. Several differences emerged between male and female rats that included changes in plasticity genes, stress and kinase markers in the circuitry of the hippocampus. For example, females showed hippocampal region-specific changes that included increases in the activity of regulated cytoskeletal-associated protein (ARC) immunoreactivity and corticotropin releasing factor receptor (Crhr2). There were also decreases in neuropeptide Y gene expression in the medial hippocampus and in phosphorylated mitogen activated protein kinase (MAPK). These changes contrast with those in males where, for
example, brain derived-neurotrophic factor (BDNF) was increased as was Mapk1, relative to females. These differences suggest mechanisms by which oxycodone can interact differently within the hippocampal opioid systems of male and female rats to affect differences in plasticity related to learning processes and, presumably in the acquisition of drug use and dependence.

Chalangal et al. (2022) have provided an informative and comprehensive review on sex differences in the rodent hippocampal opioid system following stress and oxycodone. Using electron microscopic immunocytochemistry to investigate changes in the distribution of opioid peptides and receptors in specific hippocampal circuits following stress and oxycodone induced CPP, Chalangal et al. found a number of differences between male and female rats. A key finding in this report is that, as found in the Ryan et al. study, opioid peptides and their receptors are redistributed in hippocampal circuits in females such that they would conceivably enhance sensitivity to both endogenous and exogenous opioids. In addition, the authors suggest that chronic stress ‘primes’ the opioid system in females and this would promote opioid-associated learning, again a gender-specific response that may account for the known sex differences in opioid use, abuse and in the effects of stress since these changes are not seen in males and the absence of such changes in these parameters may reduce the capacity to support opioid-mediated learning.

Beierle et al. (2022) found robust sex-dependent substrain differences when comparing the effects of oxycodone in BALB/cj and BALB/cByj mice. In CPP, the female BALB/cj mice spent more time in the side associated with oxycodone than the BALB/cByj mice, showing enhanced sensitivity to oxycodone, whereas the male strains did not differ. The female BALB/cy mice also showed an increase in the concentration of the oxycodone metabolites noroxycodone and oxymorphone when compared with the BALB/cByj mice. Using quantitative trait locus mapping and whole brain proteomics, Beirele et al. identified a candidate gene Zhx2, a transcriptional factor that has an established role in protection against hepatocellular carcinoma (Li et al, 2022). This gene also appears to be involved in gender specific sensitivity to oxycodone’s reinforcing effects that may be related to the brain concentrations of oxycodone in the specific substrain of mice.

Reinstatement of oxycodone self-administration has been studied by Guha et al. (2022) in an attempt to assess possible differences between male and female Sprague-Dawley rats.
an 8-day training period of oxycodone self-administration, rats were exposed to 14 additional
days of either short access (1 hr/day), longer access (6 hr/day), or saline. Cue-induced
reinstatement was studied following a 14-day period of abstinence. During the reinstatement
phase, lever pressing produced the light previously associated with drug delivery but there was no
delivery of oxycodone. The magnitude of responding during the long-access procedure was
higher than that under the short-access procedure but there were no differences between male and
female subjects. However, responding during the reinstatement phase was higher in females
compared to males exposed to both the long and short access procedures.

Finally, although not specifically related to abuse liability, oxycodone has been shown to
decrease anxiety-like behavior in the elevated plus-maze in both male and female rats (Bruijnzeel
et al., 2022). Anxiety, as measured by the percentage of time spent in the open arms of the maze
and the percentage of entries into the open arms, was decreased more with oxycodone in males
than in females suggesting a sex-related difference in the anxiolytic effects of oxycodone. This
result may be related to the fact that vehicle-treated males made fewer entries into the open arms
(a sign of ‘anxiety-like’ behavior) than did females treated with vehicle which would bear on the
percentage changes. Similar differences between male and female rats were also obtained using
an open field test where the females traveled greater distances than males while also showing
more rearing responses.

Taken as a whole, the studies that examined whether there were differences between males
and females in the effects specifically of oxycodone in models of substance use, point to a number
of differences with females generally responding at higher rates in self-administration
experiments, showing changes in brain circuitry, primarily in the hippocampal region, along with
sex differences in reinstatement. However, it is clear that there is a relative paucity of data on this
topic that further systematic studies are warranted.

E. Drug Discrimination

Drugs can produce interoceptive stimuli when administered to laboratory animals and to
humans. Drug discrimination has been used often to ask a number of questions about agonist –
antagonist relationships, receptor-mediated effects, generalization across drug classes, and to
provide additional information about abuse liability that adds to the information obtained in drug self-administration studies. The drug discrimination procedure establishes a discrimination, typically between a drug and saline by providing differential reinforcement of responding, typically in a two-lever procedure where, following the administration of a drug, responses on one of the levers results in the delivery of food and, on separate days, following the administration of saline, responses on the alternate lever result in food presentation. Typically, training continues until the animal is discriminating the drug from saline at approximately 90-95% correct and this step is followed by completion of a dose response curve with the training drug. Once the discrimination is established, it is then possible to substitute other drugs, including pharmacological antagonists to evaluate mechanistic studies with the training drug, to determine if those substitutions produce responding on the lever associated with the drug or on the lever associated with saline administration (Reviews by Colpaert, 1999; Craft, 2008; Glennon et al., 1983, 1991; Swedberg, 2016). It is a significant feature of drug discrimination procedures that abused drugs from with the same neuropharmacological receptor-mediated mechanism will reliably substitute for the training drug, whereas drugs from a different pharmacological class will generate responding on the saline lever. Not only is there pharmacological specificity between different drug classes, e.g., opioids and psychostimulants, but there is also discriminative specificity within a drug class. Following the establishment of a discrimination with a μ-opioid receptor agonist responding will not generalize to δ− or κ-opioid receptor agonists.

These methods have been used to establish oxycodone-saline drug discrimination as a way of evaluating other opioid compounds that are mediated by different opioid receptors. In one of the first studies of this nature, Beardsley et al. (2004) trained male Long-Evans rats to discriminate saline from 0.3 mg/kg, s.c. heroin. This training dose produced near 100% correct responding, whereas the water vehicle produced near 0% responding on the heroin lever. Substitution of oxycodone produced dose-dependent increases on the lever associated with heroin, reaching approximately 100% responding; the potencies of the two drugs were comparable. This study also reported that oxycodone substituted for heroin in self-administration studies, providing good agreement between these two behavioral procedures.

Morphine and oxycodone were also studied in C57/Bl/6 male and female mice trained to discriminate morphine from saline (Neelakantan et al., 2015), with oxycodone substituting
completely for morphine at equipotent doses in both sexes. Walentiny et al. (2019) also trained C57Bl/6 mice to discriminate 1.3 mg/kg, s.c. oxycodone from vehicle using a fixed-ratio 10 schedule of food presentation. Fentanyl and several fentanyl-related drugs were examined (ocfentanill, 3-furanyl fentanyl, crotonylfentanyl and valerylflentanyl), with all compounds completely substituting for oxycodone in a dose-related manner. Naltrexone pretreatment decreased oxycodone-like responding for fentanyl and all fentanyl-related compounds.

In another study with oxycodone established as a discriminative stimulus in mice, Walentiny et al. (2018) examined whether a nociception/orphanin FQ (NOP) agonist, Ro64-6198 could modify the discriminative stimulus effects of oxycodone. These investigators antagonized the effects of oxycodone with a naloxone pretreatment and also showed that heroin and morphine, but not the κ-opioid receptor agonist U50488, fully substituted for oxycodone. The NOP receptor agonist Ro64-6198 reduced oxycodone lever responding, shifted the oxycodone curve to the right, and the effects of Ro64-6198 were reversed following administration of the NOP receptor antagonist J-113397. Walentiny et al. (2018) suggests that the attenuation of oxycodone’s discriminative stimulus effects by NOP receptor agonists may be mediated by modulation of dopamine signaling since the endogenous NOP ligand nociceptin/orphan FQ reduces basal DA release and reverses morphine-induced increases in dopamine (Di Giannaruio, et al., 1999; Di Giannaruio and Pieretti, 2000; Murphy et al., 1996; Murphy and Maidment, 1999). Finally, since it is believed that the discriminative stimulus effects of drugs are mediated by interoceptive stimuli, and the information derived from these studies have relevance for OUDs, attenuation of the effects of oxycodone and other μ-receptor opioids by NOP agonists suggests that this class of compounds may have utility in the treatment of OUDs. Finally, the absence of substitution with κ-opioid receptor agonist U50488, reaffirms that at least the discriminative stimulus effects of oxycodone do not involve κ-opioid mediated activity.

In a slightly different approach, Withey et al. (2020) examined the effects of oxycodone on learning a discrimination in squirrel monkeys. Using touchscreen-based visual discrimination procedure, the effects of oxycodone were examined during a period when the monkeys were self-administering oxycodone and when oxycodone was administered during chronic treatment. The effects of naltrexone precipitated withdrawal and cessation of oxycodone treatment were also studied in the context of the visual discrimination procedure. When the effects on the
development or the performance of the visual discrimination were evaluated during the period when oxycodone was self-administered or when chronically treated, there was no impairment of the performance on the discrimination, but the discrimination was substantially impaired during withdrawal precipitated by naltrexone and discontinuation of oxycodone.

F. Imaging Studies

In addition to the BOLD study described earlier (Moore et al., 2013, section II.B.), there are a few studies that also have examined the effects of both acute and chronic exposure to oxycodone in experimental animals. Nasseef et al. (2019) used pharmacological magnetic resonance imaging in mice to examine whether oxycodone affects coordinated activities in brain networks (functional connectivity) typically associated with pain and substance use. Oxycodone administration produced a reduction in the communication between brain regions. Although widespread effects in the brains were observed, two regions associated with pain (periaqueductal gray) and reward centers (NAc), both rich in μ-opioid receptors, were the primary targets that underwent a marked reduction in normal functional connectivity. Oxycodone-induced alterations in these brain regions parallel their well-known behavioral involvement in pain and abuse. As with the Moore et al. study, there was no effect of oxycodone on the functional connectivity of these brain regions in the μ-opioid receptor knock-out animals.

BOLD imaging was also used by Iriah et al. (2019) to study the response to acute exposure to oxycodone in male rats. In contrast to the Moore study and to the Nasseef study, rats given 2.5 mg/kg of oxycodone i.p. did not show effects on the BOLD signal in the NAc, suggesting that the first acute administration of oxycodone may not be rewarding. In an effort to image changes in the brain following repeated administration of oxycodone, the researchers had to move away from BOLD due to movement artifacts and employ a manganese-enhanced MRI. This effort involved injecting MNCl2 into the right lateral ventricle. Manganese is readily taken up by active neurons that accumulate the ion and, once inside the neuron it can move across active synapses to label integrated neural circuits and their functional connections. Oxycodone was administered twice daily for four days, with imaging occurring following the last dose. Under these conditions, the accumbens core and shell and ventral pallidum were activated, as were the forebrain limbic system, amygdala and hippocampus. The differences in brain activity following
acute or chronic oxycodone administration are not surprising and it would be of great interest to expand these studies to female rats to examine potential gender differences in these effects.

VIII. Pharmacological Modulation of Oxycodone in Laboratory Animals

The majority of studies in animals that have been directed at evaluating potential pharmacological treatments for OUDs have established responding maintained by i.v. heroin, fentanyl, morphine, or oxycodone. Although some efforts have been made to identify ‘pan-therapies’ that also would include psychostimulant use as well as opioid use, this section will focus on experiments where oxycodone has served as the baseline drug either in self-administration experiments or when using CPP. There has been a major effort to identify novel or ‘repurposed’ compounds that prevent drug seeking behavior and relapse. Compounds described below are typically drugs that are being used therapeutically for other indications and would be repurposed if shown to be effective in these procedures.

A. Ultra-Low Dose Naltrexone

Leri and Burns (2005) followed up on a previous study (Olmstead and Burns, 2005) showing that low-dose naltrexone blocked the development of CPP in rats. Leri and Burns examined the effects of ultra-low-dose naltrexone on oxycodone self-administration and also included an assessment of whether naltrexone pretreatment would affect vulnerability to relapse that was precipitated by a priming injection of oxycodone, by foot-shock stress, or by a drug cue previously established by its association with oxycodone self-administration. Whereas the addition of naltrexone doses of 10 or 100 pg/kg/inf in combination with oxycodone (0.1 mg/kg/inf) did not alter the self-administration of oxycodone, a reduction to 1 pg/kg/inf of naloxone increased the number of oxycodone infusions which the authors suggested indicated a reduction in the reinforcing effects of oxycodone. Following a period of extinction, where lever press responding had no consequence, responding decreased significantly. However, all three doses of naltrexone significantly reduced the reinstatement of responding that was produced by a priming dose of oxycodone (0.25 mg/kg, s.c.), the presentation of the oxycodone-conditioned cue,
or foot shock. Finally, the lowest dose of naltrexone also reduced the ‘break point’ under a progressive-ratio schedule, with animals lowering the number of responses to produce oxycodone, suggesting that naltrexone decreased the reinforcing value of oxycodone. Taken together, these studies suggest that ultra-low-dose naltrexone decreases the reinforcing potency and the motivation to self-administer oxycodone and attenuates the vulnerability to relapse.

B. Kappa Opioids

As described throughout sections of this review, the possible involvement of the κ-opioid receptor has been woven inextricably into the pharmacology of oxycodone. The effects of the κ-opioid receptor agonist nalfurafine has been shown to reduce the reinforcing and respiratory depressant effects of oxycodone while augmenting the effects of oxycodone on thermal antinociception in Sprague-Dawley rats (Townsend et al., 2017). Oxycodone self-administration (56 μg/kg/inj) was conducted using a progressive-ratio schedule of reinforcement. Nalfurafine decreased the reinforcing effects of oxycodone under this self-administration procedure and, by itself, nalfurafine did not maintain responding. Both oxycodone and nalfurafine produced dose-dependent antinociception and, when given in combination, were additive, with the mixtures not producing respiratory depression. These results suggested that appropriate doses of nalfurafine in combination with oxycodone could be effective in decreasing the abuse liability, retaining a nociceptive profile, while also not impacting respiration.

Kappa opioid receptor agonists have been reported also to reduce oxycodone self-administration in rhesus monkeys (Zamarripa et al., 2020). A procedure was used by Zamarripa et al. whereby on alternate days, either cocaine or oxycodone were self-administered under a progressive-ratio schedule. On days when oxycodone was self-administered, the effects of pretreatment with salvinorin A or nalfurafine, two κ-opioid receptor agonists, were examined. Both agonists reduced the number of oxycodone injections to saline self-administration levels and the effects of nalfurafine were reversed by pretreatment with nor-BNI the κ-opioid receptor antagonist.

In effort to evaluate further the possible efficacy of κ-opioid receptor agonists to reduce oxycodone self-administration, Zamarripa et al. (2021) examined the effects of a novel κ-opioid
receptor agonist, triazole 1.1, on responding of Sprague Dawley rats maintained by intravenous delivery of 0.056 mg/kg/inj oxycodone. In addition to triazole 1.1, that had been reported to be devoid of typical κ-opioid receptor-mediated side effects, Zamarripa et al. also examined U50,488 and nalfurafine using a progressive-ratio schedule of reinforcement. All three compounds reduced oxycodone self-administration, with the order of potency nalfurafine > U50,588 > triazole 1.1.

C. Nociceptin/Orphanin FQ

Nociceptin/orphanin FQ is a 17-amino acid opioid-like peptide that binds with high affinity to the nociceptin/orphanin FQ receptor but has no affinity for μ, κ or δ-opioid receptors. It has been studied with a wide range of drugs, including opioids, but also psychostimulants and alcohol. Early studies by Mogil et al. (1996) concluded that orphanin FQ is a ‘functional anti-opioid peptide’ based on its modulation of various opioid actions that included morphine nociception. Rutten et al. (2010) studied the effects of a NOP receptor agonist, Ro65-6570, with a number of opioid and psychostimulant drugs. Ro65-6570 did not produce place preference but when given in combination with the minimally effective dose of oxycodone or tilidine, a low potency opioid agonist, the minimal effective dose of these drugs was higher than when administered alone. These effects were reversed by pre-treatment with the NOP receptor antagonist J-113397. Rutten et al. concluded that activation of NOP receptors effectively attenuates the rewarding effects of opioids since the NOP receptor agonist reduced the acquisition of place preference produced by the two opioids.

Several additional studies using CPP have reported that i.c.v. injections of nociceptin/orphanin FQ, the endogenous ligand of the opioid receptor-like 1 receptor, eliminated the CPP produced by morphine (Ciccocioppo et al., 2000), a finding that has been reproduced in several different experiments (see review by Ciccocioppo et al., 2019).

Kallupi et al. (2020) used an outbred, genetically diverse line of HS rats that were created at the NIH by outbreeding 8 inbred rat strains. These rats were characterized as having high or low addiction-like behaviors (HA and LA rats, respectively) that were determined after 3 weeks of chronic 12-hour access to oxycodone. Kallupi et al. derived a composite measure of addiction...
based on i) escalation of intake under a fixed-ratio schedule, ii) maintenance of responding under a progressive-ratio schedule, and iii) withdrawal-induced analgesia. A cue-induced reinstatement procedure revealed that the HA rats exhibited significantly increased responding in response to the cue associated with drug delivery, whereas the LA rats did not. When recording spontaneous inhibitory postsynaptic currents (sIPSCs) in slices taken from the central nucleus of the amygdala, HA rats were found to have higher basal levels of GABA release than the LA rats and there was a significant difference in sIPSC frequency between the HA and LA rats that was indicative of nociceptin mediated modulation of GABA neurotransmission. Finally, using oxycodone-maintained self-administration, delivery of nociceptin through guide cannula implanted in the central nucleus of the amygdala, selectively decreased oxycodone responding in the HA rats compared to the LA rats where there were no effects on responding. The authors of this study hypothesize that high levels of oxycodone intake in the HA rats may lead to a downregulation of the nociceptin system in the central nucleus of the amygdala and, as a consequence, the upregulation of GABA neurotransmission in this region that promotes addiction-like behaviors. Dysregulation of nociception may be a critical step in the transition to OUDs.

D. Lorcaserin

The role of serotonin (5-HT) in substance use disorders has been noted for some time where the emphasis has been primarily on the examination of a possible role in psychostimulants including cocaine and nicotine. Neelakantan et al. (2017) studied the effect of the selective 5-HT2C receptor agonist, lorcaserin, in rats self-administering oxycodone and also examined its effects on vulnerability to relapse using extinction of oxycodone self-administration and forced abstinence where lever pressing during the ‘cue reactivity’ phase produced a visual stimulus and sounds from the pump infusion that had been previously paired with the delivery of oxycodone. Responding of rats was maintained by 0.1 mg/kg/0.1 mL infusion of oxycodone. Lorcaserin (0.25-1.0 mg/kg, s.c.) significantly reduced the self-administration of oxycodone at 1.0 mg/kg of lorcaserin; these effects were reversed with the administration of the 5-HT2C antagonist SB 242084. Following extinction-induced abstinence, lorcaserin decreased the reinstatement of
responding to the cues that had been associated with oxycodone administration following extinction and following abstinence.

**E. Orexin/Hypocretin**

Orexin neurons are known to play a role in the modulation of behavior that is directed towards drugs of abuse (Aston-Jones et al., 2010; Harris et al., 2005; Mahler et al., 2012). Two G-protein coupled orexin receptors have been identified, orexin-1 and orexin-2, that appear to have different distributions in the brain and likely affect different physiological functions (Aston-Jones et al., 2010). In rodents, it has been shown that approximately 50% of orexin neurons express \( \mu \)-opioid receptors and that these receptors respond to chronic morphine administration and opioid-antagonist precipitated withdrawal (Georgescu et al., 2003). Moreover, orexin knockout mice develop attenuated dependence on morphine, and the precipitated antagonist withdrawal is less severe than that in the wild-type littermates. There are a number of studies of the relationship of orexin and opioids, particularly morphine, where administration of the orexin-1 antagonist SB 334867 reduced the expression of morphine in the CPP procedure and orexin knockout mice demonstrated a lack of preference in this procedure although these effects were not subsequently replicated (see review by Mahler et al. (2012).

Matzeu and Martin-Fardon (2020) studied an orexin-1 antagonist, SB334867 and an orexin-2 antagonist, TCSOX229, to evaluate their effects on oxycodone self-administration (0.15 mg/kg/0.1 ml, i.v.) in rats and on two measures that examined conditioned reinstatement and resistance to extinction. SB334867 produced decreases in oxycodone maintained responding at 5, 10 and 30 mg/kg, i.p. Following extinction, where responding had no scheduled consequences and responding declined to very low levels, the presentation of stimuli that previously accompanied oxycodone delivery, reinstated responding on the lever associated with oxycodone; these effects of conditioned stimuli were also reduced by all SB334867 doses. In contrast to these effects, the orexin-2 agonist, TCHOX229, did not modify oxycodone self-administration at any of the doses studied, which were identical to those of SB334867. Following reinstatement, the discriminative stimuli that were associated with oxycodone delivery produced a robust increase in
responding that was decreased by SB334867, but not reversed by TCHOX229. These findings suggest that selective orexin-1 antagonists may be beneficial for the treatment of OUD.

F. Glucagon-Like Peptide - GLP-1

Glucagon-like peptide-1 (GLP-1), a G protein-coupled receptor, is a 30-amino acid peptide hormone produced in the intestinal epithelial endocrine L- cells of the small intestine by the differential processing of proglucagon. The primary actions of GLP-1 are to stimulate insulin secretion, although it also appears to be a regulator of appetite and food intake (Holst, 2007). GLP-1 is expressed in several brain regions, including the arcuate nucleus and other hypothalamic regions, as well as in the shell of the NAc where it is expressed on dopamine D1 and D2 expressing medium spiny neurons (Merchenthaler et al., 1999). Zhang et al. (2020) reported that systemic administration of the GLP-1 receptor agonist exendin-4 which mimics the activity of GLP-1 and promotes insulin secretion and functions in the control of glucose, penetrates the blood-brain barrier and binds GLP-1 receptors expressed on both dopamine D1 and D2 receptors on medium spiny neurons in the NAc shell. There have been suggestions for a role of GLP-1 in drugs of abuse with studies that have focused primarily on alcohol, cocaine, and nicotine (Brunchmann et al., 2019) including one study in humans with cocaine use disorder (Angarita et al., 2021). The suggestion that GLP-1 could play a potential role in OUDs is based on a study with male Sprague-Dawley rats by Zhang et al. (2020) who evaluated the effects of GLP-1 on oxycodone self-administration, reinstatement, and nociception using exendin-4. Oxycodone-maintained responding under a fixed-ratio 5 schedule (0.06 mg/kg/59 ml saline infused over a 5 sec period), as well as responding under a progressive-ratio schedule, was significantly decreased by exendin-4 doses of 0.3 and 3.0 μg/kg, i.p.; the ‘breakpoint’ under the progressive-ratio schedule, was also decreased significantly by these doses. Exendin-4 also attenuated cue-induced reinstatement but had no effect on operant responding maintained by sucrose, although food consumption was transiently decreased 1- and 3-hours post experimental session. These studies suggest that the reductions in oxycodone-maintained responding by exendin-4, administered peripherally, did not result from a more generalized reduction in behaviors leading to other reinforcers. Further, when exendin-4 was administered directly into the shell of the
NAc, responding maintained by oxycodone under both the fixed- and progressive-ratio schedules was decreased, as was cue-induced reinstatement. Administration of exendin-4 directly into the NAc or systemically did not affect ad libitum food or water intake. Although there was a reduction in the reinforcing effects of oxycodone by exendin-4, there was no effect of exendin-4 on the antinociceptive effects of oxycodone, measured using the warm-water withdrawal paradigm. Douton et al. (2021) have also reported that exendin-4 reduces cue-induced heroin administration as well as heroin-induced reinstatement.

In a follow-up to their initial study Zhang et al. (2021) examined the effects of exendin-4 attenuated fentanyl self-administration (2.5 μg/kg/infusion) in male Sprague-Dawley rats but did so at doses that also produced malaise-like effects. These investigators then examined the effects of a dual-acting compound, GEP44, that is a combined GLP-1R/Neuropeptide Y2 agonist that reduced fentanyl self-administration and reinstatement but with fewer adverse effects compared to exendin-4 when administered alone. This result suggests that an approach targeting these two receptors may have therapeutic utility for the treatment of OUDs (see also Merkel et al. (2021).

Although the reports by Zhang et al. (2020, 2021) suggest a potential role for GLP-1 in the treatment of OUDs, it has been reported that there was no effect of systemic exendin-4 on mice self-administering remifentanil (Bornebusch et al. (2019). There were differences between these two reports that warrant further studies. For example, there may be a species difference related to pharmacokinetic factors, which are not well characterized in the mouse and there are also differences in the details of some of the results other than possible differences between oxycodone and remifentanil. For example, mice failed to self-administer more remifentanil than saline under the progressive-ratio schedule. However, Bornebusch et al. did find that exendin-4 produced dose-dependent decreases in the oral consumption of alcohol. The findings that exendin-4 was efficacious in abuse liability studies with oxycodone in rats, that it did not affect oxycodone’s antinociceptive effects, and displays interesting interactions in the brain with other receptors, together with the results obtained with heroin, fentanyl and the the dual-acting GLP-1/Neuropeptide Y2 suggest that further studies are essential to arrive at a clearer understanding of the potential use of GLP-1 and dual agents for therapeutic utility in OUDs (see also Klausen et al., 2022).
G. Cannabinoids

Following the acquisition of responding maintained by oxycodone (0.15 mg/kg/infusion), rats were exposed to Δ⁹-tetrahyrocannabinol (THC) either by vapor inhalation or by the i.p. injection (Nguyen et al., 2019). Under extended access to oxycodone (8 hr sessions), as well as under a 1 hr access condition, both THC vapor inhalation and i.p. administration of THC reduced oxycodone self-administration. In studies of antinociception using the warm water bath withdrawal response, the combination of THC with oxycodone, both when THC was injected and when exposed to vaporized THC, significantly increased the latency of withdrawal. Specificity of the effects of THC were obtained with the administration of the CB1 antagonist, SR 141716 which blocked the effects of THC inhalation. Nguyen et al. comment that their data demonstrate an additive effect of oxycodone and THC, suggesting that THC may enhance the therapeutic efficacy of opioids while reducing their abuse liability.

H. Biased G Protein-Based Mu Opioid Receptor Agonist TRV130

Biased signaling of μ-opioid receptor agonists has captured a great deal of attention following the reports that it might be possible to design compounds that preferentially activate the G Protein signaling pathway, responsible for analgesic effects, while minimizing or eliminating activation of the β-arrestin pathway which is responsible for the side effects that include respiratory depression and abuse liability. The first G-protein biased mu-opioid agonist, TRV130 (oliceridine or Olinvyk) was advanced into clinical development and was approved by the FDA for intravenous short-term use to treat moderate to severe pain and when alternative treatments are inadequate. Preclinical studies in rats showed that TRV130 produced antinociceptive effects but was also self-administered and comparable to oxycodone in terms of potency and efficacy (Zamarripa et al., 2018). Other preclinical studies suggesting abuse liability have been reported (Altarifi et al. 2017; Schwienteck et al, 2019). Bossert et al. (2020) examined the effects of the G protein-biased μ-opioid receptor agonist, TRV130, on relapse from oxycodone self-administration and on brain hypoxia that results from acute oxycodone-induced decreases in oxygen levels in the NAc. Using a context-induced reinstatement procedure, TRV130 modestly decreased
reinstatement following extinction of responding maintained by oxycodone in male rats but had no effect on females, a finding that also occurred during reacquisition of oxycodone self-administration. When TRV130 was delivered for 14 days via an osmotic minipump, and these rats were then administered acute doses of oxycodone, when compared to control rats, TRV130 produced a protective effect against decreases in NAc oxygen levels. The authors suggest that TRV130 be considered for opioid maintenance treatment that could protect against relapse and protect against severe respiratory depression. At this point, it appears that TRV130 shares many effects with oxycodone, including abuse liability which limits its utility as a therapeutic.

I. Neurokinin-1 (NK1) Receptor Antagonists

Speculation surrounding the potential utility of neurokinin-1 (NK1) receptor antagonists as potential agents for the treatment of OUDs has been available for some time following the publication of studies showing interactions between the peptide neurotransmitter substance P that activates the neurokinin-1 (NK1) receptor and its interaction with opioids (Gadd et al., 2003). Interest in NK1 and its relationship to opioid pharmacology likely rests in the interest in the NK1 system as a potential pain therapeutic and whether there may be a role in the modulation of analgesia (Schank, 2014). Administration of the NK1 receptor antagonist RP 67580 i.c.v. decreased some of the withdrawal signs from morphine that were precipitated by naloxone (Maldondo et al., 1993). Mice lacking the NK1 receptor failed to show typical withdrawal signs when undergoing spontaneous withdrawal and these mice did not develop conditioned place aversion in response to naloxone administration that precipitated withdrawal in morphine-dependent mice (Murtra et al., 2000). Murtra et al. also showed that the mice lacking the substance P receptor (NK1−/−) did not develop CPP following morphine administration; this finding was specific to morphine since neither cocaine nor food produced CPPs. Mutra et al. concluded that substance P plays an important role in mediating the reinforcing and motivational effects of opioids and may represent a new pharmacological approach to OUDs.

This general conclusion was also found in a study of self-administration of morphine in wild type and NK1−/− mice (Ripley et al., 2002) where lever pressing to receive morphine was established and maintained in the wild type mice but, in contrast, the NK1−/− mice responded at
low rates on both the lever that produced morphine and the lever where responding had no scheduled consequences, never really acquiring and establishing morphine self-administration. These investigators also studied cocaine self-administration in the two groups of mice and found no differences in responding, suggesting that the effects observed with morphine are specific to opioids, and that the NK1 receptor may be necessary for the development of opioid addiction but not other abused drugs. Ripley et al. concluded that their results ‘strongly support’ a role for NK1 receptors in mediating the rewarding properties of opiates.

These effects whereby NK1 appears to play a role in some of the abuse related aspects of opioids do not generalize to opioid-mediated analgesia as the analgesic actions of opioids are not attenuated in NK1\textsuperscript{-/-} mice when tested using the hot-plate assay, tail pinch or the warm water tail-flick (De Felipe et al., 1998).

In summary, some of these results are difficult to interpret due to findings reporting that substance P (NK1) tachykinins administered alone and when injected i.c.v. or intracerebrally, can produce effects that resemble the opioid withdrawal syndrome, including wet dog shakes and rearing (Elliott and Iversen, 1986). Clearly, however, the suggestive nature of these results for OUDs appears to justify studies with human volunteers. Studies with humans and two NK1 antagonists, aprepitant (Walsh et al., 2013) and tradipitant (Coe et al., 2021) are summarized in this review in section VII, Pharmacological modulation of oxycodone in humans. It appears that only a single study of NK1 and oxycodone has been published and this was summarized in the section on gender differences in reinstatement (VII.B, Fulenwider et al., 2020).

\textit{J. Dopamine D3 Receptor Compounds}

The distribution of dopamine D3 receptors in the brain and preclinical evidence indicating that these receptors are intimately involved in drug reinforcement and addiction has prompted an effort to develop dopamine D3 receptor compounds for the treatment of SUDs (Heidbreder and Newman, 2010). Several studies with novel compounds developed by Newman and colleagues at the Molecular Targets and Medications Discovery Branch in the NIDA Intramural Research Program have demonstrated that dopamine D3 antagonists/partial agonists play a significant role in inhibiting oxycodone self-administration, facilitating extinction, and inhibiting reinstatement.
(Kumar et al., 2016; You et al., 2017, 2019; de Guglielmo et al., 2020). Two D3 antagonists/partial agonists CAB2-015 and BAK4-54 produced dose-dependent decreases in oxycodone self-administration. When given as a pretreatment, both compounds facilitated extinction of oxycodone self-administration and inhibited reinstatement of responding to obtain oxycodone (You et al., 2017). In a study that examined oral sucrose self-administration, CAB2-015 decreased intake at doses that reduced oxycodone-maintained responding, whereas BAK4-54 did not.

A subsequent study by You et al. (2019) investigated VK4-116, a dopamine D3 receptor antagonist developed to avoid attributes of prior compounds in this class that include poor pharmaceutical properties (ADME) or cardiotoxicity. Pretreatment with i.p. administration of VK4-116 blocked the acquisition of oxycodone self-administration, an effect that persisted for a number of sessions when the pretreatment with VK4-116 was discontinued, gradually reaching levels maintained by the control group of rats that did not receive VK4-116. Other studies with VK4-116 indicated that it facilitated decreases in responding during extinction, did not show any effect on sucrose consumption and lowered the breaking point under a progressive ratio schedule, indicating an attenuation of the reinforcing effects of oxycodone. A hot plate assay was used to assess the effects of oxycodone analgesia in combination with VK4-116. Addition of VK4-116 to the dose-response curve of oxycodone produced a significant leftward shift, indicating an enhancement of the analgesia produced by oxycodone. This group also demonstrated that VK4-116 is metabolically stable in rat, rhesus monkey and human liver microsomes, an initial step in determining whether this compound addresses the liabilities of other D3 antagonists which would preclude preclinical development. Finally, these behavioral studies involving oxycodone self-administration and antinociception have been extended to monkeys and include the D3 receptor partial agonist VK4-40 (Woodlief et al., 2023).

Further studies with VK4-116 were conducted in the genetically diverse HS rats (de Guglielmo et al., 2020) where it was shown that both male and female rats progressively escalated oxycodone intake and there were no differences in oxycodone intake for either sex. Treatment with VK4-116 reduced oxycodone self-administration in both sexes. This study also discovered two subpopulations of rats designated as High and Low responders based on the level of oxycodone self-administration. VK4-116 selectively reduced self-administration of High
responders and was also shown to reduce withdrawal-induced hyperalgesia and aggressive responses compiled using an irritability score.

Since the dopamine D3 receptor target appears to demonstrate potential utility for a wide range of SUDs, not just μ-opioid agonists substances, but also psychostimulants such as cocaine, methamphetamine and nicotine, it will be interesting to see how these different drug classes respond to drugs directed towards this receptor. The speculative notion of a ‘pan therapeutic’ that could be used for diverse SUDs is appealing but remains to be established.

In summary, though a wide range of compounds with different receptor-mediated activity has been studied, none have yet progressed to a point where they can add to the treatment of OUDs that are currently employing methadone or buprenorphine. At this point, it is not clear whether single mechanism-based compounds will be effective or whether a polypharmacological approach may have better efficacy as treatment approaches. The approach of using biased μ-opioid receptor drugs that retain effective analgesia but are without abuse liability remains an open question, as do approaches that employ ‘bitopic’ or ‘bifunctional’ targets that, for example target two or more of the opioid receptors (see section X, Future Directions) may be developed as analgesics but whether these may add to the current approaches to drug treatment is unclear. Several of the compounds and mechanisms described in this section appear to be promising and worth further research (e.g., orexin/hypocretin, GLP-1 and dopamine D3 compounds) to determine whether the preclinical findings actually translate to clinical efficacy.

IX. Pharmacological Modulation of Oxycodone in Humans

A few laboratory-based studies have examined a small number of prescription drugs in an effort to determine whether there were any indications of potential therapeutic utility for the treatment of OUDs. In addition to the studies described in this section, new methodology to identify drugs for the treatment of opioid use disorders have proposed drug repurposing approaches to aid in the identification of potential candidate drugs (Zhou et al., 2021). This approach, though still in its infancy, combines computational prediction, patient EHR-based clinical corroboration, and mechanisms of action analysis. Genetic and functional analyses have shown that candidate drugs identified by this method target multiple OUD-associated genes and
pathways that include opioid signaling, G-protein activation, serotonin receptors and GPCR signaling, thus providing a foundation and an incentive for further evaluation of candidate drugs to treat OUDs identified by this methodology. Additionally, Cao et al. (2023) have provided a review of potential targets and treatment strategies to develop medications for OUDs.

A. Buprenorphine/Naloxone

Roux et al. (2013) studied the effectiveness of different doses of sublingual buprenorphine/naloxone in 25 patients with chronic, nonmalignant pain who were abusing their prescription opioid medications. Subjects were able to self-administer oxycodone during the experimental phases of the study. Over the 7-week period of the inpatient study, the combination of buprenorphine/naloxone was effective in reducing pain and withdrawal symptoms as well as supplemental oxycodone use. Roux et al. concluded that the adequate management of pain and withdrawal in this population may reduce the preference for oxycodone.

B. Pioglitazone, a PPARγ receptor agonist

The peroxisome proliferator-activated gamma receptor (PPARγ) agonist pioglitazone, a glial modulator, has been shown to attenuate the development of tolerance (de Guglielmo et al., 2014) and to reduce heroin self-administration under a fixed and a progressive ratio schedule (de Guglielmo et al., 2015). These findings, together with the expression of PPARs in the CNS prompted a study by Jones et al. (2016) to examine the subjective effects of oxycodone, together with the influence of pioglitazone on the analgesic, cognitive, and physiological effects when non-dependent prescription opioid abusers were maintained on various doses of pioglitazone. Despite the positive findings with heroin and pioglitazone in laboratory animals, pioglitazone did not alter the subjective, cognitive, analgesic or physiological effects of oxycodone in the subject enrolled in this study.

C. Ibidilast
Ibudilast is a nonselective phosphodiesterase inhibitor that, in studies with animals, inhibits glial cell activation and may modify opioid-mediated effects such as analgesia and withdrawal (Hutchinson et al., 2009). The effects of ibudilast were studied in non-treatment seeking opioid dependent male volunteers who underwent detoxification from morphine as inpatients and were maintained on placebo for the duration of the study. The effects of ibudilast were examined with oxycodone (0, 15 and 30 mg/70kg) on analgesia, on subjective responses to oxycodone, and on craving (Metz et al., 2017). Heroin craving, assessed using a visual analog scale and a drug effects questionnaire, was high across the different oxycodone conditions with significantly less craving for heroin in the active ibudilast condition. Modest but statistically significant decreases occurred in drug liking at the 15 mg dose of oxycodone with the active dose of ibudilast. Metz et al. also studied the reinforcing effects of oxycodone with ibudilast and found that at the 15 mg dose of oxycodone, breakpoint values were significantly lower with ibudilast compared to the placebo control. There were significant differences in pain reductions with both the 15 and 30 mg of oxycodone in combination with ibudilast using the cold pressor test and the McGill Pain Questionnaire to assess analgesia, but these results were not consistent across the different analgesia scales. Although the subjective ratings of pain were lower with ibudilast, the overall effects were relatively modest. The effects of ibudilast on craving and drug liking, together with the increased analgesic response to oxycodone, suggest that additional studies are warranted to characterize this compound more fully.

D. Cannabis

Cannabinoids and opioids have several common pharmacological properties, suggesting there may be synergistic interactions with μ-opioid receptor agonists such as oxycodone. Abrams et al. (2011) examined the interaction of inhaled vaporized cannabis with sustained release formulations of oxycodone or morphine in twenty-one individuals (11 men and 10 women) with chronic pain. The types of pain included musculoskeletal, posttraumatic, peripheral neuropathy, cancer and arthritic. Pharmacokinetic analyses showed no significant change in the area under the plasma concentration time curves for either morphine or oxycodone following cannabis exposure. Pain levels were assessed by participant ratings. Overall average pain scores for the combined
oxycodone and morphine groups decreased significantly by an average of 27%. However, whereas this measure was significantly different for those in the morphine condition, individuals in the oxycodone group did not show a significant change in pain scores. Although the reasons for this difference was unclear, it may be related to the relatively small numbers of subjects or to the baseline differences in that the initial pain ratings for the group receiving oxycodone were higher than those for the morphine group. Despite this difference, Abrams et al. concluded that vaporized cannabis augmented the analgesic effects of opioids without altering plasma opioid levels, suggesting an opioid-sparing effect that might permit lower doses of opioids with fewer side effects but enhanced analgesic efficacy. Possible differences between male and female subjects were not noted.

Cooper et al. (2018) studied the effects of co-administering oxycodone and cannabis on analgesia and abuse liability in volunteers who currently smoked greater than or equal to three cannabis cigarettes at least three times a week for the four weeks before screening. Using the cold pressor test, smoked cannabis produced analgesia when given in combination with an ineffective dose of oxycodone when neither of these drugs produced analgesia when administered alone. This finding also suggested an opioid sparing effect whereby lower doses of oxycodone, for example, in combination with cannabis produce effective analgesia. This combination did not significantly affect cannabis abuse liability but did increase opioid-related positive subjective ratings.

E. Lorcaserin

As mentioned earlier in this review, lorcaserin has been shown to decrease oxycodone self-administration and to attenuate cue-induced reinstatement. Brandt et al. (2020) studied the effects of lorcaserin on oxycodone self-administration and assessed subjective responses in participants with opioid use disorder. Males with moderate-to-severe opioid use disorder were detoxified, then stabilized on lorcaserin or placebo. Intranasal oxycodone was examined on several parameters over a 2-week period. Lorcaserin did not alter oxycodone self-administration but had a trend toward increasing ‘wanting heroin’ when oxycodone was available. Generally, although oxycodone increased participants’ ratings of oxycodone with ‘good drug effects’ and ‘drug liking’, lorcaserin had minimal effects on oxycodone subjective effects and did not alter
oxycodone self-administration. These results clearly differ from those reported by Neelakantan et al. (2017) and the authors suggest the need to examine a range of doses of both oxycodone and lorcaserin to more completely evaluate the utility of lorcaserin as a potential therapeutic.

**F. Minocycline**

A number of preclinical studies have suggested that the antibiotic minocycline interacts with the opioid system presumably by inhibiting opioid-induced glial cell activation resulting in an enhancement of the effects that include opioid-induced analgesia as well as reducing CPP following morphine administration (Ghazvini et al., 2015; Hutchinson et al., 2008; Nazemi et al., 2012; Xiao-Peng et al., 2013). In a double-blind, within-subject outpatient study, Mogali et al. (2021) investigated whether the acute administration of oral minocycline would alter the subjective, physiological, analgesic and cognitive effects of oxycodone. In addition to placebo, a single dose of 40 mg oxycodone and two doses of minocycline 100 and 200 mg were studied. The physiological effects of oxycodone on pupillary constriction were not affected by minocycline. Although there was a significant increase in expired CO2 in the oxycodone + minocycline 200 mg condition, the investigators acknowledged the variability in this measure and considered this result clinically insignificant. Neither dose of minocycline had any effect on pain induced by the cold-water pressor test or on the measures of cognition. However, the 200 mg dose of minocycline attenuated the positive subjective effects produced by oxycodone, a finding that led to the suggestion that minocycline may attenuate the abuse liability of μ-opioid receptor agonists and appears to be relatively safe in combination with oxycodone.

**G. NK1 Antagonists**

The preclinical data summarized in Section VIII.I suggested a role for NK1 compounds interacting with morphine, data that is also supported using genetically modified mice lacking the NK1 receptor. There are some questions about the full extent of these interactions in tolerance and withdrawal but the data has been sufficiently compelling to follow up on these suggestions using human subjects and with oxycodone. Walsh et al. (2013) studied the effects of the NK1 antagonist aprepitant on the response to oral and intranasal oxycodone. The subjects in this study were non-
dependent prescription opioid users. Both routes of administration of oxycodone produced significant dose-related effects that included subjective measures of abuse liability, respiratory depression and miosis. Pretreatment with the highest dose of aprepitant (200 mg) produced significantly enhanced ratings of the subjective effects of the highest dose of oxycodone (40 mg/70kg) and doubled the estimated street value of the combination for both routes of administration suggesting modulation of morphine’s effects by aprepitant’s action at the NK1 receptor. There were significant effects on end tidal CO2 with the highest dose of oxycodone in combination with the highest dose of aprepitant but there was no evidence of clinically significant respiratory depression, with all drug combinations tolerated safely.

A second study with a different NK1 antagonist, tradipitant, and oxycodone was also conducted (Coe et al., 2021) using participants who were recreational opioid users except in this study only the intranasal route for oxycodone was evaluated. Again, as with the previous study, oxycodone produced a wide range of opioid effects, but these were not altered by co-administration of tradipitant. The authors of this manuscript concluded that, whereas the animal data provide meaningful interactions between NK1 antagonists and morphine, the human data with oxycodone do not support continued pursuit of NK1 antagonists for the treatment of OUDs.

Taken together, these two studies, the first showing an enhancement of the effects of oxycodone implicating abuse liability, and the second study showing an absence of support for a role of NK1 in oxycodone’s effects raise a number of questions about the potential role of NK1 antagonists in modulating the effects of μ-opioid receptor agonists. The authors of the two studies acknowledge possible factors that might contribute to differences in the two studies and the lack of positive translation from preclinical models and conclude that, despite these differences, it is clear that there is an interaction between the opioid and the NK1 systems that is worthy of further exploration.

These experimental studies in humans provide useful approaches to the evaluation of the analgesic and subjective effects of drugs, along with efforts to examine potential drugs that may have clinical treatment efficacy. As such, these experiments are restricted somewhat to investigating early-stage compounds (e.g., Phase I or II) that are safe and well tolerated or drugs that might potentially be ‘repurposed’ if there is a degree of efficacy. Both approaches are
essential and complementary in the experimental analysis of drugs in development or those readily available where there is some rationale for study.

X. Vaccines to Treat Opioid Use Disorders

A. General Introduction

The effort to develop vaccines for the treatment of substance use disorders has been underway for almost 50 years. Both active immunization (vaccination) and passive immunization (through the transfer of pre-made antibodies) approaches to treat SUDs are based on the pharmacokinetic principle of developing anti-drug antibodies to bind drugs in the serum and extracellular fluids and prevent passage through the blood-brain barrier and into the CNS, thereby precluding the constellation of pharmacological events contributing to CNS receptor activation and psychoactive drug effects (Skolnick, 2015). Because vaccines have a long half-life, they should provide longer-lasting protection compared to small molecule therapeutics targeted to antagonize the pharmacological effects of the substance of abuse. Immunopharmacotherapeutic approaches with a focus on OUDs have captured a great deal of interest and have been reviewed extensively over the past few years as the momentum to develop vaccine alternatives to small molecules has increased in light of the widespread issues related to the opioid epidemic (Baehr and Pravetoni, 2019; Baer et al., 2020; Banks et al., 2018; Hossain et al., 2022; Martinez et al., 2023; Pravetoni, 2016; Pravetoni and Comer, 2019; Townsend and Banks, 2020; Vasiliu et al., 2022).

Drugs that are abused are small molecules (haptens) and are too small to stimulate an immune response. Drugs of abuse are made immunogenic by conjugation to a carrier protein (e.g., cholera toxin, keyhole limpet hemocyanin (KLH), or tetanus toxoid) mixed with an adjuvant such as alum to enhance the immunogenic response. There are a number of challenges unique to the development of opioid vaccines, due to the availability of several different opioids, most of which have active metabolites, raising the question of whether a vaccine against one opioid would also apply to others. In addition, it would be important to have alternative options for opioid management of pain if someone is vaccinated against an opioid that would attenuate the analgesic effect of another opioid.
B. Historical Background

The initial impetus for pursuing vaccines for the treatment of OUDs was precipitated by a series of early methodological studies in the 1970’s by Spector and colleagues reporting on the development of a quantitative and sensitive method for determining morphine in the serum by a radioimmunoassay (Spector and Parker, 1970; Spector, 1971; Spector et al., 1973). These studies raised the question of whether active or passive immunization of animals could modify the pharmacological and physiological effects of opioids. Berkowitz and Spector (1972) subsequently reported immunization to morphine in rodents where the morphine immunogen selectively reduced morphine-induced analgesia in mice and also altered the concentration of morphine in plasma. This report was followed by a study demonstrating a reduction in i.v. heroin self-administration in rhesus monkeys following antibody activation with a vaccine consisting of a morphine-based hapten conjugated to bovine serum albumin (Bonese et al., 1974). Killian et al. (1978) subsequently examined the effects of passive immunization against morphine on heroin self-administration, also in rhesus monkeys and under a fixed-ratio 19 schedule of drug delivery. In contrast to the results shown by Bonese et al. following active immunization, heroin self-administration was increased in the study by Killian et al. Several reasons for the different results were suggested by Killian et al. that included lower levels of circulating antibodies in the passively immunized animals, the rate of decay in circulating antibody activity in the passive immunization monkeys that paralleled the return of heroin self-administration, differences in the experimental protocols (the intervals between initiating drug self-administration and immunization), and differences in antibody levels in the CSF which were not found in one of the passively immunized animals but were found in the actively immunized monkeys.

Since these initial reports, multiple efforts over the past several years have been directed towards the development of vaccines against methamphetamine, cocaine, nicotine and opioids. Pravetoni and Comer (2019) have provided a very thorough review of the mechanisms of action of OUD vaccines, together with their preclinical development, the clinical status for SUDs and OUDs, as well as manufacturing and regulatory requirements. Truong and Kosten (2022 have reviewed the current status of vaccines for a number of substance use disorders, pointing out that
despite promising findings in animal models of SUDs, clinical trials with humans to date have been disappointing. For the most part, as Truong and Kosten point out, most of the vaccines have not achieved sufficient antibody levels and, even when doing so, only a small percentage of antibodies may have had a high affinity for the antigen. The focus of the remaining section of this review will cover vaccines directed towards oxycodone.

C. Recent Research and Development

Pravetoni et al. (2012) developed an opioid conjugate vaccine (Oxy(Gly)_4-sKLH) that when injected into rats produced high antibody titers to oxycodone and its metabolite oxymorphone. Immunization increased the retention of oxycodone in serum and reduced oxycodone distribution in the brain while also reducing the effects of oxycodone in a thermal antinociception procedure. Lower affinities also were obtained with the related opioid agonists and antagonists that included methadone, buprenorphine and naltrexone. The absence of cross reactivity with these drugs suggested that continued use of these therapeutic agents would still be possible following the administration of the oxycodone vaccine. A follow up to this study (Pravetoni et al. (2013) demonstrated that modifications of oxycodone at the C6 position conjugated to KLH (6 OXY(Gly)_4 - KLH) produced effective immunogens for eliciting antibodies against oxycodone and hydrocodone. This immunogen was also effective in attenuating the distribution of oxycodone and hydrocodone into the brain and in blunting the analgesic effects of oxycodone and hydrocodone in mice and rats.

Pravetoni et al. (2014) also studied the oxycodone conjugate vaccine on oxycodone self-administration in rats. Vaccination reduced the proportion of rats acquiring oxycodone self-administration and also significantly reduced the number of infusions and total intake of oxycodone. Vaccine efficacy correlated with serum antibody titers and immunization with this conjugate vaccine reduced oxycodone-induced analgesia in a thermal nociception assay while also shifting the dose response curve to the right for respiratory depression (Raleigh et al., 2017). Raleigh et al. (2018) showed that the dose of oxycodone and the route of administration can play a major role in determining the efficacy of the vaccine. Vaccination with the oxycodone conjugate was more effective when immunized rats were challenged with oxycodone
administered subcutaneously rather than intravenously and distribution of oxycodone in the brain was also greater following subcutaneously administered oxycodone. A subsequent study (Raleigh et al., 2021) reported that, in rats, vaccination with Oxy(Gly)4-sKLH produced sustained antibody titers that lasted over 5 months following the initial vaccination. Further, the vaccine did not interfere with fentanyl-induced nociception or the distribution of fentanyl to the brain, demonstrating in vivo selectivity, and markedly altering the pharmacokinetics of oxycodone, increasing the half-life of oxycodone in serum in both male and female rats. While there were significant differences between male and female rats in the levels of oxycodone-specific antibody titers, there were no sex differences in other experiments. This oxycodone antibody also reduced the self-administration of oxycodone.

This group also demonstrated that it is possible to combine an oxycodone vaccine with a long-acting opioid receptor antagonist, naltrexone, to offer better protection against OUD and overdose (Raleigh et al., 2020). Over a range of oxycodone doses, the combination provided greater antinociceptive efficacy while also reducing respiratory depression.

Nguyen et al. (2018) examined the effects of an Oxy-Tetanus Toxoid (Oxy-TT) vaccine that had previously shown efficacy attenuating the antinociceptive effects and oxycodone overdose in mice (Kimishima et al., 2017). Vaccination with Oxy-TT resulted in fewer rats acquiring stable self-administration of oxycodone, showing an effect on reinforcing efficacy. Although rats were less sensitive to the effects of oxycodone, there was no loss of sensitivity with heroin, demonstrating selectivity of the vaccine.

Altogether, these studies suggest that active immunization with Oxy(Gly)4-sKLH results in long-lasting selective antibodies that effectively decrease the reinforcing effects of oxycodone while maintaining the efficacy of medications to treat OUD and overdose. Oxy(Gly)4-sKLH has recently completed pre-clinical safety and toxicology studies with no indication of toxicological findings, while also showing that it is well tolerated, immunogenic, and does not produce undesirable effects in rats (Hamid et al., 2022). At the time of this review, Oxy(Gly)4-sKLH was in Phase 1A/1B clinical trials to evaluate safety, degree of antibody production, and efficacy (reduction of drug liking following the administration of an opioid) in participants with OUD (Clinical Trials.gov identifier NCT04458545, Phase 1A/1B Clinical Trials of Multivalent Opioid Vaccine Components).
Although there has been growing evidence over the last several years that vaccines may be beneficial addition to the pharmacological options to treat OUDs, the field has been hampered somewhat by the failure to translate preclinical findings with non-OUDs such as cocaine, nicotine and methamphetamine into clinical efficacy (Ohia-Nwoko et al. 2016). The entry of oxycodone vaccines into clinical development based on several preclinical findings are encouraging and the results of clinical trials are enthusiastically awaited.

XI. Future Directions: Opioid Analgesia Without Opioid-Related Side Effects?

The quest to discover and develop opioid analgesics that do not carry the untoward effects of current μ-opioid receptor agonists, but which retain their potent analgesic efficacy, has been the holy grail of this field of research, ongoing for nearly a century. Indeed, Deneau and Seevers (1964) wrote nearly 60 years ago that the ‘search for an analgesic devoid of morphine’s undesirable properties continues unabated’ (p. 274) and the quest for the holy grail continues. Recall that oxycodone was initially synthesized as an attempt to develop a potent opioid analgesic devoid of the dependence and abuse liability surrounding heroin, which was marketed at the time as an analgesic. Several relatively recent approaches to the development of drugs that may succeed either as effective analgesics without abuse liability or as potential treatment medications have included opioids targeting multiple receptors (i.e., bitopic or bivalent dual multifunctional μ-κ, μ-δ or μ-NOP agonists, or μ-dopamine D3 dual partial agonists/antagonists), splice variants of the μ receptor, G-protein biased agonism with signaling directed towards separating the analgesic effects from the side effects and abuse liability, allosteric activation of the opioid receptor, heteromers of the μ receptor, and a focus on natural products (Bonifazi et al., 2021; Burford et al., 2013; Candeia et al., 2022; Chakraborty and Majumdar, 2021; Corbett et al, 2006; Fujita et al., 2015; Kenakin, 1999; Lane et al., 2013; Majumdar et al., 2011; Newman et al., 2012, 2020; Schmid et al., 2017; Varga et al., 2020). Together with the efforts underway for vaccine development, this collective activity and the diverse approaches being studied bodes well for the possibility of significant breakthroughs, but always and necessarily viewed with the appropriate cautious optimism. These efforts, some of which are in the early stages, present an exciting
breadth of approaches that represent and build upon several significant advances in pharmacology and in our understanding of G-protein coupled receptors and vaccines. This progress also demonstrates the integration of different disciplines into pharmacology that include computational approaches to drug design and development (Feng et al., 2015) that are required to target multiple opioid receptors and to aid in the design of suitable compounds. The publication of the structures of the entire human opioid family (Wang et al., 2023), together with biochemical results, provide a structural framework to aid and facilitate the design of opioid drugs that are devoid of unwanted side effects.

In conducting a comprehensive molecular pharmacology screening of several clinically relevant opioids, including oxycodone, against multiple potential targets such as monoamine transporters and sigma-1, Olson et al. (2019) identified a number of novel receptor interactions that might address or clarify some of the disparities in the effects of these drugs mentioned in previous sections of this review. These include the absence of cross tolerance between some opioids and discrepancies between various in vitro and in vivo results. Among the findings and implications of this approach was the identification, based on in vitro radioligand binding and in vivo verification, that buprenorphine was activated by the monoamine transporters in vitro and, in vivo, duloxetine, which had no effect administered separately, increased the antinociceptive response of buprenorphine in the tail flick procedure. Hydrocodone and taptentadol were also shown to bind to Sigma-1 target which suggests that this binding may amplify signaling, thereby also enhancing the antinociceptive responses of these two drugs. This approach may also facilitate the search for repurposing drugs with potential treatment for OUDs and for developing more effective analgesics devoid of the current limitations.

The impediments are well known and not trivial. Many past compounds have fallen into the ‘valley of death’, a demise that is due in part, to the significant challenges of identifying appropriate pharmacological targets and mechanisms with the goal of treating pain without abuse liability along with the translational difficulties of moving from preclinical to clinical assessment. However, the goal of identifying a non-addicting opioid analgesic is an imperative objective. At the present time, it appears to be ever increasingly more achievable, and should include comparable efforts to continue to identify potential medications to enhance the ability to treat OUDs.
XII. Conclusions

Lemberg et al. published an article in 2009 that was titled the “Pharmacology of oxycodone: does it explain why oxycodone has become a bestselling opioid?”. Lemberg et al. concluded that “oxycodone is an effective analgesic, but its more liberal use has also increased iatrogenic addiction and individuals seeking detoxification from oxycodone” (p. 521). This article was followed approximately 4 years later by another article “Does the pharmacology of oxycodone justify its increasing use as an analgesic?” (Olkola et al, 2013). Olkola et al. echoed a portion of the comments of Lemberg et al., concluding that “our current understanding of the pharmacology of oxycodone does not explain the significant increase in its clinical use” (p.212). Several studies summarized here point to the strong positive subjective effects in human volunteers that appear to have contributed directly to the use and abuse of oxycodone, quite apart from its clinical utility. For several years oxycodone played a dominant role in opioid misuse and overdose mortalities. Olkola et al. comment on the many similarities between oxycodone and morphine but also acknowledge several properties that differ with oxycodone including a faster onset of action, good oral bioavailability, a longer duration of action, less suppression of the immune system and lessened tendency to produce hallucinations. As treated in this review, and as pointed out by Olkola et al., a number of questions still remain despite the intensive research efforts surrounding oxycodone. These include a poor understanding of why oxycodone is less effective than morphine following spinal than after intravenous administration, the role of κ-opioid receptors in the analgesic activity of oxycodone, along with how these two drugs might differ in second messenger signaling and immunological effects.

Despite the lack of present clarity around these questions, oxycodone is unquestionably an effective analgesic. The intensive research over the past several decades has produced additional insights not only with regard to oxycodone but into μ-opioid behavioral and molecular neuropharmacology generally. Experimental studies that have probed other features of oxycodone, including gene expression, use in adolescence and the longer-term effects in adulthood, together with studies of its subjective effects in human volunteers and variables contributing to its abuse, have increased our understanding of this drug and have also provided
opportunities to address other features of importance to opioid pharmacology more broadly. Studies with oxycodone and comparisons with other μ-opioid receptor compounds have demonstrated that, despite what appear to be similarities in their pharmacological effects, these similarities betray the multiple intriguing differences between μ-receptor opioids that can be exploited, hopefully, to arrive at the holy grail.

Authorship Contributions
James E. Barrett wrote the majority of the manuscript. Aryan Shekarabi and Saadet Inan contributed to the content and to the writing of the manuscript.
References


De Moura FB, Booth RG, Kohut SJ (2023) Oxycodone self-administration and reinstatement in male and female squirrel monkeys: Effects of alternative reinforcer availability. bioRxiv (preprint)


Hamilton WG, Gargiulo JM, Reynolds TR, Parks NL (2022) Prospective randomized study using pharmacogenetics to customize postoperative pain medication following hip and knee arthroplasty. *J Arth* **37**:S76-S81.


Jones JD, Mumtaz M, Manubay JM, Mogali, S, Sherwin E, Martinez S, Comer SD (2019)
Assessing the contribution of opioid-and dopamine-related genetic polymorphisms to the
abuse liability of oxycodone. Pharmacol Biochem Behav 186: 172778.

Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD (1996)
Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin
Pharmacol Ther 59: 52-61.

disorder: from neurobiology to clinical practice. Front Psychiatry 10: 592.


Kallupi M, Carrette LLG, Kononoff J, Woods LCS, Palmer AA, Schweitzer P, George, de
Guglielmo G (2020) Nociceptin attenuates the escalation of oxycodone self-administration
by normalizing CeA-GABA transmission in highly addicted rats. Proc Nat Acad Sci 117:
2140-2148.

Kalso E, Vaino A (1990) Morphine and oxycodone hydrochloride in the management of cancer

selectively alters the potency of analgesia produced by m-opioid agonists, but not by δ-and
κ–opioid agonists.

Kanbara T, Nakamura A, Takasu K, Ogawa K, Shibasaki M, Mori T, Suzuki T, Hasegawa M,
antinociception in an oxaliplatin-induced neuropathy rat model. J Pharmacol Sci 126: 264-
273.

1828.

Kanouse AB, Compton, P (2015) The epidemic of prescription opioid abuse, the subsequent
rising prevalence of heroin use, and the Federal response. J. Pain Palliative Care
Pharmacother 29: 102-114.


Townsend EA, Banks ML (2020) Preclinical evaluation of vaccines to treat opioid use disorders: How close are we to a clinically viable therapeutic? *CNS Drugs* **34**: 449-461.


Woodlief K, Allen MI, Cornelissen JC, Banks ML, Newman AH, Nader MA (2023) Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys. Neuropsychopharmacol published online, 


compromising the antinociceptive effects of oxycodone in rats. *Neuropsychopharmacology 45*: 451-461.


**FOOTNOTE**

Partial support for the preparation of this manuscript was provided by NIDA Award DA047700. None of the authors declare any conflicts of interest.
FIGURE CAPTION

Figure 1. Structures of Opioid Receptor Drugs
Table 1
Mean ED50 values (with 95% CI) of four opioid agonists for producing antinociception, constipation, and respiratory depression in Sprague Dawley rats

<table>
<thead>
<tr>
<th>Opioid</th>
<th>Antinociception</th>
<th>Constipation</th>
<th>Respiratory Depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>52.2 (27.6 - 98.5)</td>
<td>111.5 (111.4 - 111.7)</td>
<td>88.5 (39.7 - 197.4)</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>287.9 (199.2 - 416.2)</td>
<td>355.6 (335.4 - 377.1)</td>
<td>ND</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>4.9 (1.53 - 15.7)</td>
<td>9.9 (9.6 - 10.2)</td>
<td>13.9 (10.0 - 19.3)</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>~20 (13.0 - 31.7)</td>
<td>~7.5</td>
<td>12.3 (8.7 - 17.4)</td>
</tr>
</tbody>
</table>

Adapted from Kuo et al., 2015. A ceiling effect and the ED50 was estimated using doses up to that which produced the maximal effect. ND, not determinable.
Table 2

Potency rank order for opioids for producing antinociception, respiratory depression and constipation following i.c.v. administration

<table>
<thead>
<tr>
<th>Opioid</th>
<th>Rank Order of Potency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>Antinociception &gt; respiratory depression &gt; constipation</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>Antinociception &gt; constipation &gt; respiratory depression</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>Antinociception &gt; constipation &gt; respiratory depression</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>Constipation &gt; respiratory depression &gt; antinociception</td>
</tr>
</tbody>
</table>

* Adapted from Kuo et al., 2015.
### Table 3

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>Class – Clinical Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clozapine, Quetiapine, Risperidone</td>
<td>Atypical Antipsychotics</td>
</tr>
<tr>
<td>Diazepam</td>
<td>Benzodiazepine - Anxiety</td>
</tr>
<tr>
<td>Zolpidem</td>
<td>Imidazopyridine - Insomnia</td>
</tr>
<tr>
<td>Trazodone</td>
<td>Serotonin receptor antagonist and reuptake inhibitor</td>
</tr>
<tr>
<td></td>
<td>– Major Depressive Disorder</td>
</tr>
<tr>
<td>Carisoprodol</td>
<td>GABA</td>
</tr>
<tr>
<td>Cyclobenzaprine</td>
<td>– Tricyclic – Serotonin 5-HT2 receptor antagonist</td>
</tr>
<tr>
<td></td>
<td>– Skeletal muscle relaxants</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>Atypical Tricyclic Antidepressant</td>
</tr>
<tr>
<td>Topiramate</td>
<td>Blocks voltage-gated sodium channels &amp; enhances GABA receptor activity</td>
</tr>
<tr>
<td></td>
<td>– Anticonvulsant</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>Selective serotonin reuptake inhibitor</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>Serotonin &amp; noradrenaline reuptake inhibitor</td>
</tr>
<tr>
<td></td>
<td>– Depression</td>
</tr>
<tr>
<td>Ramelteon</td>
<td>Melatonin receptor antagonist</td>
</tr>
<tr>
<td></td>
<td>– Insomnia</td>
</tr>
<tr>
<td>Suvorexant</td>
<td>Orexin receptor antagonist</td>
</tr>
<tr>
<td></td>
<td>– Insomnia</td>
</tr>
</tbody>
</table>

Drugs, Drug Classes and Clinical Use for Interaction Studies with Oxycodone
Table adapted from Xu et al. (2021); copyright CC-BY-NC-ND
Figure 1

- Oxycodone
- Thebaine
- Naloxone
- Morphine
- Buprenorphine
- Fentanyl